<html lang="en" class="pb-page js" data-request-id="9523aece44e40cec-GRU"><head data-pb-dropzone="head"><style type="text/css" nonce="9523aece44e40cec-GRU">@font-face {font-family: "Source Sans Pro";src: url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.ttf) format("truetype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.woff) format("woff"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.otf) format("opentype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.eot) format("embedded-opentype");}.truste_cursor_pointer {cursor: pointer;}.truste_border_none {border: none;}.truste_accessible_link {font-family: "Source Sans Pro", sans-serif;color: #1D4ED8;font-size: 14px;font-weight: 600;text-decoration: underline;}.truste_accessible_link:hover {color: #1D4ED8;text-decoration: none !important;}.truste_accessible_link:focus-visible {outline: none;border-radius: 4px;box-shadow: 0 0 0 1px #FFFFFF, 0 0 0 4px #3699F1;}</style>
            

<meta charset="UTF-8">






    
        
            
        
    
        
            
        
    
        
            
        
    
        
            
        
    
        
    
        
    
        
            
                
                
<title>Atogepant for the Preventive Treatment of Migraine | New England Journal of Medicine</title>





                
            
        
    







    
        
            
        
    
        
            
        
    
        
            
                
                



                
            
        
    
        
            
        
    
        
    
        
    
        
            
        
    











    








    

    
    

    
    
    
    
        
            
                <link rel="stylesheet" type="text/css" href="/wro/1125813~article-metrics.css">
            
            
            
        
    

    
    
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_nejm_1-994b0160d1eb33dc79517ef0295aab1b.ico" type="image/x-icon">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_16-4aa032aa775940f725817b7ff42f0e2c.png" type="image/png" sizes="16x16">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_32-0a94fa44823476ffa0bb15bdb320fb34.png" type="image/png" sizes="32x32">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_152-d6c3522864a8e483996b7e9c132c901a.png" sizes="152x152">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_180-f2538afc53a365d4cd3f10ab73c56aad.png" sizes="180x180">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_167-8e888012bbdd31a00c3e54bc5b8ca5b6.png" sizes="167x167">
        
    

    
    
            <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-5b89b331018866a4a965.css" media="all">
        <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/print-5b89b331018866a4a965.css" media="print">
           <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css" media="all" id="article-style-sheet">
    
        <script src="https://ssl-cdn.janraincapture.com/widget_data/flow.js:7h8bznq6j7bvyvzqcrwvyp8dfb:en-US:20240514181256512029:standard" type="text/javascript"></script><script src="https://cssjs.nejm.org/akamai/capture:login" type="text/javascript"></script><script src="https://ssl-widget-cdn.rpxnow.com/translations/login/en-US" type="text/javascript"></script><script type="text/javascript" id="janrainAuthWidget" src="https://cssjs.nejm.org/akamai/mms-prod.js"></script><script nonce="9523aece44e40cec-GRU">
        try {
            document.documentElement.classList.add('js');
        } catch (e) {
        }
    </script>
     
    

















    
        
            
                
                
                
                    
                    <!-- TrustArc Scripts -->
<script async="async" src="https://consent.trustarc.com/notice?domain=nejm.com&amp;c=teconsent&amp;js=nj&amp;noticeType=bb&amp;gtm=1&amp;text=true&amp;pcookie" crossorigin="" id="truste_0.32623158716235556"></script>
<script src="https://consent.trustarc.com/autoblockasset/core.min.js?domain=nejm.com"></script>
<script src="https://consent.trustarc.com/autoblockoptout?domain=nejm.com"></script>
<!-- /TrustArc Scripts -->
<!-- BlueConic Scripts -->
<script src="https://bc.nejm.org/script.js"></script>
    <!-- /BlueConic Scripts -->
<!-- Printing Meta Tags -->
    <meta name="articleType" content="Original Article">
<meta name="Specialties" content="Clinical Medicine|Neurology/Neurosurgery">
<meta name="topics" content="Clinical Medicine General|Neurology/Neurosurgery General">
<meta name="articleCategory" content="Research"><script type="text/javascript">var mmsData = {"access":{"isFreeCountry":"n"},"ad":{"category":"article"},"imageChallenge":{"id":null},"article":{"doi":"10.1056/NEJMoa2035908","title":"Atogepant for the Preventive Treatment of Migraine","category":"Research","type":"Original Article","topics":"Clinical Medicine General|Neurology/Neurosurgery General","specialties":"Clinical Medicine|Neurology/Neurosurgery","seriesTitle":"","viewType":"Full","age":"2Years-1990","issueDate":"2021-08-19T00:00Z","isFree":"y","broadTopics":"","perspectiveTopics":"","granularTopics":"","methodologicalArea":"","isOnlineFirst":"n","isCurrentIssue":"n","metaTags":"\u003cmeta name\u003d\"articleType\" content\u003d\"Original Article\"/\u003e\n\u003cmeta name\u003d\"Specialties\" content\u003d\"Clinical Medicine|Neurology/Neurosurgery\"/\u003e\n\u003cmeta name\u003d\"topics\" content\u003d\"Clinical Medicine General|Neurology/Neurosurgery General\"/\u003e\n\u003cmeta name\u003d\"articleCategory\" content\u003d\"Research\"/\u003e"},"page":{"activity":"showFullText","url":"www.nejm.org/doi/full/10.1056/NEJMoa2035908","viewType":"desktop","journal":"NEJM"},"user":{"ucid":null,"audienceSegment":null,"specialtyGroupCode":null,"meterCountRemaining":null,"totalMeterCount":null},"object":{"type":"Visual Abstract","title":"Atogepant for the Preventive Treatment of Migraine","doi":"10.1056/NEJMdo006169","issueDate":"2021-08-19T00:00Z","age":"6Months-1990","isFree":"y","topics":"Clinical Medicine General|Neurology/Neurosurgery General","viewType":"Full","specialties":"Clinical Medicine|Neurology/Neurosurgery"}};</script>
    <script type="text/javascript">var mmsDataAdd = {"user":{"customerType":"null","accessInstitutionID":"null"}};</script>
    <!-- Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- placeholder id=null, description=Adobe-Target-Prehiding-Snippet --><!--
  Adobe Target - Prehiding Snippet
  v2.0.0
-->
<script nonce="9523aece44e40cec-GRU">
function tgtNoFlicker(e,n,t,o,i,c,l,r){function d(){return n.getElementsByTagName("head")[0]}function a(e,t){if(e){var o=n.getElementById(t);o&&e.removeChild(o)}}function f(e,o){!function(e,t,o){if(e){var i=n.createElement("style");i.id=t,i.innerHTML=o,e.appendChild(i)}}(d(),t,e),setTimeout(function(){a(d(),t)},o)}var m;n.location.href.indexOf(c)>-1?f(l,r):f(o,i),n.location.href.indexOf("mboxDisable")>-1?(a(d(),t),console.log("[TARGET] - Disabled, removing prehiding style")):(m=function(e){e&&(a(d(),t),console.log("[TARGET] - Blocked, removing prehiding style"))},fetch("//cdn.tt.omtrdc.net/cdn/target-vec.js",{method:"HEAD",mode:"no-cors"}).then(e=>m(!1)).catch(e=>m(!0)))}

tgtNoFlicker(window, document, 'at-body-style', 'div[data-location-name="Anonymous Module"], div[data-location-name="Anonymous Banner"], main > div.page-body > div > div > div > div.col-md-2-3.o-col.o-col--primary > div[class*="u-hide"], main > div.page-body > div > div > div > div.col-md-1-3.o-col.o-col--secondary > aside, header > h1#mainContent, a.m-article__link[href*="/10.1056/NEJMoa2116747"] > span.m-article__blurb > p, li.g-nejm-group__user-tool-secondary {opacity: 0 !important}', 3000);

tgtNoFlicker(window, document, 'at-mbox-style', '.N-ad-global-top-right, #N-ad-myNEJM-contextual-top, .N-ad-recentArticles, #N-ad-article-rightRail-1, #N-ad-siteWide-rightRail-1, #N-ad-imageChallenge-rightRail-2 {opacity: 0 !important}', 3000);


</script><!-- /Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- Launch Header Embed Code -->
    <script src="//assets.adobedtm.com/launch-ENcd6450fae3ae4870becbe6a2b01ab2e1.min.js" async="" type="ta-blocked" data-ta-blocked="1"></script>
    <!-- /Launch Header Embed Code -->

                    
                
            
        
    
        
            
                
                
                
                    
                    <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="New England Journal of Medicine"><meta name="dc.Title" content="Atogepant for the Preventive Treatment of Migraine"><meta name="dc.Creator" content="Jessica Ailani"><meta name="dc.Creator" content="Richard B. Lipton"><meta name="dc.Creator" content="Peter J. Goadsby"><meta name="dc.Creator" content="Hua Guo"><meta name="dc.Creator" content="Rosa Miceli"><meta name="dc.Creator" content="Lawrence Severt"><meta name="dc.Creator" content="Michelle Finnegan"><meta name="dc.Creator" content="Joel M. Trugman"><meta name="dc.Description" content="Atogepant is an oral, small-molecule, calcitonin gene–related peptide receptor antagonist that is being investigated for the preventive treatment of migraine.In a phase 3, double-blind trial, we ra..."><meta name="Description" content="Atogepant is an oral, small-molecule, calcitonin gene–related peptide receptor antagonist that is being investigated for the preventive treatment of migraine.In a phase 3, double-blind trial, we ra..."><meta name="dc.Publisher" content="Massachusetts Medical Society"><meta name="dc.Date" scheme="WTN8601" content="2021-08-19"><meta name="dc.Type" content="research-article"><meta name="dc.Format" content="text/HTML"><meta name="dc.Identifier" scheme="doi" content="10.1056/NEJMoa2035908"><meta name="dc.Identifier" scheme="publisher-id" content="NJ202108193850806"><meta name="dc.Language" content="EN"><meta name="dc.Coverage" content="world"><meta name="dc.Rights" content="Copyright © 2021 Massachusetts Medical Society. All rights reserved.">




<link rel="meta" type="application/atom+xml" href="https://doi.org/10.1056%2FNEJMoa2035908">
<link rel="meta" type="application/rdf+json" href="https://doi.org/10.1056%2FNEJMoa2035908">
<link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1056%2FNEJMoa2035908">


                    
                
            
        
    
        
            
                
                
                
                
                
            
        
    
        
            
                
                
                
                    
                    





<meta name="robots" content="noarchive">





    





    
    
        
        <meta name="twitter:title" content="Atogepant for the Preventive Treatment of Migraine | NEJM">
        <meta property="og:title" content="Atogepant for the Preventive Treatment of Migraine | NEJM">
    


    <meta property="og:type" content="article">


    
    
        <meta property="og:url" content="https://www.nejm.org/doi/full/10.1056/NEJMoa2035908">
    
    


    
    
        <meta property="og:image" content="https://www.nejm.org/cms/asset/2bb4f5ab-4ae7-47e5-8e14-9177e4a46c61/nejmoa2035908_f1.jpg">
        <meta name="twitter:image" content="https://www.nejm.org/cms/asset/2bb4f5ab-4ae7-47e5-8e14-9177e4a46c61/nejmoa2035908_f1.jpg">
    



    <meta property="og:site_name" content="The New England Journal of Medicine">


    
    
        
        <meta property="og:description" content="Atogepant is an oral, small-molecule, calcitonin gene–related peptide receptor antagonist
that is being investigated for the preventive treatment of migraine. In a phase 3,
double-blind trial, we r...">
        <meta name="twitter:description" content="Atogepant is an oral, small-molecule, calcitonin gene–related peptide receptor antagonist
that is being investigated for the preventive treatment of migraine. In a phase 3,
double-blind trial, we r...">
    


    
    
        <meta property="og:image:width" content="2640">
    


    
    
        <meta property="og:image:height" content="2647">
    


    <meta name="twitter:card" content="summary">


    <meta name="twitter:site" content="@NEJM">


<meta name="viewport" content="width=device-width,initial-scale=1"><meta name="publication_doi" content="10.1056/NEJMoa2035908">


    















                    
                
            
        
    
        
    
        
    
        
 <script src="https://consent.trustarc.com/asset/notice.js/v/v1.7-402" async="async" crossorigin="" importance="high" nonce="9523aece44e40cec-GRU"></script>           
                
                
                
                
                
            
        
    




<meta name="format-detection" content="telephone=no">

<meta http-equiv="X-UA-Compatible" content="IE=edge">
    




    
        
        
        <link rel="canonical" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2035908">
    
    







<meta name="pbContext" content=";requestedJournal:journal:nejm;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:doi\:10.1056/nejm_2021.385.issue-8;article:article:doi\:10.1056/NEJMoa2035908;wgroup:string:MMS NextGen Website Group;pageGroup:string:Publication Pages;subPage:string:Full Text;website:website:mms-site;journal:journal:nejms">
        <script id="altmetric-embed-js" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-288192a491f0ad9cc434f05ea175659426f5ab0cfd6befb3f3592f96bb90b0d1.js"></script><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-933-8e181dff8b36ea01dc4c.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-34-6ea546d794fb7a1cea52.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-743-ddd329e1530654ec0846.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-305-9eee37798fdfe5196307.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-388-bb098c62445f518c0b46.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-556-8e58ca05fb5497e541ef.css"><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/0-dfd243c732a07d3608f6.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/7-10d355ba95f7ec1fddf2.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/11-04bf2a0da30146b4a5d0.js"></script><style type="text/css" id="bc_async_1750342992110">div[id='bc_home_trend'] {opacity:0.0;filter:alpha(opacity=0);}
</style><script src="https://static.addtoany.com/menu/modules/core.pt5ow5lr.js" type="module"></script><style type="text/css">.a2a_hide{display:none}.a2a_logo_color{background-color:#0166ff}.a2a_menu,.a2a_menu *{-moz-box-sizing:content-box;-webkit-box-sizing:content-box;box-sizing:content-box;float:none;margin:0;padding:0;position:static;height:auto;width:auto}.a2a_menu{border-radius:6px;display:none;direction:ltr;background:#FFF;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;color:#000;line-height:12px;border:1px solid #CCC;vertical-align:baseline;overflow:hidden}.a2a_mini{min-width:200px;position:absolute;width:300px;z-index:9999997}.a2a_overlay{display:none;background:#616c7deb;backdrop-filter:blur(4px);-webkit-backdrop-filter:blur(4px);position:fixed;top:0;right:0;left:0;bottom:0;z-index:9999998;-webkit-tap-highlight-color:transparent;transition:opacity .14s,backdrop-filter .14s}.a2a_full{background:#FFF;border:1px solid #FFF;box-shadow:#2a2a2a1a 0 0 20px 10px;height:auto;height:calc(320px);top:15%;left:50%;margin-left:-320px;position:fixed;text-align:center;width:640px;z-index:9999999;transition:transform .14s,opacity .14s}.a2a_full_footer,.a2a_full_header,.a2a_full_services{border:0;margin:0;padding:12px;box-sizing:border-box}.a2a_full_header{padding-bottom:8px}.a2a_full_services{height:280px;overflow-y:scroll;padding:0 12px;-webkit-overflow-scrolling:touch}.a2a_full_services .a2a_i{display:inline-block;float:none;width:181px;width:calc(33.334% - 18px)}div.a2a_full_footer{font-size:12px;text-align:center;padding:8px 14px}div.a2a_full_footer a,div.a2a_full_footer a:visited{display:inline;font-size:12px;line-height:14px;padding:8px 14px}div.a2a_full_footer a:focus,div.a2a_full_footer a:hover{background:0 0;border:0;color:#0166FF}div.a2a_full_footer a span.a2a_s_a2a,div.a2a_full_footer a span.a2a_w_a2a{background-size:14px;border-radius:3px;display:inline-block;height:14px;line-height:14px;margin:0 3px 0 0;vertical-align:top;width:14px}.a2a_modal{height:0;left:50%;margin-left:-320px;position:fixed;text-align:center;top:15%;width:640px;z-index:9999999;transition:transform .14s,opacity .14s;-webkit-tap-highlight-color:transparent}.a2a_modal_body{background:0 0;border:0;font:24px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;position:relative;height:auto;width:auto}.a2a_thanks{color:#fff;height:auto;margin-top:20px;width:auto}.a2a_thanks>div:first-child{margin:0 0 40px 0}.a2a_thanks div *{height:inherit}#a2a_copy_link{background:#FFF;border:1px solid #FFF;cursor:pointer;margin-top:15%}label.a2a_s_link#a2a_copy_link_icon,label.a2a_w_link#a2a_copy_link_icon{background-size:48px;border-radius:0;display:inline-block;height:48px;left:0;line-height:48px;margin:0 3px 0 0;position:absolute;vertical-align:top;width:48px}#a2a_modal input#a2a_copy_link_text{background-color:transparent;border:0;color:#2A2A2A;cursor:pointer;font:inherit;height:48px;left:62px;max-width:initial;min-height:auto;padding:0;position:relative;width:564px;width:calc(100% - 76px)}#a2a_copy_link_copied{background-color:#0166ff;color:#fff;display:none;font:inherit;font-size:16px;margin-top:1px;padding:3px 8px}@media (forced-colors:active){.a2a_color_buttons a,.a2a_svg{forced-color-adjust:none}}@media (prefers-color-scheme:dark){.a2a_menu a,.a2a_menu a.a2a_i,.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more,i.a2a_i{border-color:#2a2a2a!important;color:#fff!important}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover,.a2a_menu_find_container{border-color:#444!important;background-color:#444!important}.a2a_menu:not(.a2a_thanks){background-color:#2a2a2a;border-color:#2a2a2a}.a2a_menu_find{color:#fff!important}.a2a_menu label.a2a_s_find svg{background-color:transparent!important}.a2a_menu label.a2a_s_find svg path{fill:#fff!important}.a2a_full{box-shadow:#00000066 0 0 20px 10px}.a2a_overlay{background-color:#373737eb}}@media print{.a2a_floating_style,.a2a_menu,.a2a_overlay{visibility:hidden}}@keyframes a2aFadeIn{from{opacity:0}to{opacity:1}}.a2a_starting{opacity:0}.a2a_starting.a2a_full,.a2a_starting.a2a_modal{transform:scale(.8)}@media (max-width:639px){.a2a_full{border-radius:0;top:15%;left:0;margin-left:auto;width:100%}.a2a_modal{left:0;margin-left:10px;width:calc(100% - 20px)}}@media (min-width:318px) and (max-width:437px){.a2a_full .a2a_full_services .a2a_i{width:calc(50% - 18px)}}@media (max-width:317px){.a2a_full .a2a_full_services .a2a_i{width:calc(100% - 18px)}}@media (max-height:436px){.a2a_full{bottom:40px;height:auto;top:40px}}@media (max-height:550px){.a2a_modal{top:30px}}@media (max-height:360px){.a2a_modal{top:20px}.a2a_thanks>div:first-child{margin-bottom:20px}}.a2a_menu a{color:#0166FF;text-decoration:none;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;line-height:14px;height:auto;width:auto;outline:0}.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more{color:#0166FF}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover{color:#2A2A2A;border-color:#EEE;border-style:solid;background-color:#EEE;text-decoration:none}.a2a_menu label.a2a_s_find{background-size:24px;height:24px;left:8px;pointer-events:auto;position:absolute;top:7px;width:24px}.a2a_menu label.a2a_s_find svg{background-color:#FFF}.a2a_menu label.a2a_s_find svg path{fill:#CCC}#a2a_menu_container{display:inline-block}.a2a_menu_find_container{border:1px solid #CCC;border-radius:6px;padding:2px 24px 2px 0;position:relative;text-align:left}.a2a_cols_container .a2a_col1{overflow-x:hidden;overflow-y:auto;-webkit-overflow-scrolling:touch}#a2a_modal input,#a2a_modal input[type=text],.a2a_menu input,.a2a_menu input[type=text]{display:block;background-image:none;box-shadow:none;line-height:100%;margin:0;outline:0;overflow:hidden;padding:0;-moz-box-shadow:none;-webkit-box-shadow:none;-webkit-appearance:none}#a2afeed_find_container input,#a2afeed_find_container input[type=text],#a2apage_find_container input,#a2apage_find_container input[type=text]{background-color:transparent;border:0;box-sizing:content-box;color:#2A2A2A;float:none;font:inherit;font-size:16px;height:28px;line-height:20px;left:38px;outline:0;margin:0;max-width:initial;min-height:initial;padding:2px 0;position:relative;width:99%}.a2a_clear{clear:both}.a2a_svg{background-repeat:no-repeat;display:block;overflow:hidden;height:32px;line-height:32px;padding:0;pointer-events:none;width:32px}.a2a_svg svg{background-repeat:no-repeat;background-position:50% 50%;border:none;display:block;left:0;margin:0 auto;overflow:hidden;padding:0;position:relative;top:0;width:auto;height:auto}a.a2a_i,i.a2a_i{display:block;float:left;border:1px solid #FFF;line-height:24px;padding:6px 8px;text-align:left;white-space:nowrap;overflow:hidden;text-overflow:ellipsis;width:132px}a.a2a_i span,a.a2a_more span{display:inline-block;overflow:hidden;vertical-align:top}a.a2a_i .a2a_svg{margin:0 6px 0 0}a.a2a_i .a2a_svg,a.a2a_more .a2a_svg{background-size:24px;height:24px;line-height:24px;width:24px}a.a2a_sss:hover{border-left:1px solid #CCC}a.a2a_more{border-bottom:1px solid #FFF;border-left:0;border-right:0;line-height:24px;margin:6px 0 0;padding:6px;-webkit-touch-callout:none}a.a2a_more span{height:24px;margin:0 6px 0 0}.a2a_kit .a2a_svg{background-repeat:repeat}.a2a_default_style a:empty,.a2a_flex_style a:empty,.a2a_floating_style a:empty,.a2a_overlay_style a:empty{display:none}.a2a_color_buttons a,.a2a_floating_style a{text-decoration:none}.a2a_default_style:not(.a2a_flex_style) a{float:left;line-height:16px;padding:0 2px}.a2a_default_style a:hover .a2a_svg,.a2a_floating_style a:hover .a2a_svg,.a2a_overlay_style a:hover .a2a_svg svg{opacity:.7}.a2a_overlay_style.a2a_default_style a:hover .a2a_svg{opacity:1}.a2a_default_style .a2a_count,.a2a_default_style .a2a_svg,.a2a_floating_style .a2a_svg,.a2a_menu .a2a_svg,.a2a_vertical_style .a2a_count,.a2a_vertical_style .a2a_svg{border-radius:4px}.a2a_default_style .a2a_counter img,.a2a_default_style .a2a_dd,.a2a_default_style .a2a_svg{float:left}.a2a_default_style .a2a_img_text{margin-right:4px}.a2a_default_style .a2a_divider{border-left:1px solid #000;display:inline;float:left;height:16px;line-height:16px;margin:0 5px}.a2a_kit a{cursor:pointer;transition:none}.a2a_floating_style{background-color:#fff;border-radius:6px;position:fixed;z-index:9999995}.a2a_overlay_style{z-index:2147483647}.a2a_floating_style,.a2a_overlay_style{animation:a2aFadeIn .2s ease-in;padding:4px}.a2a_vertical_style:not(.a2a_flex_style) a{clear:left;display:block;overflow:hidden;padding:4px}.a2a_floating_style.a2a_default_style{bottom:0}.a2a_floating_style.a2a_default_style a,.a2a_overlay_style.a2a_default_style a{padding:4px}.a2a_count{background-color:#fff;border:1px solid #ccc;box-sizing:border-box;color:#2a2a2a;display:block;float:left;font:12px Arial,Helvetica,sans-serif;height:16px;margin-left:4px;position:relative;text-align:center;width:50px}.a2a_count:after,.a2a_count:before{border:solid transparent;border-width:4px 4px 4px 0;content:"";height:0;left:0;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:50%;width:0}.a2a_count:before{border-right-color:#ccc}.a2a_count:after{border-right-color:#fff;margin-left:-3px}.a2a_count span{animation:a2aFadeIn .14s ease-in}.a2a_vertical_style .a2a_counter img{display:block}.a2a_vertical_style .a2a_count{float:none;margin-left:0;margin-top:6px}.a2a_vertical_style .a2a_count:after,.a2a_vertical_style .a2a_count:before{border:solid transparent;border-width:0 4px 4px 4px;content:"";height:0;left:50%;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:0;width:0}.a2a_vertical_style .a2a_count:before{border-bottom-color:#ccc}.a2a_vertical_style .a2a_count:after{border-bottom-color:#fff;margin-top:-3px}.a2a_color_buttons .a2a_count,.a2a_color_buttons .a2a_count:after,.a2a_color_buttons .a2a_count:before,.a2a_color_buttons.a2a_vertical_style .a2a_count:after,.a2a_color_buttons.a2a_vertical_style .a2a_count:before{background-color:transparent;border:none;color:#fff;float:none;width:auto}.a2a_color_buttons.a2a_vertical_style .a2a_count{margin-top:0}.a2a_flex_style{display:flex;align-items:flex-start;gap:0}.a2a_default_style.a2a_flex_style{left:0;right:0;width:100%}.a2a_vertical_style.a2a_flex_style{flex-direction:column;top:0;bottom:0}.a2a_flex_style a{display:flex;justify-content:center;flex:1;padding:4px}.a2a_flex_style.a2a_vertical_style a{flex-direction:column}.a2a_floating_style.a2a_color_buttons,.a2a_floating_style.a2a_flex_style{border-radius:0;padding:0}.a2a_floating_style.a2a_default_style.a2a_flex_style{bottom:0}.a2a_kit.a2a_flex_style .a2a_counter img,.a2a_kit.a2a_flex_style .a2a_dd,.a2a_kit.a2a_flex_style .a2a_svg{float:none}.a2a_nowrap{white-space:nowrap}.a2a_note{margin:0 auto;padding:9px;font-size:12px;text-align:center}.a2a_note .a2a_note_note{margin:0;color:#2A2A2A}.a2a_wide a{display:block;margin-top:3px;border-top:1px solid #EEE;text-align:center}.a2a_label{position:absolute!important;clip-path:polygon(0px 0px,0px 0px,0px 0px);-webkit-clip-path:polygon(0px 0px,0px 0px,0px 0px);overflow:hidden;height:1px;width:1px}.a2a_kit,.a2a_menu,.a2a_modal,.a2a_overlay{-ms-touch-action:manipulation;touch-action:manipulation;outline:0}.a2a_dd{-webkit-user-drag:none}.a2a_dd img{border:0}.a2a_button_facebook_like iframe{max-width:none}</style><link rel="preconnect" href="https://use.typekit.net"><meta http-equiv="P3P" content="CP=&quot;NOI DSP ADM OUR IND OTC&quot;"><link rel="stylesheet" href="https://quilt-cdn.janrain.com/HEAD/providers.css" type="text/css"><link id="altmetric-embed-css" rel="stylesheet" type="text/css" href="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed-59614f5c46b49b21eeef3bb28c4fb38d1e7069e8d014752fcb66e84942556802.css"></head>
    

    



    
        
        
        
            <body class="pb-ui website-mms-site loaded">
            






    
    
        





    
    
        
        
    
    
    







<input type="hidden" id="isRoMode" name="isRoMode" value="false">

        <div id="pb-page-content" data-ng-non-bindable="">
                
            <div data-pb-dropzone="main" data-pb-dropzone-name="Main">
                
                    
                        



        
        <header data-sticky="false" class="ng-header js_stickyAd"><a href="#mainContent" class="ng-skipToMainContent">Skip to main content</a><div class="ng-header_topAd"><div class="ng-header_topAd-content d-flex justify-content-center align-items-center">



        
        <div id="DTM_Position_Topbanner" class="ad">
 <!--emptycomment-->
</div>
</div></div><div class="ng-header_journal-navbar"><div class="ng-header_journal-navbar-content"><div class="container-fluid"><div class="row"><div class="ng-header_journal-navbar_left col-lg-8 col-sm-12 pr-lg-0 d-flex align-items-center"><div data-location="nejm_group_product_nav" class="ng-header_journalNavMenu">



        
        <nav data-location="nejm_group_product_nav" role="navigation" class="ng-journalNavMenu">
<ul class="ng-journalNavMenu_list">
<li class="ng-journalNavMenu_list-item"><a href="/" class="ng-journalNavMenu_mainLink active" aria-current="page" aria-label="The New England Journal of Medicine selected item"><span class="ng-journalNavMenu_mainLink-text d-lg-block d-none">The New England Journal of Medicine</span><span class="ng-journalNavMenu_mainLink-text d-lg-none d-block">NEJM</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://evidence.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Evidence</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://ai.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> AI</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://catalyst.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Catalyst</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://www.jwatch.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Journal Watch</span></a></li>
</ul>
</nav>

</div></div><div class="ng-header_journal-navbar_right col-lg-4 pl-lg-0 d-none d-xl-flex align-items-center justify-content-end"><div class="ng-header_loginBar d-xl-flex align-items-lg-center">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2035908" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div></div><div class="ng-header_instBanner d-none d-lg-block"></div><div class="ng-header_logoBar"><div class="container-fluid"><div class="row"><div data-location="logo" class="ng-header_logoBar_left col-lg-4 col-6 d-flex align-items-center justify-content-start"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-logo-166667e91992a5212bc723b03e45d39f.svg" alt="The New England Journal of Medicine homepage" width="366" height="58" class="ng-header_logo-image"></a></div><div class="ng-header_logoBar_right ng-header_navBar col-lg-8 col-sm-12 p-lg-0 align-items-center justify-content-end"><div class="ng-header_navBar-content"><div class="container-fluid"><div class="row"><div class="ng-header_instBanner-md col-12 d-block d-lg-none"></div><div class="ng-header_loginBar-md col-12 d-block d-xl-none">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2035908" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div><div class="ng-header_navBar_left col-lg-8 col-sm-12 d-flex align-items-center"><div class="ng-header_stickyLogo mr-32"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-small-logo-070df7a3f4d8cfa2e71c3c45bb4b172f.svg" alt="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-image"></a></div><div class="ng-header_mainMenu">









    
    
        <div data-widget-def="menuWidget" data-widget-id="97fb3983-db63-4b0b-97dd-d9bb7929fce1" data-location="main_nav">
        



        
        <nav class="ng-menu"><ul class="ng-menu_list ng-simple-menu"><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/toc/nejm/current" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">current issue</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/toc/nejm/current" class="ng-simple-menu_list-link">VIEW CURRENT ISSUE</a></li><li class="ng-simple-menu_list-item"><a href="/toc/nejm/recently-published" class="ng-simple-menu_list-link">BROWSE RECENTLY PUBLISHED</a></li><li class="ng-simple-menu_list-item"><a href="/loi/nejm" class="ng-simple-menu_list-link">BROWSE ALL ISSUES</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/medical-specialties" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">SPECIALTIES</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/browse/specialty/cardiology" class="ng-simple-menu_list-link">Cardiology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/clinical-medicine" class="ng-simple-menu_list-link">Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/endocrinology" class="ng-simple-menu_list-link">Endocrinology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/gastroenterology" class="ng-simple-menu_list-link">Gastroenterology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/hematology-oncology" class="ng-simple-menu_list-link">Hematology/Oncology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/infectious-disease" class="ng-simple-menu_list-link">Infectious Disease</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/nephrology" class="ng-simple-menu_list-link">Nephrology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/neurology-neurosurgery" class="ng-simple-menu_list-link">Neurology/Neurosurgery</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/obstetrics-gynecology" class="ng-simple-menu_list-link">Obstetrics/Gynecology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pediatrics" class="ng-simple-menu_list-link">Pediatrics</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pulmonary-critical-care" class="ng-simple-menu_list-link">Pulmonary/Critical Care</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/surgery" class="ng-simple-menu_list-link">Surgery</a></li><li class="ng-simple-menu_list-item"><a href="/medical-specialties" class="ng-simple-menu_list-link">View All Specialties</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/topics" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">TOPICS</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/ai-in-medicine" class="ng-simple-menu_list-link">AI in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/climate-change" class="ng-simple-menu_list-link">Climate Change</a></li><li class="ng-simple-menu_list-item"><a href="/coronavirus" class="ng-simple-menu_list-link">Coronavirus</a></li><li class="ng-simple-menu_list-item"><a href="/equity" class="ng-simple-menu_list-link">Efforts toward Equity</a></li><li class="ng-simple-menu_list-item"><a href="/firearm-injury-prevention" class="ng-simple-menu_list-link">Firearm Injury Prevention</a></li><li class="ng-simple-menu_list-item"><a href="/nam" class="ng-simple-menu_list-link">From the National Academy of Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/fundamentals-of-medical-ethics" class="ng-simple-menu_list-link">Fundamentals of Medical Ethics</a></li><li class="ng-simple-menu_list-item"><a href="/gray-matters" class="ng-simple-menu_list-link">Gray Matters</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/health-policy" class="ng-simple-menu_list-link">Health Policy</a></li><li class="ng-simple-menu_list-item"><a href="/medicine-and-society" class="ng-simple-menu_list-link">Medicine and Society</a></li><li class="ng-simple-menu_list-item"><a href="/nutrition-in-medicine" class="ng-simple-menu_list-link">Nutrition in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/outbreaks" class="ng-simple-menu_list-link">Outbreaks Center</a></li><li class="ng-simple-menu_list-item"><a href="/race-and-medicine" class="ng-simple-menu_list-link">Race and Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/recognizing-historical-injustices" class="ng-simple-menu_list-link">Recognizing Historical Injustices and the Journal</a></li><li class="ng-simple-menu_list-item"><a href="/tobacco-use-reduction" class="ng-simple-menu_list-link">Tobacco Use Reduction</a></li><li class="ng-simple-menu_list-item"><a href="/topics" class="ng-simple-menu_list-link">View All Topics</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/multimedia" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">MULTIMEDIA</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/rss-feed" class="ng-simple-menu_list-link">Podcasts</a></li><li class="ng-simple-menu_list-item"><a href="/double-take" class="ng-simple-menu_list-link">Double Takes</a></li><li class="ng-simple-menu_list-item"><a href="https://illustrated-glossary.nejm.org/" class="ng-simple-menu_list-link">Illustrated Glossary</a></li><li class="ng-simple-menu_list-item"><a href="/image-challenge" class="ng-simple-menu_list-link">Image Challenge</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/images-in-clinical-medicine" class="ng-simple-menu_list-link">Images in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/interactive-medical-case" class="ng-simple-menu_list-link">Interactive Medical Cases</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/research-summary" class="ng-simple-menu_list-link">Research Summaries</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia/quick-take-video" class="ng-simple-menu_list-link">Quick Takes</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/videos-in-clinical-medicine" class="ng-simple-menu_list-link">Videos in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia" class="ng-simple-menu_list-link">View All Multimedia</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/learning" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">LEARNING/CME</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/continuing-medical-education" class="ng-simple-menu_list-link">Weekly CME</a></li><li class="ng-simple-menu_list-item"><a href="/cme-ce/obesity" class="ng-simple-menu_list-link">Obesity CME/CE</a></li><li class="ng-simple-menu_list-item"><a href="/learning" class="ng-simple-menu_list-link">VIEW ALL LEARNING/CME</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item"><a href="/author-center/home" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">AUTHOR CENTER</span></a></li></ul></nav>

        </div>
    

</div><button aria-label="Search" class="ng-header_searchBtn searchBtnNav d-block ml-24"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button></div><div class="ng-header_loginBar ng-header_loginBar-sticky col-4">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2035908" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div><div class="ng-header_logoBar_right-lg col-lg-8 col-6 d-flex align-items-center justify-content-end d-xl-none"><button aria-label="Search" class="ng-header_searchBtn d-flex justify-content-end"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><div class="ng-header_openCloseBtns d-flex align-items-center justify-content-end"><button aria-label="Open" class="ng-header_openBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#burger"></use></svg></span></button><button aria-label="Close" class="ng-header_closeBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></button></div></div><div class="ng-header_quickSearch col-12"><div class="ng-header_quickSearch-content">



        
        <div class="ng-quick-search js-ng-quick-search"><form action="/search" method="get" class="ng-quick-search_form js-form"><div class="ng-quick-search_inputArea js-inputArea"><input type="search" name="q" placeholder="Enter keyword, author, title or citation" autocomplete="off" value="" required="required" class="ng-quick-search_allField ng-large-text-input js-allField js-allField-def-tmpl ui-autocomplete-input"><button type="submit" aria-label="Search Button" class="ng-quick-search_iconBtn d-xl-none d-block js-submitBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><ul id="ui-id-1" tabindex="0" class="ui-menu ui-widget ui-widget-content ui-autocomplete ui-front" style="display: none;"></ul></div><div class="ng-quick-search_btnsArea d-none d-xl-flex align-items-center justify-content-end"><a href="/search/advanced" class="ng-quick-search_advSearchLink ng-btn_link js-advancedSearchLink">Advanced Search</a><button type="submit" class="ng-quick-search_textBtn ng-btn_secondary ng-btn_iconRight js-submitBtn"><span class="ng-btn_text">SEARCH</span><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-right"></use></svg></span></button></div></form></div>
</div></div></div></div></div></header><div class="ng-header_overlay"></div><div class="ng-header_after">









    
    
        <div data-widget-def="literatumAd" data-widget-id="4931ddbd-d46e-4597-b4fd-92549e9847ca" id="ad-global-banner-FULLx64-1">
        



        
        



    

    

    
        
    



        </div>
    

</div>

                    
                        



        
        <div>









    
    
        <main data-widget-def="axelPublicationContent" data-widget-id="fcdb5261-d6a2-4a9c-81d5-3a3e2304e9c1" id="mainContent">
        



        
        <div class="article-tools__savePopup"><div class="ng-save"><input type="hidden" value="/action/getSavedTags" class="getKeywordsServiceUrl"><input type="hidden" value="/action/mmsSaveItemsService?itemType=article" class="saveServiceUrl"><input type="hidden" value="article" class="saveType"><input type="hidden" value="10.1056/NEJMoa2035908" class="inputDoi"><input type="hidden" value="J. Ailani and Others" class="inputAuthor"><input type="hidden" value="N Engl J Med 2021;385:695-706" class="inputCitation"><input type="hidden" value="08-18-2021" class="inputEPubDate"><input type="hidden" value="August 2021" class="inputCoverDate"><input type="hidden" value="Original Article" class="inputContentType"><input type="hidden" value="Atogepant for the Preventive Treatment of Migraine" class="inputArticleTitle"><input type="hidden" value="/browse/nejm-article-type/original-article" class="inputContentTypeUrl"><button type="button" id="saveArticleShowPopupBtn" aria-hidden="true" tabindex="-1" class="ng-save-btn ng-btn_secondary isLoggedOut">Save</button></div></div><div class="article-tools__articleAlertPopup"><div id="articleAlertModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="articleAlertModalTitle" class="ng-modal_title modal-title">Create an E-mail Alert for This Article</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><div class="ng-do-media_popup modal-lg"><div id="doPopup" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><link id="build-style-article" rel="stylesheet" type="text/css" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css"><article xmlns="http://www.w3.org/1999/xhtml" data-design="pill" data-has="right-rail" data-type="research-article" vocab="http://schema.org/" typeof="ScholarlyArticle" lang="en" dir="ltr"><header data-extent="frontmatter" data-location="header_article"><div class="core-container"><div data-article-access="free" data-article-access-type="free" class="meta-panel"><div class="meta-panel__left-content"><div class="meta-panel__type"><a href="/browse/nejm-article-type/original-article">Original Article</a></div></div><div class="meta-panel__right-content"><div class="meta-panel__share">









    
    
        <div data-widget-def="UX3share" data-widget-id="eee5f139-16f2-48f8-97ea-1b114367da16" data-location="share_tools_article">
        



        
        <!-- Go to https://www.addtoany.com/buttons/customize/ to customize your tools --><script type="text/javascript" defer="defer" src="https://static.addtoany.com/menu/page.js" nonce="9523aece44e40cec-GRU"></script><div class="share"><div class="share__block share__inline-links"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="d-flex list-unstyled a2a a2a_kit a2a_default_style mb-0 a2a_kit_size_32" style="line-height: 32px;"><li class="a2a_listitem_custom"><a role="link" title="Facebook" data-interactiontype="social" class="share__link a2a_button_facebook" target="_blank" rel="nofollow noopener" href="/#facebook"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-facebook"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="X (formerly Twitter)" data-interactiontype="social" class="share__link a2a_button_twitter" target="_blank" rel="nofollow noopener" href="/#twitter"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-twitter"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Linked In" data-interactiontype="social" class="share__link a2a_button_linkedin" target="_blank" rel="nofollow noopener" href="/#linkedin"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-linkedin"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Email" data-interactiontype="content_email_click" class="share__link a2a_button_email" target="_blank" rel="nofollow noopener" href="/#email"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-email"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Bluesky" data-interactiontype="social" class="share__link a2a_button_bluesky" target="_blank" rel="nofollow noopener" href="/#bluesky"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-bluesky"></use></svg></span></a></li></ul></div></div>

        </div>
    

</div></div></div><h1 property="name">Atogepant for the Preventive Treatment of Migraine</h1><div class="core-relations my-3"></div><div class="contributors"><span class="authors"><span class="heading">Authors</span>: <span role="list"><span property="author" typeof="Person" role="listitem"><span property="givenName">Jessica</span> <span property="familyName">Ailani</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Richard B.</span> <span property="familyName">Lipton</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Peter J.</span> <span property="familyName">Goadsby</span>, <span property="honorificSuffix">M.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0003-3260-5904" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0003-3260-5904</a></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Hua</span> <span property="familyName">Guo</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Rosa</span> <span property="familyName">Miceli</span>, <span property="honorificSuffix">B.S.N.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Lawrence</span> <span property="familyName">Severt</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Michelle</span> <span property="familyName">Finnegan</span>, <span property="honorificSuffix">M.P.H.</span></span>, and <span property="author" typeof="Person" role="listitem"><span property="givenName">Joel M.</span> <span property="familyName">Trugman</span>, <span property="honorificSuffix">M.D.</span></span>, for <span property="author" typeof="Person" role="listitem">the ADVANCE Study Group<sup><a href="#fn1" role="doc-noteref">*</a></sup></span></span></span><a href="#tab-contributors" class="to-authors-affiliations" data-id="article-authors-viewall">Author Info &amp; Affiliations</a></div><div class="core-self-citation"><div class="core-date-published">Published <span property="datePublished">August 18, 2021</span></div><div property="isPartOf" typeof="Periodical"><span property="name">N Engl J Med</span> 2021<span property="isPartOf" typeof="PublicationVolume">;<span property="volumeNumber">385</span></span>:<span property="pageStart">695</span>-<span property="pageEnd">706</span></div><div class="doi">DOI: 10.1056/NEJMoa2035908</div><div class="core-enumeration"><a href="/toc/nejm/385/8"><span property="isPartOf" typeof="PublicationVolume">VOL. <span property="volumeNumber">385</span></span> <span property="isPartOf" typeof="PublicationIssue">NO. <span property="issueNumber">8</span></span></a></div><div><a href="#tab-information">Copyright © 2021</a></div></div><div class="info-panel"><div class="info-panel__left-content"><div class="info-panel__metrics info-panel__item"></div></div><div data-location="tools_article" class="info-panel__right-content"><div class="info-panel__article_tools info-panel__item">



        
        <div data-permission="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DJessica%2BAilani%252C%2BRichard%2BB.%2BLipton%252C%2BPeter%2BJ.%2BGoadsby%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D385%26issueNum%3D8%26contentID%3D10.1056%252FNEJMoa2035908%26title%3DAtogepant%2Bfor%2Bthe%2BPreventive%2BTreatment%2Bof%2BMigraine%26publicationDate%3D08%252F19%252F2021" class="article-tools"><button id="articleToolsAlertBtn" data-url="/action/addCitationAlert?doi=10.1056%2FNEJMoa2035908" data-toggle="" data-target="#articleAlertModal" aria-label="Sign in or create account to add an article alert" data-interactiontype="article_alert" class="article-tools__citation btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to add an article alert"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#alerts"></use></svg></span></span></button><button id="articleToolsSaveBtn" data-toggle="modal" data-target="#saveArticle" aria-label="Sign in or create account to save this article" data-interactiontype="article_tools_save_click" class="article-tools__favorite btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to save this article"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#bookmarkFilled"></use></svg></span></span></button><a href="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DJessica%2BAilani%252C%2BRichard%2BB.%2BLipton%252C%2BPeter%2BJ.%2BGoadsby%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D385%26issueNum%3D8%26contentID%3D10.1056%252FNEJMoa2035908%26title%3DAtogepant%2Bfor%2Bthe%2BPreventive%2BTreatment%2Bof%2BMigraine%26publicationDate%3D08%252F19%252F2021" target="_blank" title="" data-toggle="tooltip" aria-label="Permissions" data-interactiontype="article_tools_permissions_click" class="article-tools__permissions btn btn--slim" data-original-title="Permissions"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#permissions"></use></svg></span></a><a href="/about-nejm/reprints" title="" data-toggle="tooltip" aria-label="Reprints" data-interactiontype="article_tools_reprints_click" class="article-tools__reprints btn btn--slim" data-original-title="Reprints"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#reprints"></use></svg></span></a><a href="/cms/asset/d1a10229-8f6f-465c-81e1-dcbd14473761/nejmoa2035908.pptx" target="_blank" title="" data-toggle="tooltip" aria-label="Download Slides" data-interactiontype="article_tools_slide_set_download" data-multimedia-type="Article Slideset" data-multimedia-filename="nejmoa2035908.pptx" class="article-tools__downloadSlides btn btn--slim" data-original-title="Download Slides"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#download"></use></svg></span></a><div class="article-tools__permissionsPopup"><div id="permissionsModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="permissionsModalTitle" class="ng-modal_title modal-title">Permissions</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body">For permission requests, please contact NEJM Reprints at <a href="mailto:reprints@nejm.org">reprints@nejm.org</a></div></div></div></div></div></div>
</div><div class="info-panel__citations info-panel__item"><a href="#tab-citations" class="btn btn--slim" aria-label="View Citations" data-toggle="tooltip" data-original-title="View Citations" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><i aria-hidden="true" class="icon-format_quote"></i></a></div><div class="info-panel__formats info-panel__item"><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2035908" class="btn btn--pdf btn--slim" aria-label="View PDF" data-toggle="tooltip" data-original-title="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2035908" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2035908.pdf"><i aria-hidden="true" class="icon-PDF"></i></a></div></div></div></div></header><div data-core-nav="header" data-extent="frontmatter"><div class="core-nav-wrapper core-container" aria-label="Article navigation"><div class="core-sections-menu"><button data-id="article-toolbar-showhide" aria-controls="article_sections_menu" aria-expanded="false" aria-label="Toggle section navigation menu" style="margin-top: 0px;"><i class="icon-list" aria-hidden="true"></i><span>Contents</span></button><nav id="article_sections_menu" aria-label="Contents" data-core-nav="article" style="margin-top: 0px;"><ul><li><a href="#summary-abstract" aria-current="true">Abstract</a></li><li><a href="#sec-1" aria-current="false">Methods</a></li><li><a href="#sec-2" aria-current="false">Results</a></li><li><a href="#sec-3" aria-current="false">Discussion</a></li><li class="bordered"><a href="#backnotes" aria-current="false">Notes</a></li><li><a href="#supplementary-materials" aria-current="false">Supplementary Material</a></li><li><a href="#bibliography" aria-current="false">References</a></li></ul></nav></div><nav id="article_collateral_menu"><ul data-core-nav="collateral" class="collateral-pill" style="margin-top: 0px;"><li><a href="#core-collateral-info" data-id="article-nav-menubar-info" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Information &amp; Authors"><i aria-hidden="true" class="icon-info"></i><span class="sr-only">Information &amp; Authors</span></a></li><li><a href="#core-collateral-metrics" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Metrics &amp; Citations"><i aria-hidden="true" class="icon-timeline"></i><span class="sr-only">Metrics &amp; Citations</span></a></li><li><a href="#core-collateral-fulltext-options" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="View Options"><i aria-hidden="true" class="icon-eye"></i><span class="sr-only">View Options</span></a></li><li><a href="#core-collateral-references" data-id="article-nav-menubar-references" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="References"><i aria-hidden="true" class="icon-references"></i><span class="sr-only">References</span></a></li><li><a href="#core-collateral-media" data-id="article-nav-menubar-media" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Media"><i aria-hidden="true" class="icon-photo"></i><span class="sr-only">Media</span></a></li><li><a href="#core-collateral-tables" data-id="article-nav-menubar-tables" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Tables"><i aria-hidden="true" class="icon-tables"></i><span class="sr-only">Tables</span></a></li><li><a href="#core-collateral-share" data-id="article-nav-menubar-share" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Share"><i aria-hidden="true" class="icon-share"></i><span class="sr-only">Share</span></a></li></ul></nav></div></div><div data-core-wrapper="content"><div id="abstracts" data-extent="frontmatter" data-location="articleTab_article"><div class="core-container"><section id="summary-abstract" property="abstract" typeof="Text" role="doc-abstract"><h2 property="name">Abstract</h2><section id="abs-sec-1"><h3>Background</h3><div role="paragraph">Atogepant is an oral, small-molecule, calcitonin gene–related peptide receptor antagonist that is being investigated for the preventive treatment of migraine.</div></section><section id="abs-sec-2"><h3>Methods</h3><div role="paragraph">In a phase 3, double-blind trial, we randomly assigned adults with 4 to 14 migraine days per month in a 1:1:1:1 ratio to receive a once-daily dose of oral atogepant (10 mg, 30 mg, or 60 mg) or placebo for 12 weeks. The primary end point was the change from baseline in the mean number of migraine days per month across the 12 weeks. Secondary end points included headache days per month, a reduction from baseline of at least 50% in the 3-month average of migraine days per month, quality of life, and scores on the Activity Impairment in Migraine–Diary (AIM-D).</div></section><section id="abs-sec-3"><h3>Results</h3><div role="paragraph">A total of 2270 participants were screened, 910 were enrolled, and 873 were included in the efficacy analysis; 214 were assigned to the 10-mg atogepant group, 223 to the 30-mg atogepant group, 222 to the 60-mg atogepant group, and 214 to the placebo group. The mean number of migraine days per month at baseline ranged from 7.5 to 7.9 in the four groups. The changes from baseline across 12 weeks were −3.7 days with 10-mg atogepant, −3.9 days with 30-mg atogepant, −4.2 days with 60-mg atogepant, and −2.5 days with placebo. The mean differences from placebo in the change from baseline were −1.2 days with 10-mg atogepant (95% confidence interval [CI], −1.8 to −0.6), −1.4 days with 30-mg atogepant (95% CI, −1.9 to −0.8), and −1.7 days with 60-mg atogepant (95% CI, −2.3 to −1.2) (P&lt;0.001 for all comparisons with placebo). Results for the secondary end points favored atogepant over placebo with the exceptions of the AIM-D Performance of Daily Activities score and the AIM-D Physical Impairment score for the 10-mg dose. The most common adverse events were constipation (6.9 to 7.7% across atogepant doses) and nausea (4.4 to 6.1% across atogepant doses). Serious adverse events included one case each of asthma and optic neuritis in the 10-mg atogepant group.</div></section><section id="abs-sec-4"><h3>Conclusions</h3><div role="paragraph">Oral atogepant once daily was effective in reducing the number of migraine days and headache days over a period of 12 weeks. Adverse events included constipation and nausea. Longer and larger trials are needed to determine the effect and safety of atogepant for migraine prevention. (Funded by Allergan; ADVANCE ClinicalTrials.gov number, <a href="http://clinicaltrials.gov/show/NCT03777059" target="_blank">NCT03777059</a>.)</div></section></section><div class="core-digital-object visual-abstract">
<div class="ng-page_separator pt-24"></div>
<div class="ng-do-media">
    <button data-toggle="modal" data-target="#doPopup" class="ng-do-media_btn" modal-size="lg"></button>
    <div data-ajaxurl="/do/10.1056/NEJMdo006169/full/?ajaxRequest=true" class="ng-do-media_item">
        <div class="ng-do-media_item-left">
            <a href="#" class="ng-do-media_item-img-link" data-interactiontype="multimedia_click" data-multimedia-type="Visual Abstract" data-multimedia-contentid="10.1056/NEJMdo006169" data-multimedia-filename="NEJMdo006169_600x400.jpg">
                <img src="/cms/asset/f302087f-34b1-42aa-a1dc-5e7e40dccc60/media/NEJMdo006169_300x200.jpg" class="ng-do-media_item-img">
                <span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#tooltip-visual"></use></svg></span>
            </a>
        </div>
        <div class="ng-do-media_item-right">
            <div class="ng-do-media_item-type">
                <a href="/browse/nejm-media-type/visual-abstract" class="ng-do-media_item-type-link">Visual Abstract</a>
            </div>
            <h6 class="ng-do-media_item-title">
                <a href="#" class="ng-do-media_item-title-link" data-interactiontype="multimedia_click" data-multimedia-type="Visual Abstract" data-multimedia-contentid="10.1056/NEJMdo006169" data-multimedia-filename="NEJMdo006169_600x400.jpg">Atogepant for the Preventive Treatment of Migraine</a>
            </h6>
        </div>
    </div>
</div>

</div></div></div><section id="bodymatter" data-extent="bodymatter" property="articleBody" typeof="Text" data-location="articleTab_article"><div class="core-container"><div role="paragraph">Migraine attacks may be frequent, disabling, or both. Preventive treatments are used to reduce the frequency and severity of attacks. Approved oral preventive medications include divalproex sodium, flunarizine, topiramate, propranolol, and timolol. Injectable treatments, such as monoclonal antibodies that target calcitonin gene–related peptide (CGRP) and onabotulinumtoxinA, are also used.<sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1 r2 r3" id="body-ref-r3-1" href-manipulated="true">1-3</a></sup> Other medications are used in the United States and elsewhere without regulatory approval.<sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1" id="body-ref-r1-2" href-manipulated="true" aria-label="Reference 1">1</a></sup></div><div role="paragraph"><a id="exam-tint-one-c"></a><a id="exam-tint-one-d"></a><span id="tint1" class="named-content" data-type="exam-tint" data-answer-ids="one-c one-d">CGRP appears to be involved in the pathophysiology of migraine, as evidenced by increased blood levels of CGRP during migraine attacks, the induction of migrainelike headaches by infusion of CGRP, and the effects of CGRP-targeted therapies in the treatment of migraine attacks and preventive treatment of migraine.<sup><a href="#core-r4" role="doc-biblioref" data-xml-rid="r4 r5 r6 r7 r8 r9 r10" id="body-ref-r10" href-manipulated="true">4-10</a></sup> Currently approved CGRP-targeted preventive treatments are monoclonal antibodies administered by injection that target the CGRP receptor or ligand. Oral CGRP receptor antagonists (gepants) are approved for the treatment of migraine attacks but not for preventive treatment of migraine.</span></div><div role="paragraph"><a id="exam-tint-one-a"></a><a id="exam-tint-one-b"></a><span id="tint2" class="named-content" data-type="exam-tint" data-answer-ids="one-a one-b">Atogepant is an orally available, small-molecule CGRP receptor antagonist with an elimination half-life of approximately 11 hours; maximum plasma concentrations are reached by 1 to 2 hours.</span><sup><a href="#core-r11" role="doc-biblioref" data-xml-rid="r11" id="body-ref-r11-1" href-manipulated="true" aria-label="Reference 11">11</a></sup> The efficacy of atogepant in reducing migraine days was shown in a phase 2–3 dose-ranging trial involving 834 participants.<sup><a href="#core-r12" role="doc-biblioref" data-xml-rid="r12" id="body-ref-r12-1" href-manipulated="true" aria-label="Reference 12">12</a></sup> The current phase 3 trial (ADVANCE) examines the efficacy and safety of atogepant administered once daily at a dose of 10 mg, 30 mg, or 60 mg as compared with placebo for the prevention of migraine in participants with episodic migraine.</div><section id="sec-1" data-type="methods"><h2>Methods</h2><section id="sec-1-1"><h3>Trial Design</h3><div role="paragraph">This was a multicenter, double-blind, parallel-group, randomized, placebo-controlled trial conducted from December 14, 2018, to June 19, 2020, in the United States. A total of 128 sites enrolled at least one participant. Participants were randomly assigned in a 1:1:1:1 ratio to receive a once-daily dose of atogepant (10 mg, 30 mg, or 60 mg) or placebo. Randomization was stratified according to the participants’ previous exposure to an oral migraine-prevention medication with efficacy shown in trials, including approved and investigative treatments such as antiepileptic agents, tricyclic antidepressants, beta-blockers, calcium-channel blockers, angiotensin-receptor blockers or angiotensin-converting–enzyme inhibitors, and serotonin–norepinephrine reuptake inhibitors.<sup><a href="#core-r3" role="doc-biblioref" data-xml-rid="r3 r13 r14 r15" id="body-ref-r15" href-manipulated="true">3,13–15</a></sup> An automated interactive Web-response system was used to generate the stratified randomization sequence. Each site was dynamically assigned entire blocks on the basis of strata, and the atogepant dose or placebo was assigned sequentially within a block.</div><div role="paragraph">The trial included a 4-week screening and baseline period, a 12-week double-blind treatment period, and a 4-week safety follow-up period. There were eight scheduled clinic visits. After screening (visit 1) and randomization (visit 2), participants returned to the clinic for five visits during the double-blind treatment period, at week 2 (visit 3), week 4 (visit 4), week 6 (visit 5), week 8 (visit 6), and week 12 (visit 7). The final visit occurred at week 16 (visit 8), 4 weeks after the end of the treatment period. Owing to the coronavirus disease 2019 pandemic, the protocol was amended to allow remote visits for up to 8 weeks without an in-person visit; safety laboratory assessments were required every 8 weeks, at a minimum. Trial visit 8 was conducted remotely for all participants after the protocol amendment, including the following safety assessments: urine pregnancy tests, Columbia–Suicide Severity Rating Scale (C-SSRS), adverse events, and concomitant medications. Investigators were allowed to conduct an in-person follow-up visit at their discretion if there were safety concerns. The <a href="#ap1">protocol</a> is available with the full text of this article at NEJM.org.</div><div role="paragraph">All participating sites obtained approval from a local or central institutional review board. Participants provided written informed consent before enrollment in the trial. The sponsor, Allergan (before acquisition by AbbVie), developed the trial protocol in collaboration with external consultants, provided atogepant and placebo, collected and analyzed the data, and funded the trial. The authors vouch for the completeness and accuracy of the data, the comprehensive reporting of adverse events, and the fidelity of the trial to the protocol. A medical writer who was employed by the sponsor assisted the authors in preparing the article. Confidentiality agreements were in place between the external authors and the sponsor. The authors agreed to delay submission for 30 days to allow the sponsor the right to address any factual inaccuracies regarding the data or to request the redaction of information that the sponsor deemed to be confidential or proprietary.</div></section><section id="sec-1-2"><h3>Trial Participants</h3><div role="paragraph">Adults 18 to 80 years of age with 4 to 14 migraine days per month in the 3 months before visit 1 and 4 to 14 migraine days during the 28-day baseline period according to an electronic diary were deemed to be appropriate candidates for preventive therapy and were allowed to enroll. Participants had to have at least a 1-year history of migraine with or without aura, diagnosed as specified in the International Classification of Headache Disorders, 3rd edition (ICHD-3), and with migraine onset before 50 years of age.<sup><a href="#core-r16" role="doc-biblioref" data-xml-rid="r16" id="body-ref-r16-1" href-manipulated="true" aria-label="Reference 16">16</a></sup></div><div role="paragraph">Participants were excluded if they had a current diagnosis of chronic migraine, new daily persistent headache, trigeminal autonomic cephalalgia (e.g., cluster headache), or painful cranial neuropathy as defined by the ICHD-3 or if they averaged 15 or more headache days per month across the 3 months before visit 1 or during the 28-day baseline period.<sup><a href="#core-r16" role="doc-biblioref" data-xml-rid="r16" id="body-ref-r16-2" href-manipulated="true" aria-label="Reference 16">16</a></sup> Participants were also excluded if they had had an inadequate response to more than four oral medications prescribed for the preventive treatment of migraine, two of which needed to have different mechanisms of action. Participants who used opioids or barbiturates on more than 2 days per month, triptans or ergots on 10 or more days per month, or simple analgesic agents (e.g., aspirin, nonsteroidal antiinflammatory drugs [NSAIDs], or acetaminophen) on 15 or more days per month in the 3 months before visit 1 or during the 28-day baseline period were also excluded. Use of barbiturates was also not permitted 30 days before screening and throughout the duration of the trial. Any female participant who was pregnant, planning to become pregnant, or lactating was excluded; participants had to use a medically acceptable and effective method of birth control during the trial.</div></section><section id="sec-1-3"><h3>Trial Treatment</h3><div role="paragraph">Participants were instructed to take three tablets of the assigned atogepant or placebo orally at approximately the same time once daily for 12 weeks. The tablets were provided in identical blister cards: participants in the atogepant groups received one tablet of atogepant at a dose of 10 mg, 30 mg, or 60 mg and two placebo tablets, and participants in the placebo group received three placebo tablets. Sites assessed adherence to the trial regimen at every clinic visit; blister cards were collected, and participants were interviewed to assess adherence. Details on the composition of the atogepant tablets and placebo tablets are provided in Table S1 in the <a href="#ap2">Supplementary Appendix</a>, available at NEJM.org. Participants were allowed to take treatments for migraine attacks, which included triptans, ergot derivatives, opioids, analgesics, NSAIDs, and antiemetic agents. Participants were not allowed to take any preventive treatments for migraine 30 days before visit 1 and throughout the trial.</div></section><section id="sec-1-4"><h3>Trial Assessments</h3><div role="paragraph">Participants, site personnel, and trial sponsor personnel were unaware of the trial-group assignments. Efficacy assessments, including baseline values, were recorded by the participant in an electronic diary at home or through an electronic tablet at the trial site during trial visits. The electronic diaries had daily reminder alarms set to repeat if data were not entered. Data were allowed to be entered within a 24-hour recall window and closed every evening at 11:59 p.m., with the entry window for the following day opening at midnight. Headache duration, headache clinical features (pain severity, unilateral location, and aggravated by or causing avoidance of routine physical activity), non–headache-associated symptoms (nausea or vomiting, photophobia, phonophobia, and aura), and use of medication for the treatment of migraine attacks were recorded.</div><div role="paragraph">Data from additional health outcome measures were collected. The Activity Impairment in Migraine–Diary (AIM-D) is an 11-item daily diary measure that assesses the effect of migraine on two domains: Performance of Daily Activities (7 items) and Physical Impairment (4 items).<sup><a href="#core-r17" role="doc-biblioref" data-xml-rid="r17" id="body-ref-r17" href-manipulated="true" aria-label="Reference 17">17</a></sup> The AIM-D domain scores range from 0 to 100, with higher scores indicating greater effect of migraine and with reductions from baseline in scores indicating improvement. The Migraine-Specific Quality of Life Questionnaire (MSQ), version 2.1, is a 14-item questionnaire that measures health-related quality-of-life impairments attributed to migraine and includes three domains: Role Function–Restrictive, Role Function–Preventive, and Emotional Function.<sup><a href="#core-r18" role="doc-biblioref" data-xml-rid="r18" id="body-ref-r18" href-manipulated="true" aria-label="Reference 18">18</a></sup> Scores on the Role Function–Restrictive domain range from 0 to 100, with higher scores indicating a lesser effect of migraine on daily activities.</div></section><section id="sec-1-5"><h3>End Points</h3><div role="paragraph">The primary efficacy end point was the change from baseline in the mean number of migraine days per month across the 12-week treatment period (the average of month 1, month 2, and month 3) as recorded in the diaries or reported during visits. Secondary efficacy end points, which were tested in hierarchical order, were the change from baseline in the mean number of headache days per month across the 12-week treatment period; the change from baseline in the mean number of days of use of medication for the treatment of migraine attacks across the 12-week treatment period; a reduction from baseline of at least 50% in the 3-month average of migraine days per month; the change from baseline in the score on the Role Function–Restrictive domain of the MSQ, version 2.1, at week 12; the change from baseline in the mean monthly score on the Performance of Daily Activities domain of the AIM-D across the 12-week treatment period; and the change from baseline in the mean monthly score on the Physical Impairment domain of the AIM-D across the 12-week treatment period. An exploratory analysis of the time course of efficacy for atogepant according to 4-week intervals, which was based on the least-squares mean change from baseline in the number of migraine days per month over the 12-week treatment period, was also conducted. The full list of additional prespecified end points is available in the trial protocol.</div></section><section id="sec-1-6"><h3>Safety</h3><div role="paragraph">Adverse events were reported by the participants throughout the trial and at each 4-week follow-up visit. Information on adverse events was collected and documented during each clinic visit. Participants could also report adverse events by telephone call between visits. During clinic visits, participants were queried in a general, nondirected manner. The severity and causality of each adverse event were determined by the investigator, who was unaware of the trial-group assignments. Serious adverse events were defined as those that resulted in death, were considered to be life-threatening, resulted in hospitalization or prolongation of existing hospitalization, resulted in persistent disability or incapacity, or were congenital anomalies or birth defects. In addition, clinical laboratory tests, vital signs, electrocardiograms, and the score on the C-SSRS were evaluated. Because of the potential hepatotoxicity of previous gepants,<sup><a href="#core-r19" role="doc-biblioref" data-xml-rid="r19 r20" id="body-ref-r20" href-manipulated="true">19,20</a></sup> elevated levels of alanine aminotransferase (ALT) or aspartate aminotransferase (AST) that were at least 3 times the upper limit of the normal range, as well as cases that met the criteria for potential Hy’s law, were evaluated as prespecified adverse events of special interest and were reviewed by an independent panel of liver experts who were unaware of the trial-group assignments.</div></section><section id="sec-1-7"><h3>Statistical Analysis</h3><div role="paragraph">We calculated that a sample size of 218 participants per trial group would provide at least 98% power to detect a difference of 1.5 migraine days between each of the three atogepant doses (assumed to be equally effective for power analysis) and placebo for the primary efficacy end point, assuming a common standard deviation of 3.5 days. The sample size was selected to provide at least 89% power for the first three secondary end points for each dose. Assumptions of between-group differences and standard deviations were based on the results of other trials of preventive migraine treatment involving participants with episodic migraine.<sup><a href="#core-r12" role="doc-biblioref" data-xml-rid="r12 r21 r22 r23 r24" id="body-ref-r24" href-manipulated="true">12,21–24</a></sup> The power calculation considered multiplicity adjustment in a conservative way with the use of an alpha level of 0.05÷3 for each dose. All efficacy analyses used the modified intention-to-treat population, defined as all randomly assigned participants who received at least one dose of atogepant or placebo, had a baseline period of electronic-diary data that could be evaluated, and had at least one postbaseline 4-week period (weeks 1 to 4, 5 to 8, or 9 to 12) of electronic-diary data that could be evaluated during the double-blind treatment period. The statistical analysis plan is available with the protocol at NEJM.org.</div><div role="paragraph">To test the three primary hypotheses that each dose of atogepant is superior to placebo for the primary efficacy end point, the change from baseline to each postbaseline month in migraine days per month was analyzed with the use of a general linear model for repeated measures with model terms including trial group, visit, previous exposure (yes or no) to a migraine-prevention medication with proven efficacy, interaction between trial group and visit, baseline score, and interaction between baseline score and visit. An unstructured covariance matrix was used to model the covariance of within-participant repeated measurements. Pairwise contrasts in the general linear model for repeated measures were used to make the pairwise comparisons of each atogepant dose with placebo for the primary end point.</div><div role="paragraph">For repeated measures that used the general linear model, the model variables were estimated with the use of restricted likelihood estimation that incorporated all observed data. Data after the discontinuation of atogepant or placebo were assumed to be missing at random and handled by a general linear model for repeated measures with an unstructured covariance matrix — that is, information from the observed outcomes was used by means of the within-participant correlation structure to provide information about the unobserved outcomes, but missing data were not explicitly imputed.<sup><a href="#core-r25" role="doc-biblioref" data-xml-rid="r25" id="body-ref-r25" href-manipulated="true" aria-label="Reference 25">25</a></sup> Sensitivity analyses that imputed missing data under a missing-not-at-random assumption were conducted to assess the robustness of the primary analysis for possible violation of the missing-at-random assumption. Robust regression was conducted to evaluate possible violation of the normality assumption. (Details on sensitivity analyses and robust regression are provided in Table S2.)</div><div role="paragraph">The six secondary end points were analyzed in the same manner as that used to analyze the primary end point. For the score on the Role Function–Restrictive domain of the MSQ, the analysis focused on the pairwise contrasts of each dose group with placebo at week 12, the primary analysis time point for this end point. The occurrence of a reduction from baseline of at least 50% in the 3-month average of migraine days per month (one of the six prespecified secondary end points) was assessed for each participant. A logistic-regression model was used to analyze the data for participants who had such a reduction across the 12-week treatment period. This model assumes a binary distribution for the response and uses a logit link. The analysis model included trial group, previous exposure (yes or no) to a migraine-prevention medication with proven efficacy, and migraine days per month at baseline.</div><div role="paragraph">The overall type I error rate for multiple comparisons across the three atogepant doses and the primary and secondary efficacy end points was controlled at the 0.05 level with the use of a graphical approach with a weighted Bonferroni test procedure.<sup><a href="#core-r26" role="doc-biblioref" data-xml-rid="r26" id="body-ref-r26" href-manipulated="true" aria-label="Reference 26">26</a></sup> The three doses were treated equally. The initial allocation of the overall significance level to the three primary hypotheses was one third of the overall significance level for each dose, and no initial alpha level was allocated to the hypotheses for secondary end points. Within each individual dose, testing started from the primary end point, and the secondary end points were then tested in a prespecified order. Further details on the testing hierarchy and alpha propagation among hypotheses across doses are provided in Figure S1. Safety analyses involved all randomly assigned participants who received at least one dose of atogepant or placebo. Statistical analyses were performed with the use of SAS software, version 9.4 (SAS Institute).</div></section></section><section id="sec-2" data-type="results"><h2>Results</h2><section id="sec-2-1"><h3>Participants</h3><div role="paragraph">A total of 2270 persons were screened, and 910 participants were randomly assigned to a trial group: 222 to the 10-mg atogepant group, 230 to the 30-mg atogepant group, 235 to the 60-mg atogepant group, and 223 to the placebo group. The safety population included 902 participants, and the modified intention-to-treat population that was used in the efficacy analyses included 873 participants (<a href="#f1">Figure 1</a>). Of the 910 participants who underwent randomization, 805 (88.5%) completed the trial, with a similar frequency of completion across trial groups. The most common reason for discontinuation was withdrawal of consent by the participant (in 35 of 910 participants [3.8%]).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 1</div><nav><a href="#f1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2035908_f1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f1" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2035908_f1.jpg"><img src="/cms/10.1056/NEJMoa2035908/asset/2bb4f5ab-4ae7-47e5-8e14-9177e4a46c61/assets/images/large/nejmoa2035908_f1.jpg" height="2647" width="2640" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Screening, Randomization, and Follow-up.</div><div class="notes"><div role="doc-footnote">Participants could have more than one reason for exclusion before randomization. The safety population included all randomly assigned participants who received at least one dose of atogepant or placebo. The modified intention-to-treat population included all randomly assigned participants who received at least one dose of atogepant or placebo, had a baseline period of electronic-diary data that could be evaluated, and had at least one postbaseline 4-week period of electronic-diary data during the double-blind treatment period that could be evaluated.</div></div></figcaption></figure></div><div role="paragraph">The demographic and clinical characteristics of the participants at baseline were similar across trial groups in the safety population (<a href="#t1">Table 1</a>) and in the modified intention-to-treat population (Table S3). The participants were between 18 and 73 years of age, with a mean age of 41.6 years. Most of the participants were female (88.8%), and the majority were White (83.4%); the mean body-mass index (the weight in kilograms divided by the square of the height in meters) at baseline was 30.6. Overall, the participants reported an average of 7.4 migraine days per month in the past 3 months. At screening, 99.3% of the participants reported current use of medication for the treatment of migraine attacks, and 70.3% reported having previously used a preventive treatment for migraine.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 1</div><nav><a href="#t1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2035908_t1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t1" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2035908_t1.jpg"><img src="/cms/10.1056/NEJMoa2035908/asset/1a251a34-95ba-4831-b494-d41cf3175af1/assets/images/large/nejmoa2035908_t1.jpg" height="1654" width="1999" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders">Placebo<br>(N=222)</th><th class="txxx-borders">Atogepant, 10 mg<br>(N=221)</th><th class="txxx-borders">Atogepant, 30 mg<br>(N=228)</th><th class="txxx-borders">Atogepant, 60 mg<br>(N=231)</th><th class="txxr-borders">Total<br>(N=902)</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading">Age — yr</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Mean</td><td class="xxxx-borders">40.3±12.8</td><td class="xxxx-borders">41.4±12.0</td><td class="xxxx-borders">42.1±11.7</td><td class="xxxx-borders">42.5±12.4</td><td class="xxxr-borders">41.6±12.2</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Range</td><td class="xxxx-borders shading">18–69</td><td class="xxxx-borders shading">18–73</td><td class="xxxx-borders shading">19–70</td><td class="xxxx-borders shading">18–72</td><td class="xxxr-borders shading">18–73</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Sex — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Male</td><td class="xxxx-borders shading">24 (10.8)</td><td class="xxxx-borders shading">21 (9.5)</td><td class="xxxx-borders shading">24 (10.5)</td><td class="xxxx-borders shading">32 (13.9)</td><td class="xxxr-borders shading">101 (11.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Female</td><td class="xxxx-borders">198 (89.2)</td><td class="xxxx-borders">200 (90.5)</td><td class="xxxx-borders">204 (89.5)</td><td class="xxxx-borders">199 (86.1)</td><td class="xxxr-borders">801 (88.8)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Race or ethnic group — no. (%)<a href="#t1fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">White</td><td class="xxxx-borders">194 (87.4)</td><td class="xxxx-borders">181 (81.9)</td><td class="xxxx-borders">185 (81.1)</td><td class="xxxx-borders">192 (83.1)</td><td class="xxxr-borders">752 (83.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Black</td><td class="xxxx-borders shading">24 (10.8)</td><td class="xxxx-borders shading">34 (15.4)</td><td class="xxxx-borders shading">38 (16.7)</td><td class="xxxx-borders shading">28 (12.1)</td><td class="xxxr-borders shading">124 (13.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Asian</td><td class="xxxx-borders">2 (0.9)</td><td class="xxxx-borders">2 (0.9)</td><td class="xxxx-borders">1 (0.4)</td><td class="xxxx-borders">7 (3.0)</td><td class="xxxr-borders">12 (1.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">American Indian or Alaska Native</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (0.5)</td><td class="xxxx-borders shading">1 (0.4)</td><td class="xxxx-borders shading">1 (0.4)</td><td class="xxxr-borders shading">3 (0.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Multiple<a href="#t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">2 (0.9)</td><td class="xxxx-borders">3 (1.4)</td><td class="xxxx-borders">3 (1.3)</td><td class="xxxx-borders">2 (0.9)</td><td class="xxxr-borders">10 (1.1)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Body-mass index</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Mean</td><td class="xxxx-borders">30.8±8.7</td><td class="xxxx-borders">30.3±7.6</td><td class="xxxx-borders">31.1±7.6</td><td class="xxxx-borders">29.9±7.3</td><td class="xxxr-borders">30.6±7.8</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Range</td><td class="xxxx-borders shading">16.9–82.0</td><td class="xxxx-borders shading">16.4–60.3</td><td class="xxxx-borders shading">17.1–66.2</td><td class="xxxx-borders shading">16.3–57.3</td><td class="xxxr-borders shading">16.3–82.0</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">No. of migraine days per month in past 3 mo</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Mean</td><td class="xxxx-borders shading">7.7±2.6</td><td class="xxxx-borders shading">7.2±2.5</td><td class="xxxx-borders shading">7.3±2.4</td><td class="xxxx-borders shading">7.3±2.4</td><td class="xxxr-borders shading">7.4±2.5</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Range</td><td class="xxxx-borders">4–14</td><td class="xxxx-borders">4–14</td><td class="xxxx-borders">4–14</td><td class="xxxx-borders">4–13</td><td class="xxxr-borders">4–14</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">No. of headache days per month in past 3 mo</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Mean</td><td class="xxxx-borders">9.5±2.8</td><td class="xxxx-borders">9.3±2.7</td><td class="xxxx-borders">9.2±2.7</td><td class="xxxx-borders">9.1±2.7</td><td class="xxxr-borders">9.3±2.7</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12 shading" data-xml-align="left">Range</td><td class="xbxx-borders shading">4–14</td><td class="xbxx-borders shading">4–14</td><td class="xbxx-borders shading">4–14</td><td class="xbxx-borders shading">4–14</td><td class="xbxr-borders shading">4–14</td></tr></tbody></table></div><figcaption><div class="caption">Demographic and Clinical Characteristics of the Participants at Baseline (Safety Population).<a href="#t1fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t1fn1" role="paragraph">Plus–minus values are means ±SD. The safety population included all randomly assigned participants who received at least one dose of atogepant or placebo. Percentages may not total 100 because of rounding.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t1fn2" role="paragraph">Race and ethnic group were reported by the participants. One participant in the 60-mg atogepant group had missing data.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t1fn3" role="paragraph">Shown are participants who reported multiple races or ethnic groups.</div></div></div></figcaption></figure></div></section><section id="sec-2-2"><h3>Efficacy End Points</h3><div role="paragraph">The mean number of migraine days per month at baseline ranged from 7.5 to 7.9 in the four trial groups (<a href="#t2">Table 2</a>). <a id="exam-tint-two-a"></a><a id="exam-tint-two-b"></a><a id="exam-tint-two-c"></a><a id="exam-tint-two-d"></a><span id="tint3" class="named-content" data-type="exam-tint" data-answer-ids="two-a two-b two-c two-d">The mean change from baseline in the mean number of migraine days per month across the 12-week treatment period (the primary efficacy end point) was −3.7 with 10-mg atogepant, −3.9 with 30-mg atogepant, −4.2 with 60-mg atogepant, and −2.5 with placebo. The mean difference from placebo was −1.2 days with 10-mg atogepant (95% confidence interval [CI], −1.8 to −0.6), −1.4 days with 30-mg atogepant (95% CI, −1.9 to −0.8), and −1.7 days with 60-mg atogepant (95% CI, −2.3 to −1.2) (P&lt;0.001 for all comparisons with placebo).</span> The results of sensitivity analyses were consistent with those of the primary analysis (Table S4).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 2</div><nav><a href="#t2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2035908_t2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t2" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2035908_t2.jpg"><img src="/cms/10.1056/NEJMoa2035908/asset/2d32edcb-d879-4d83-a5de-3822603bcdfd/assets/images/large/nejmoa2035908_t2.jpg" height="3062" width="1999" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">End Point</th><th class="txxx-borders">Placebo<br>(N=214)</th><th class="txxx-borders">Atogepant, 10 mg<br>(N=214)</th><th class="txxx-borders">Atogepant, 30 mg <br>(N=223)</th><th class="txxr-borders">Atogepant, 60 mg<br>(N=222)</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Primary efficacy end point</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Migraine days per month</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Mean no. of days at baseline</td><td class="xxxx-borders shading">7.5±2.4</td><td class="xxxx-borders shading">7.5±2.5</td><td class="xxxx-borders shading">7.9±2.3</td><td class="xxxr-borders shading">7.8±2.3</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Change from baseline in mean no. of days across the 12-wk treatment period</td><td class="xxxx-borders">−2.5±0.2</td><td class="xxxx-borders">−3.7±0.2</td><td class="xxxx-borders">−3.9±0.2</td><td class="xxxr-borders">−4.2±0.2</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Difference vs. placebo (95% CI)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">−1.2 (−1.8 to −0.6)</td><td class="xxxx-borders shading">−1.4 (−1.9 to −0.8)</td><td class="xxxr-borders shading">−1.7 (−2.3 to −1.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Adjusted P value</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&lt;0.001</td><td class="xxxx-borders">&lt;0.001</td><td class="xxxr-borders">&lt;0.001</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Secondary efficacy end points</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Headache days per month</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Mean no. of days at baseline</td><td class="xxxx-borders shading">8.4±2.6</td><td class="xxxx-borders shading">8.4±2.8</td><td class="xxxx-borders shading">8.8±2.6</td><td class="xxxr-borders shading">9.0±2.6</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Change from baseline in mean no. of days across the 12-wk treatment period</td><td class="xxxx-borders">−2.5±0.2</td><td class="xxxx-borders">−3.9±0.2</td><td class="xxxx-borders">−4.0±0.2</td><td class="xxxr-borders">−4.2±0.2</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Difference vs. placebo (95% CI)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">−1.4 (−2.0 to −0.8)</td><td class="xxxx-borders shading">−1.5 (−2.1 to −0.9)</td><td class="xxxr-borders shading">−1.7 (−2.3 to −1.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Adjusted P value</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&lt;0.001</td><td class="xxxx-borders">&lt;0.001</td><td class="xxxr-borders">&lt;0.001</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Days of use of medication for the treatment of migraine attacks per month</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Mean no. of days at baseline</td><td class="xxxx-borders">6.5±3.1</td><td class="xxxx-borders">6.6±3.0</td><td class="xxxx-borders">6.7±3.0</td><td class="xxxr-borders">6.9±3.2</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Change from baseline in mean no. of days across the 12-wk treatment period</td><td class="xxxx-borders shading">−2.4±0.2</td><td class="xxxx-borders shading">−3.7±0.2</td><td class="xxxx-borders shading">−3.7±0.2</td><td class="xxxr-borders shading">−3.9±0.2</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Difference vs. placebo (95% CI)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">−1.3 (−1.8 to −0.8)</td><td class="xxxx-borders">−1.3 (−1.8 to −0.8)</td><td class="xxxr-borders">−1.5 (−2.0 to −1.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Adjusted P value</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&lt;0.001</td><td class="xxxx-borders shading">&lt;0.001</td><td class="xxxr-borders shading">&lt;0.001</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">≥50% Reduction in 3-mo average of mean no. of migraine days per month — no. (%)</td><td class="xxxx-borders">62 (29.0)</td><td class="xxxx-borders">119 (55.6)</td><td class="xxxx-borders">131 (58.7)</td><td class="xxxr-borders">135 (60.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Odds ratio vs. placebo (95% CI)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">3.1 (2.0 to 4.6)</td><td class="xxxx-borders shading">3.5 (2.4 to 5.3)</td><td class="xxxr-borders shading">3.8 (2.6 to 5.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Adjusted P value</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&lt;0.001</td><td class="xxxx-borders">&lt;0.001</td><td class="xxxr-borders">&lt;0.001</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Score on Role Function–Restrictive domain of MSQ<a href="#t2fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Mean monthly score at baseline</td><td class="xxxx-borders">46.8±19.7</td><td class="xxxx-borders">44.9±21.4</td><td class="xxxx-borders">44.0±19.6</td><td class="xxxr-borders">46.8±20.4</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Change from baseline in score at wk 12</td><td class="xxxx-borders shading">20.4±1.6</td><td class="xxxx-borders shading">30.3±1.6</td><td class="xxxx-borders shading">30.5±1.6</td><td class="xxxr-borders shading">31.2±1.6</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Difference vs. placebo (95% CI)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">9.9 (5.4 to 14.4)</td><td class="xxxx-borders">10.1 (5.7 to 14.5)</td><td class="xxxr-borders">10.8 (6.4 to 15.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Adjusted P value</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&lt;0.001</td><td class="xxxx-borders shading">&lt;0.001</td><td class="xxxr-borders shading">&lt;0.001</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Score on Performance of Daily Activities domain of AIM-D<a href="#t2fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Mean monthly score at baseline</td><td class="xxxx-borders shading">15.2±8.3</td><td class="xxxx-borders shading">15.5±8.9</td><td class="xxxx-borders shading">16.9±8.0</td><td class="xxxr-borders shading">15.9±8.3</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Change from baseline in mean monthly score across the 12-wk treatment period</td><td class="xxxx-borders">−6.1±0.5</td><td class="xxxx-borders">−7.3±0.5</td><td class="xxxx-borders">−8.6±0.5</td><td class="xxxr-borders">−9.4±0.5</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Difference vs. placebo (95% CI)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">−1.2 (−2.6 to 0.2)</td><td class="xxxx-borders shading">−2.5 (−3.9 to −1.2)</td><td class="xxxr-borders shading">−3.3 (−4.7 to −2.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Adjusted P value</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">0.09</td><td class="xxxx-borders">&lt;0.001</td><td class="xxxr-borders">&lt;0.001</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Score on Physical Impairment domain of AIM-D<a href="#t2fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Mean monthly score at baseline</td><td class="xxxx-borders">11.2±8.1</td><td class="xxxx-borders">11.7±8.5</td><td class="xxxx-borders">13.0±8.0</td><td class="xxxr-borders">11.6±7.9</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Change from baseline in mean monthly score across the 12-wk treatment period</td><td class="xxxx-borders shading">−4.0±0.4</td><td class="xxxx-borders shading">−5.1±0.4</td><td class="xxxx-borders shading">−6.0±0.4</td><td class="xxxr-borders shading">−6.5±0.4</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Difference vs. placebo (95% CI)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">−1.1 (−2.3 to 0.1)</td><td class="xxxx-borders">−2.0 (−3.2 to −0.8)</td><td class="xxxr-borders">−2.5 (−3.7 to −1.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12 shading" data-xml-align="left">Adjusted P value</td><td class="xbxx-borders shading">&nbsp;</td><td class="xbxx-borders shading">0.09</td><td class="xbxx-borders shading">0.002</td><td class="xbxr-borders shading">&lt;0.001</td></tr></tbody></table></div><figcaption><div class="caption">Primary and Secondary Efficacy End Points, According to Trial Group (Modified Intention-to-Treat Population).<a href="#t2fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t2fn1" role="paragraph">Plus–minus values are means ±SD for baseline values and least-squares means ±SE for changes from baseline. Differences from placebo are least-squares mean differences. The confidence intervals (CIs) were not adjusted for multiple comparisons. P values were adjusted for multiple comparisons and are from the test between the atogepant dose group and placebo as described in Figure 1 in the <a href="#ap2">Supplementary Appendix</a> and in the statistical analysis plan. The analyses were performed with the use of observed cases only, without imputation of missing values. The modified intention-to-treat population included all randomly assigned participants who received at least one dose of atogepant or placebo, had a baseline period of electronic-diary data that could be evaluated, and had at least one postbaseline 4-week period of electronic-diary data during the double-blind treatment period that could be evaluated.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t2fn2" role="paragraph">The Migraine-Specific Quality of Life Questionnaire (MSQ), version 2.1, is a 14-item questionnaire that measures health-related quality-of-life impairments attributed to migraine in the past 4 weeks, divided into three domains. Scores on the Role Function–Restrictive domain range from 0 to 100, with higher scores indicating a lesser effect of migraine on daily activities; the minimally important difference is 3.2 points.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t2fn3" role="paragraph">The Activity Impairment in Migraine–Diary (AIM-D) is an 11-item daily diary measure that assesses the effect of migraine on two domains: Performance of Daily Activities (7 items) and Physical Impairment (4 items). The AIM-D domain scores range from 0 to 100, with higher scores indicating greater effect of migraine.</div></div></div></figcaption></figure></div><div role="paragraph">Results for the secondary efficacy end points are shown in <a href="#t2">Table 2</a>. The mean change from baseline in the mean number of headache days per month across the 12-week treatment period was −3.9 for 10-mg atogepant, −4.0 for 30-mg atogepant, −4.2 for 60-mg atogepant, and −2.5 for placebo (P&lt;0.001 for all comparisons with placebo). The mean change from baseline in the mean number of days of use of medication for the treatment of migraine attacks per month across the 12-week treatment period was −3.7 for 10-mg atogepant, −3.7 for 30-mg atogepant, −3.9 for 60-mg atogepant, and −2.4 for placebo (P&lt;0.001 for all comparisons with placebo). A reduction of 50% or more in the 3-month average of migraine days per month occurred in 55.6% of the participants in the 10-mg atogepant group, 58.7% of those in the 30-mg atogepant group, 60.8% of those in the 60-mg atogepant group, and 29.0% of those in the placebo group (P&lt;0.001 for all comparisons with placebo). Significant differences between all three atogepant doses and placebo were observed for the secondary end points, with the exception of the score on the Performance of Daily Activities domain of the AIM-D (difference, −1.2; 95% CI, −2.6 to 0.2) and the score on the Physical Impairment domain of the AIM-D (difference, −1.1; 95% CI, −2.3 to 0.1) for 10-mg atogepant. Additional end-point measures are shown in <a href="#t2">Table 2</a>.</div><div role="paragraph">In a prespecified exploratory analysis, the atogepant groups visually separated from the placebo group in a graphical representation of the mean change from baseline in the number of migraine days for each 4-week interval during the treatment period, but no definite conclusions can be drawn from these data (<a href="#f2">Figure 2</a>). Differences from placebo were observed within the first 4 weeks after the initiation of treatment and were maintained during each subsequent 4-week interval.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 2</div><nav><a href="#f2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2035908_f2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f2" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2035908_f2.jpg"><img src="/cms/10.1056/NEJMoa2035908/asset/ff30f63f-0710-4fc3-b304-6a06c0dcc963/assets/images/large/nejmoa2035908_f2.jpg" height="1312" width="2231" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Time Course of Efficacy (Modified Intention-to-Treat Population).</div><div class="notes"><div role="doc-footnote">Shown is the least-squares mean change from baseline in migraine days per month. 𝙸 bars indicate standard errors.</div></div></figcaption></figure></div></section><section id="sec-2-3"><h3>Safety</h3><div role="paragraph">Adverse events that began or worsened on or after the date of the first dose of atogepant or placebo until 30 days after the last dose were reported in 486 of 902 participants (53.9%); the frequency of events was similar between the placebo and atogepant groups, and no dose relationship was observed (<a href="#t3">Table 3</a>). <a id="exam-tint-three-a"></a><a id="exam-tint-three-b"></a><a id="exam-tint-three-c"></a><a id="exam-tint-three-d"></a><span id="tint4" class="named-content" data-type="exam-tint" data-answer-ids="three-a three-b three-c three-d">In the atogepant groups, the most commonly reported adverse events were constipation (6.9 to 7.7% across doses), nausea (4.4 to 6.1% across doses), and upper respiratory tract infection (3.9 to 5.7% across doses).</span> In the placebo group, the most common adverse events were upper respiratory tract infection (4.5%), urinary tract infection (3.6%), and nasopharyngitis (3.6%). The incidence of constipation was higher in the atogepant groups (6.9 to 7.7%) than in the placebo group (0.5%); no cases were reported as serious as determined by the investigators and defined as serious in the protocol. Serious adverse events were reported in 2 participants who received 10-mg atogepant (asthma attack and optic neuritis in 1 participant each) and in 2 participants who received placebo (gastric ulcer hemorrhage in 1 participant and postsurgical laryngospasm with hypoxic brain injury in 1 participant) (Table S5). The incidence of discontinuation due to adverse events was similar across the trial groups.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 3</div><nav><a href="#t3" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2035908_t3.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t3" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2035908_t3.jpg"><img src="/cms/10.1056/NEJMoa2035908/asset/ec286228-5c77-457e-8691-aa225ccf8f09/assets/images/large/nejmoa2035908_t3.jpg" height="1864" width="1711" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Adverse Event</th><th class="txxx-borders">Placebo<br>(N=222)</th><th class="txxx-borders">Atogepant, 10 mg<br>(N=221)</th><th class="txxx-borders">Atogepant, 30 mg<br>(N=228)</th><th class="txxr-borders">Atogepant, 60 mg<br>(N=231)</th></tr><tr class="head3" data-type="row head3"><td class="xxlx-borders">&nbsp;</td><th class="xxxr-borders" colspan="4"><span>number of participants (percent)</span></th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Any adverse event</td><td class="xxxx-borders shading">126 (56.8)</td><td class="xxxx-borders shading">117 (52.9)</td><td class="xxxx-borders shading">119 (52.2)</td><td class="xxxr-borders shading">124 (53.7)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Adverse events reported in ≥2% of participants in any trial group<a href="#t3fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Constipation</td><td class="xxxx-borders shading">1 (0.5)</td><td class="xxxx-borders shading">17 (7.7)</td><td class="xxxx-borders shading">16 (7.0)</td><td class="xxxr-borders shading">16 (6.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Upper respiratory tract infection</td><td class="xxxx-borders">10 (4.5)</td><td class="xxxx-borders">9 (4.1)</td><td class="xxxx-borders">13 (5.7)</td><td class="xxxr-borders">9 (3.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Nausea</td><td class="xxxx-borders shading">4 (1.8)</td><td class="xxxx-borders shading">11 (5.0)</td><td class="xxxx-borders shading">10 (4.4)</td><td class="xxxr-borders shading">14 (6.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Urinary tract infection</td><td class="xxxx-borders">8 (3.6)</td><td class="xxxx-borders">3 (1.4)</td><td class="xxxx-borders">9 (3.9)</td><td class="xxxr-borders">9 (3.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Nasopharyngitis</td><td class="xxxx-borders shading">8 (3.6)</td><td class="xxxx-borders shading">4 (1.8)</td><td class="xxxx-borders shading">8 (3.5)</td><td class="xxxr-borders shading">8 (3.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Fatigue</td><td class="xxxx-borders">4 (1.8)</td><td class="xxxx-borders">3 (1.4)</td><td class="xxxx-borders">7 (3.1)</td><td class="xxxr-borders">9 (3.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Somnolence</td><td class="xxxx-borders shading">2 (0.9)</td><td class="xxxx-borders shading">7 (3.2)</td><td class="xxxx-borders shading">4 (1.8)</td><td class="xxxr-borders shading">4 (1.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Increased blood creatine kinase level</td><td class="xxxx-borders">2 (0.9)</td><td class="xxxx-borders">5 (2.3)</td><td class="xxxx-borders">2 (0.9)</td><td class="xxxr-borders">7 (3.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Sinusitis</td><td class="xxxx-borders shading">3 (1.4)</td><td class="xxxx-borders shading">4 (1.8)</td><td class="xxxx-borders shading">3 (1.3)</td><td class="xxxr-borders shading">5 (2.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Gastroenteritis</td><td class="xxxx-borders">4 (1.8)</td><td class="xxxx-borders">2 (0.9)</td><td class="xxxx-borders">5 (2.2)</td><td class="xxxr-borders">3 (1.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Increased alanine aminotransferase level</td><td class="xxxx-borders shading">6 (2.7)</td><td class="xxxx-borders shading">3 (1.4)</td><td class="xxxx-borders shading">2 (0.9)</td><td class="xxxr-borders shading">2 (0.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Influenza</td><td class="xxxx-borders">2 (0.9)</td><td class="xxxx-borders">3 (1.4)</td><td class="xxxx-borders">2 (0.9)</td><td class="xxxr-borders">5 (2.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Sinus congestion</td><td class="xxxx-borders shading">5 (2.3)</td><td class="xxxx-borders shading">1 (0.5)</td><td class="xxxx-borders shading">2 (0.9)</td><td class="xxxr-borders shading">4 (1.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Increased aspartate aminotransferase level</td><td class="xxxx-borders">6 (2.7)</td><td class="xxxx-borders">2 (0.9)</td><td class="xxxx-borders">2 (0.9)</td><td class="xxxr-borders">1 (0.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Anxiety</td><td class="xxxx-borders shading">2 (0.9)</td><td class="xxxx-borders shading">2 (0.9)</td><td class="xxxx-borders shading">1 (0.4)</td><td class="xxxr-borders shading">5 (2.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Adverse event related to atogepant or placebo<a href="#t3fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">20 (9.0)</td><td class="xxxx-borders">51 (23.1)</td><td class="xxxx-borders">34 (14.9)</td><td class="xxxr-borders">45 (19.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Serious adverse event</td><td class="xxxx-borders shading">2 (0.9)</td><td class="xxxx-borders shading">2 (0.9)</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Serious adverse event related to atogepant or placebo<a href="#t3fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">0</td><td class="xxxx-borders">1 (0.5)</td><td class="xxxx-borders">0</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Death</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging02" data-xml-align="left">Adverse event leading to discontinuation of atogepant or placebo</td><td class="xbxx-borders">6 (2.7)</td><td class="xbxx-borders">9 (4.1)</td><td class="xbxx-borders">4 (1.8)</td><td class="xbxr-borders">6 (2.6)</td></tr></tbody></table></div><figcaption><div class="caption">Adverse Events, According to Trial Group (Safety Population).<a href="#t3fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t3fn1" role="paragraph">Participants were counted only once within each category.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t3fn2" role="paragraph">Adverse events are listed in decreasing order of the frequency reported in the overall population.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t3fn3" role="paragraph">The relatedness of adverse events to atogepant or placebo was determined by the investigator.</div></div></div></figcaption></figure></div><div role="paragraph">Postbaseline ALT and AST values were assessed at various cutoff points from 1 to 20 times the upper limit of the normal range (Table S6). Two participants in the 10-mg atogepant group, two participants in the 30-mg atogepant group, one participant in the 60-mg atogepant group, and four participants in the placebo group had elevated ALT or AST levels that were at least 3 times the upper limit of the normal range (Table S7). No serious cases of liver disease were reported, and no case met the criteria for potential Hy’s law.<sup><a href="#core-r27" role="doc-biblioref" data-xml-rid="r27" id="body-ref-r27" href-manipulated="true" aria-label="Reference 27">27</a></sup></div></section></section><section id="sec-3" data-type="discussion"><h2>Discussion</h2><div role="paragraph"><span id="tint5" class="named-content" data-type="exam-tint" data-answer-ids="two-a two-b two-c two-d">Oral atogepant at doses of 10 mg, 30 mg, and 60 mg once daily resulted in significantly greater reductions in the number of migraine days than did placebo in this 12-week trial. For the primary end point, atogepant was associated with a reduction of 3.7 to 4.2 days in the mean number of migraine days per month, as compared with a 2.5-day reduction with placebo.</span> For the secondary end points, significant differences between all three doses of atogepant and placebo occurred across the 12-week treatment period, with the exception of the scores on the Performance of Daily Activity domain and the Physical Impairment domain of the AIM-D for the 10-mg dose. These results extend those of a previous phase 2–3 trial.<sup><a href="#core-r12" role="doc-biblioref" data-xml-rid="r12" id="body-ref-r12-3" href-manipulated="true" aria-label="Reference 12">12</a></sup></div><div role="paragraph">The percentage of participants with a reduction of at least 50% in the 3-month average of the mean number of migraine days per month has been recommended as an alternative primary end point in controlled trials of preventive treatment.<sup><a href="#core-r28" role="doc-biblioref" data-xml-rid="r28" id="body-ref-r28" href-manipulated="true" aria-label="Reference 28">28</a></sup> In our trial, the percentage of participants who met this criterion ranged from 55.6% for the 10-mg dose to 60.8% for the 60-mg dose of atogepant, as compared with 29.0% for placebo.</div><div role="paragraph">Adverse events were reported by 52.2 to 53.7% of the participants across atogepant doses and by 56.8% of those who received placebo. Constipation, the most commonly reported adverse event, was observed in 6.9 to 7.7% of the participants across atogepant doses and in 0.5% of those who received placebo. Previous studies have indicated an association between CGRP receptor blockade and a decrease in gastrointestinal motility.<sup><a href="#core-r29" role="doc-biblioref" data-xml-rid="r29 r30" id="body-ref-r30" href-manipulated="true">29,30</a></sup> Although no serious cases of constipation were reported in this trial, continued monitoring and evaluation for this adverse event in clinical practice will be appropriate. Two participants in the 10-mg atogepant group, two participants in the 30-mg atogepant group, one participant in the 60-mg atogepant group, and four participants in the placebo group had elevated ALT or AST levels that were at least 3 times the upper limit of the normal range.</div><div role="paragraph">Other CGRP-targeted therapies are available for the preventive treatment of migraine. CGRP-targeted monoclonal antibodies, administered parenterally, reach peak plasma concentrations in 5 to 7 days after subcutaneous injection and immediately after a 30-minute intravenous infusion and have half-lives of 21 to 27 days.<sup><a href="#core-r31" role="doc-biblioref" data-xml-rid="r31 r32" id="body-ref-r32" href-manipulated="true">31,32</a></sup> The longer half-lives of monoclonal antibodies make monthly or quarterly injections feasible, with the drug being largely eliminated within approximately 105 to 135 days. Atogepant is administered orally, reaching maximum plasma concentrations by 1 to 2 hours, with a half-life of approximately 11 hours.<sup><a href="#core-r11" role="doc-biblioref" data-xml-rid="r11" id="body-ref-r11-2" href-manipulated="true" aria-label="Reference 11">11</a></sup> The shorter half-life of atogepant indicates that daily dosing, as was used in the current trial, is needed and that the drug is largely eliminated within approximately 2 days.</div><div role="paragraph">This trial included participants with 4 to 14 migraine days per month and excluded participants with 15 or more headache days per month, so the results cannot be generalized to the latter group. The trial also excluded participants with clinically significant coexisting conditions, participants taking triptans or ergots on 10 or more days per month, and participants who did not have a response to more than four preventive treatments; trials and real-world studies that include these patients are needed. The safety of atogepant in pregnant women was not evaluated in this trial. The 12-week treatment duration is not adequate to assess the long-term safety and side effects of atogepant. The findings of a 52-week safety trial (<a href="http://clinicaltrials.gov/show/NCT03939312" target="_blank">NCT03939312</a>) will be reported separately; these findings were consistent with the data reported here, and no new safety concerns have been identified.</div><div role="paragraph">In our trial, atogepant once daily was effective for reducing the number of migraine days and headache days in the preventive treatment of migraine over 12 weeks. Adverse events included constipation, nausea, and upper respiratory tract infection. Longer and larger trials are needed to determine the effect and safety of atogepant for migraine prevention.</div></section>



        
        
</div></section><section id="backmatter" data-extent="backmatter" data-location="articleTab_article"><div class="core-container"><section id="backnotes" data-location="notes_article"><h2>Notes</h2><div data-type="published/updated" role="paragraph">This article was updated on August 24, 2021, at NEJM.org.</div><div data-type="data-sharing" role="paragraph">A <a href="#ap4">data sharing statement</a> provided by the authors is available with the full text of this article at NEJM.org.</div><div role="paragraph">Supported by Allergan (before acquisition by AbbVie).</div><div role="paragraph"><a href="#ap3">Disclosure forms</a> provided by the authors are available with the full text of this article at NEJM.org.</div><div role="paragraph">We thank all the trial participants and investigators for their participation in this trial, and Amy Kuang, Ph.D. (full-time employee of AbbVie), for medical writing support.</div></section><section id="supplementary-materials" class="core-supplementary-materials"><h2>Supplementary Material</h2><div role="list"><div id="ap1" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Protocol</span> <span class="core-filename">(nejmoa2035908_protocol.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2035908/suppl_file/nejmoa2035908_protocol.pdf" download="nejmoa2035908_protocol.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2035908_protocol.pdf" data-doi="10.1056/NEJMoa2035908">Download</a></li><li>4.63 MB</li></ul></div></div><div id="ap2" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Supplementary Appendix</span> <span class="core-filename">(nejmoa2035908_appendix.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2035908/suppl_file/nejmoa2035908_appendix.pdf" download="nejmoa2035908_appendix.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2035908_appendix.pdf" data-doi="10.1056/NEJMoa2035908">Download</a></li><li>334.50 KB</li></ul></div></div><div id="ap3" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Disclosure Forms</span> <span class="core-filename">(nejmoa2035908_disclosures.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2035908/suppl_file/nejmoa2035908_disclosures.pdf" download="nejmoa2035908_disclosures.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2035908_disclosures.pdf" data-doi="10.1056/NEJMoa2035908">Download</a></li><li>543.33 KB</li></ul></div></div><div id="ap4" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Data Sharing Statement</span> <span class="core-filename">(nejmoa2035908_data-sharing.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2035908/suppl_file/nejmoa2035908_data-sharing.pdf" download="nejmoa2035908_data-sharing.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2035908_data-sharing.pdf" data-doi="10.1056/NEJMoa2035908">Download</a></li><li>72.79 KB</li></ul></div></div></div></section><section id="bibliography" class="core-reference-list" role="doc-bibliography" data-location="references_article"><h2>References</h2><div role="list" data-method="clamp" id="collapsible-text"><div role="listitem" data-has="label"><div class="label">1.</div><div id="r1" class="citations"><div class="citation"><div class="citation-content">American Headache Society. The American Headache Society position statement on integrating new migraine treatments into clinical practice. <em>Headache</em> 2019;59:1-18.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r1" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/head.13456" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30536394/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000454118200001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+American+Headache+Society+position+statement+on+integrating+new+migraine+treatments+into+clinical+practice.&amp;publication_year=2019&amp;journal=Headache&amp;pages=1-18&amp;doi=10.1111%2Fhead.13456&amp;pmid=30536394" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r1" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r3-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] and onabotulinumtoxinA, are also used. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r1-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] and elsewhere without regulatory approval. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="r2" class="citations"><div class="citation"><div class="citation-content">Loder E, Burch R, Rizzoli P. The 2012 AHS/AAN guidelines for prevention of episodic migraine: a summary and comparison with other recent clinical practice guidelines. <em>Headache</em> 2012;52:930-945.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r3-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/j.1526-4610.2012.02185.x" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22671714/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000304800600002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+2012+AHS%2FAAN+guidelines+for+prevention+of+episodic+migraine%3A+a+summary+and+comparison+with+other+recent+clinical+practice+guidelines.&amp;publication_year=2012&amp;journal=Headache&amp;pages=930-945&amp;doi=10.1111%2Fj.1526-4610.2012.02185.x&amp;pmid=22671714" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="r3" class="citations"><div class="citation"><div class="citation-content">Evers S, Afra J, Frese A, et al. EFNS guideline on the drug treatment of migraine — revised report of an EFNS task force. <em>Eur J Neurol</em> 2009;16:968-981.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r3" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/j.1468-1331.2009.02748.x" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19708964/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000268791500005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=EFNS+guideline+on+the+drug+treatment+of+migraine+%E2%80%94+revised+report+of+an+EFNS+task+force.&amp;publication_year=2009&amp;journal=Eur+J+Neurol&amp;pages=968-981&amp;doi=10.1111%2Fj.1468-1331.2009.02748.x&amp;pmid=19708964" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r3" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r3-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] and onabotulinumtoxinA, are also used. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r15" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] reuptake inhibitors. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="r4" class="citations"><div class="citation"><div class="citation-content">Croop R, Lipton RB, Kudrow D, et al. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. <em>Lancet</em> 2021;397:51-60.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(20)32544-7" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33338437/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000607268300026" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Oral+rimegepant+for+preventive+treatment+of+migraine%3A+a+phase+2%2F3%2C+randomised%2C+double-blind%2C+placebo-controlled+trial.&amp;publication_year=2021&amp;journal=Lancet&amp;pages=51-60&amp;doi=10.1016%2FS0140-6736%2820%2932544-7&amp;pmid=33338437" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="r5" class="citations"><div class="citation"><div class="citation-content">Dodick DW, Lipton RB, Ailani J, et al. Ubrogepant for the treatment of migraine. <em>N Engl J Med</em> 2019;381:2230-2241.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_6_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2035908&amp;key=10.1056%2FNEJMoa1813049&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31800988/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000505219800008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Ubrogepant+for+the+treatment+of+migraine.&amp;publication_year=2019&amp;journal=N+Engl+J+Med&amp;pages=2230-2241&amp;doi=10.1056%2FNEJMoa1813049&amp;pmid=31800988" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="r6" class="citations"><div class="citation"><div class="citation-content">Goadsby PJ, Reuter U, Hallström Y, et al. A controlled trial of erenumab for episodic migraine. <em>N Engl J Med</em> 2017;377:2123-2132.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_7_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2035908&amp;key=10.1056%2FNEJMoa1705848&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29171821/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000416555000006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+controlled+trial+of+erenumab+for+episodic+migraine.&amp;publication_year=2017&amp;journal=N+Engl+J+Med&amp;pages=2123-2132&amp;doi=10.1056%2FNEJMoa1705848&amp;pmid=29171821" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="r7" class="citations"><div class="citation"><div class="citation-content">Hansen JM, Hauge AW, Olesen J, Ashina M. Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura. <em>Cephalalgia</em> 2010;30:1179-1186.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1177/0333102410368444" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20855363/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000285052900005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Calcitonin+gene-related+peptide+triggers+migraine-like+attacks+in+patients+with+migraine+with+aura.&amp;publication_year=2010&amp;journal=Cephalalgia&amp;pages=1179-1186&amp;doi=10.1177%2F0333102410368444&amp;pmid=20855363" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="r8" class="citations"><div class="citation"><div class="citation-content">Ho TW, Edvinsson L, Goadsby PJ. CGRP and its receptors provide new insights into migraine pathophysiology. <em>Nat Rev Neurol</em> 2010;6:573-582.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nrneurol.2010.127" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20820195/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000282643100009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=CGRP+and+its+receptors+provide+new+insights+into+migraine+pathophysiology.&amp;publication_year=2010&amp;journal=Nat+Rev+Neurol&amp;pages=573-582&amp;doi=10.1038%2Fnrneurol.2010.127&amp;pmid=20820195" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="r9" class="citations"><div class="citation"><div class="citation-content">Lipton RB, Croop R, Stock EG, et al. Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine. <em>N Engl J Med</em> 2019;381:142-149.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_10_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2035908&amp;key=10.1056%2FNEJMoa1811090&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31291516/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000475668100009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Rimegepant%2C+an+oral+calcitonin+gene-related+peptide+receptor+antagonist%2C+for+migraine.&amp;publication_year=2019&amp;journal=N+Engl+J+Med&amp;pages=142-149&amp;doi=10.1056%2FNEJMoa1811090&amp;pmid=31291516" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="r10" class="citations"><div class="citation"><div class="citation-content">Silberstein SD, Dodick DW, Bigal ME, et al. Fremanezumab for the preventive treatment of chronic migraine. <em>N Engl J Med</em> 2017;377:2113-2122.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_11_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2035908&amp;key=10.1056%2FNEJMoa1709038&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29171818/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000416555000005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Fremanezumab+for+the+preventive+treatment+of+chronic+migraine.&amp;publication_year=2017&amp;journal=N+Engl+J+Med&amp;pages=2113-2122&amp;doi=10.1056%2FNEJMoa1709038&amp;pmid=29171818" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="r11" class="citations"><div class="citation"><div class="citation-content">Min KC, Kraft WK, Bondiskey P, et al. Atogepant is not associated with clinically meaningful alanine aminotransferase elevations in healthy adults. <em>Clin Transl Sci</em> 2021;14:599-605.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r11" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/cts.12917" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33142014/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000591846800001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Atogepant+is+not+associated+with+clinically+meaningful+alanine+aminotransferase+elevations+in+healthy+adults.&amp;publication_year=2021&amp;journal=Clin+Transl+Sci&amp;pages=599-605&amp;doi=10.1111%2Fcts.12917&amp;pmid=33142014" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r11" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r11-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] concentrations are reached by 1 to 2 hours. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r11-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] with a half-life of approximately 11 hours. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="r12" class="citations"><div class="citation"><div class="citation-content">Goadsby PJ, Dodick DW, Ailani J, et al. Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial. <em>Lancet Neurol</em> 2020;19:727-737.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r12" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1474-4422(20)30234-9" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32822633/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000562556500015" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Safety%2C+tolerability%2C+and+efficacy+of+orally+administered+atogepant+for+the+prevention+of+episodic+migraine+in+adults%3A+a+double-blind%2C+randomised+phase+2b%2F3+trial.&amp;publication_year=2020&amp;journal=Lancet+Neurol&amp;pages=727-737&amp;doi=10.1016%2FS1474-4422%2820%2930234-9&amp;pmid=32822633" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r12" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r12-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] trial involving 834 participants. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r24" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] participants with episodic migraine. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r12-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] extend those of a previous phase 2–3 trial. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="r13" class="citations"><div class="citation"><div class="citation-content">Hoffmann J, Akerman S, Goadsby PJ. Efficacy and mechanism of anticonvulsant drugs in migraine. <em>Expert Rev Clin Pharmacol</em> 2014;7:191-201.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r15"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1586/17512433.2014.885835" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24494792/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000349989200011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Efficacy+and+mechanism+of+anticonvulsant+drugs+in+migraine.&amp;publication_year=2014&amp;journal=Expert+Rev+Clin+Pharmacol&amp;pages=191-201&amp;doi=10.1586%2F17512433.2014.885835&amp;pmid=24494792" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="r14" class="citations"><div class="citation"><div class="citation-content">Schürks M, Diener HC, Goadsby P. Update on the prophylaxis of migraine. <em>Curr Treat Options Neurol</em> 2008;10:20-29.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r15"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s11940-008-0003-3" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/18325296/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000258902900003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Update+on+the+prophylaxis+of+migraine.&amp;publication_year=2008&amp;journal=Curr+Treat+Options+Neurol&amp;pages=20-29&amp;doi=10.1007%2Fs11940-008-0003-3&amp;pmid=18325296" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="r15" class="citations"><div class="citation"><div class="citation-content">Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. <em>Neurology</em> 2012;78:1337-1345.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r15"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1212/WNL.0b013e3182535d20" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22529202/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000303324100017" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Evidence-based+guideline+update%3A+pharmacologic+treatment+for+episodic+migraine+prevention+in+adults%3A+report+of+the+Quality+Standards+Subcommittee+of+the+American+Academy+of+Neurology+and+the+American+Headache+Society.&amp;publication_year=2012&amp;journal=Neurology&amp;pages=1337-1345&amp;doi=10.1212%2FWNL.0b013e3182535d20&amp;pmid=22529202" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="r16" class="citations"><div class="citation"><div class="citation-content">Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. <em>Cephalalgia</em> 2018;38:1-211.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r16" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1177/0333102417738202" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29368949/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000425149500001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+International+Classification+of+Headache+Disorders%2C+3rd+edition.&amp;publication_year=2018&amp;journal=Cephalalgia&amp;pages=1-211&amp;doi=10.1177%2F0333102417738202&amp;pmid=29368949" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r16" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r16-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] with migraine onset before 50 years of age. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r16-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] 1 or during the 28-day baseline period. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="r17" class="citations"><div class="citation"><div class="citation-content">Cala ML, Graham CA, Lipton RB, et al. The activity impairment in migraine–diary (AIM-D): a novel migraine-specific patient-reported outcome measure to assess functioning based on activity impairment in episodic and chronic migraine patients. <em>Cephalalgia</em> 2018;38:Suppl:4-5. abstract.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r17"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000443829800006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+activity+impairment+in+migraine%E2%80%93diary+%28AIM-D%29%3A+a+novel+migraine-specific+patient-reported+outcome+measure+to+assess+functioning+based+on+activity+impairment+in+episodic+and+chronic+migraine+patients.&amp;publication_year=2018&amp;journal=Cephalalgia&amp;pages=4-5" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="r18" class="citations"><div class="citation"><div class="citation-content">Cole JC, Lin P, Rupnow MFT. Minimal important differences in the Migraine-Specific Quality of Life Questionnaire (MSQ) version. <em>Cephalalgia</em> 2009;29:1180-1187.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r18"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/j.1468-2982.2009.01852.x" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19830883/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000270587600006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Minimal+important+differences+in+the+Migraine-Specific+Quality+of+Life+Questionnaire+%28MSQ%29+version.&amp;publication_year=2009&amp;journal=Cephalalgia&amp;pages=1180-1187&amp;doi=10.1111%2Fj.1468-2982.2009.01852.x&amp;pmid=19830883" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="r19" class="citations"><div class="citation"><div class="citation-content">Negro A, Lionetto L, Simmaco M, Martelletti P. CGRP receptor antagonists: an expanding drug class for acute migraine? <em>Expert Opin Investig Drugs</em> 2012;21:807-818.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r20"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1517/13543784.2012.681044" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22512641/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000304063400006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=CGRP+receptor+antagonists%3A+an+expanding+drug+class+for+acute+migraine%3F&amp;publication_year=2012&amp;journal=Expert+Opin+Investig+Drugs&amp;pages=807-818&amp;doi=10.1517%2F13543784.2012.681044&amp;pmid=22512641" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="r20" class="citations"><div class="citation"><div class="citation-content">Messina R, Goadsby PJ. CGRP — a target for acute therapy in migraine: clinical data. <em>Cephalalgia</em> 2019;39:420-427.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r20"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1177/0333102418768095" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29616830/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000460298300009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=CGRP+%E2%80%94+a+target+for+acute+therapy+in+migraine%3A+clinical+data.&amp;publication_year=2019&amp;journal=Cephalalgia&amp;pages=420-427&amp;doi=10.1177%2F0333102418768095&amp;pmid=29616830" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="r21" class="citations"><div class="citation"><div class="citation-content">Bigal ME, Dodick DW, Rapoport AM, et al. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. <em>Lancet Neurol</em> 2015;14:1081-1090.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1474-4422(15)00249-5" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26432182/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000362975200012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Safety%2C+tolerability%2C+and+efficacy+of+TEV-48125+for+preventive+treatment+of+high-frequency+episodic+migraine%3A+a+multicentre%2C+randomised%2C+double-blind%2C+placebo-controlled%2C+phase+2b+study.&amp;publication_year=2015&amp;journal=Lancet+Neurol&amp;pages=1081-1090&amp;doi=10.1016%2FS1474-4422%2815%2900249-5&amp;pmid=26432182" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="r22" class="citations"><div class="citation"><div class="citation-content">Dodick DW, Goadsby PJ, Silberstein SD, et al. Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. <em>Lancet Neurol</em> 2014;13:1100-1107.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1474-4422(14)70209-1" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25297013/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000343783900017" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Safety+and+efficacy+of+ALD403%2C+an+antibody+to+calcitonin+gene-related+peptide%2C+for+the+prevention+of+frequent+episodic+migraine%3A+a+randomised%2C+double-blind%2C+placebo-controlled%2C+exploratory+phase+2+trial.&amp;publication_year=2014&amp;journal=Lancet+Neurol&amp;pages=1100-1107&amp;doi=10.1016%2FS1474-4422%2814%2970209-1&amp;pmid=25297013" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="r23" class="citations"><div class="citation"><div class="citation-content">Dodick DW, Goadsby PJ, Spierings ELH, Scherer JC, Sweeney SP, Grayzel DS. Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study. <em>Lancet Neurol</em> 2014;13:885-892.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1474-4422(14)70128-0" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25127173/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000341405400013" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Safety+and+efficacy+of+LY2951742%2C+a+monoclonal+antibody+to+calcitonin+gene-related+peptide%2C+for+the+prevention+of+migraine%3A+a+phase+2%2C+randomised%2C+double-blind%2C+placebo-controlled+study.&amp;publication_year=2014&amp;journal=Lancet+Neurol&amp;pages=885-892&amp;doi=10.1016%2FS1474-4422%2814%2970128-0&amp;pmid=25127173" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="r24" class="citations"><div class="citation"><div class="citation-content">Ho TW, Connor KM, Zhang Y, et al. Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention. <em>Neurology</em> 2014;83:958-966.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1212/WNL.0000000000000771" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25107879/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000341883600005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Randomized+controlled+trial+of+the+CGRP+receptor+antagonist+telcagepant+for+migraine+prevention.&amp;publication_year=2014&amp;journal=Neurology&amp;pages=958-966&amp;doi=10.1212%2FWNL.0000000000000771&amp;pmid=25107879" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">25.</div><div id="r25" class="citations"><div class="citation"><div class="citation-content">Mallinckrodt CH, Lane PW, Schnell D, Peng Y, Mancuso JP. Recommendations for the primary analysis of continuous endpoints in longitudinal clinical trials. <em>Drug Inf J</em> 2008;42:303-319.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r25"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1177/009286150804200402" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000257155100002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Recommendations+for+the+primary+analysis+of+continuous+endpoints+in+longitudinal+clinical+trials.&amp;publication_year=2008&amp;journal=Drug+Inf+J&amp;pages=303-319&amp;doi=10.1177%2F009286150804200402" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">26.</div><div id="r26" class="citations"><div class="citation"><div class="citation-content">Bretz F, Maurer W, Brannath W, Posch M. A graphical approach to sequentially rejective multiple test procedures. <em>Stat Med</em> 2009;28:586-604.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r26"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/sim.3495" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19051220/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000263005700004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+graphical+approach+to+sequentially+rejective+multiple+test+procedures.&amp;publication_year=2009&amp;journal=Stat+Med&amp;pages=586-604&amp;doi=10.1002%2Fsim.3495&amp;pmid=19051220" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">27.</div><div id="r27" class="citations"><div class="citation"><div class="citation-content">Temple R. Hy’s law: predicting serious hepatotoxicity. <em>Pharmacoepidemiol Drug Saf</em> 2006;15:241-243.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r27"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/pds.1211" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/16552790/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000236995000005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Hy%E2%80%99s+law%3A+predicting+serious+hepatotoxicity.&amp;publication_year=2006&amp;journal=Pharmacoepidemiol+Drug+Saf&amp;pages=241-243&amp;doi=10.1002%2Fpds.1211&amp;pmid=16552790" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">28.</div><div id="r28" class="citations"><div class="citation"><div class="citation-content">Diener HC, Tassorelli C, Dodick DW, et al. Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine attacks in episodic migraine in adults. <em>Cephalalgia</em> 2020;40:1026-1044.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r28"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1177/0333102420941839" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32722936/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000555082600001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Guidelines+of+the+International+Headache+Society+for+controlled+trials+of+preventive+treatment+of+migraine+attacks+in+episodic+migraine+in+adults.&amp;publication_year=2020&amp;journal=Cephalalgia&amp;pages=1026-1044&amp;doi=10.1177%2F0333102420941839&amp;pmid=32722936" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">29.</div><div id="r29" class="citations"><div class="citation"><div class="citation-content">Falkenberg K, Bjerg HR, Olesen J. Two-hour CGRP infusion causes gastrointestinal hyperactivity: possible relevance for CGRP antibody treatment. <em>Headache</em> 2020;60:929-937.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r30"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/head.13795" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32227602/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000522313600001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Two-hour+CGRP+infusion+causes+gastrointestinal+hyperactivity%3A+possible+relevance+for+CGRP+antibody+treatment.&amp;publication_year=2020&amp;journal=Headache&amp;pages=929-937&amp;doi=10.1111%2Fhead.13795&amp;pmid=32227602" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">30.</div><div id="r30" class="citations"><div class="citation"><div class="citation-content">L’Heureux MC, St-Pierre S, Trudel L, Plourde V, Lepage R, Poitras P. Digestive motor effects and vascular actions of CGRP in dog are expressed by different receptor subtypes. <em>Peptides</em> 2000;21:425-430.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r30"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0196-9781(00)00160-1" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/10793227/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000086995900016" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Digestive+motor+effects+and+vascular+actions+of+CGRP+in+dog+are+expressed+by+different+receptor+subtypes.&amp;publication_year=2000&amp;journal=Peptides&amp;pages=425-430&amp;doi=10.1016%2FS0196-9781%2800%2900160-1&amp;pmid=10793227" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">31.</div><div id="r31" class="citations"><div class="citation"><div class="citation-content">Ashina M. Migraine. <em>N Engl J Med</em> 2020;383:1866-1876.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r32"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_32_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2035908&amp;key=10.1056%2FNEJMra1915327&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33211930/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000604334000015" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Migraine.&amp;publication_year=2020&amp;journal=N+Engl+J+Med&amp;pages=1866-1876&amp;doi=10.1056%2FNEJMra1915327&amp;pmid=33211930" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">32.</div><div id="r32" class="citations"><div class="citation"><div class="citation-content">Kielbasa W, Helton DL. A new era for migraine: pharmacokinetic and pharmacodynamic insights into monoclonal antibodies with a focus on galcanezumab, an anti-CGRP antibody. <em>Cephalalgia</em> 2019;39:1284-1297.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r32"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1177/0333102419840780" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30917684/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000482243200010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+new+era+for+migraine%3A+pharmacokinetic+and+pharmacodynamic+insights+into+monoclonal+antibodies+with+a+focus+on+galcanezumab%2C+an+anti-CGRP+antibody.&amp;publication_year=2019&amp;journal=Cephalalgia&amp;pages=1284-1297&amp;doi=10.1177%2F0333102419840780&amp;pmid=30917684" target="_blank">Google Scholar</a></div></div></div></div></div></div><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary" aria-expanded="false" aria-controls="collapsible-text"><span>Show all references</span></button></div></section></div></section></div><div class="core-collateral"><div id="core-collateral-info" role="tabpanel" data-core-tabs="core-collateral-info" tabindex="-1" aria-labelledby="pane-core-collateral-info"><header><h2 id="pane-core-collateral-info"><i class="icon-info" aria-hidden="true"></i>Information &amp; Authors</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-information" role="tab" id="tab-information-label" aria-selected="true" class="active">Information</button><button aria-controls="tab-contributors" role="tab" id="tab-contributors-label" tabindex="-1" aria-selected="false">Authors</button></div><section id="tab-information" aria-labelledby="tab-information-label" role="tabpanel" tabindex="0"><h3>Information</h3><section class="core-self-citation"><h4>Published In</h4><div class="core-journal-presentation"><div class="core-journal-description"><div property="isPartOf" typeof="Periodical"><span property="name">New England Journal of Medicine</span></div><div class="core-enumeration"><a href="/toc/nejm/385/8"><span property="isPartOf" typeof="PublicationVolume">Volume <span property="volumeNumber">385</span></span> • <span property="isPartOf" typeof="PublicationIssue">Number <span property="issueNumber">8</span></span> • <span property="datePublished">August 19, 2021</span></a></div><div class="core-pagination"><span class="heading">Pages</span>: <span class="content"><span property="pageStart">695</span>-<span property="pageEnd">706</span></span></div></div></div></section><section class="core-copyright"><h4>Copyright</h4><div role="paragraph">Copyright © 2021 Massachusetts Medical Society. All rights reserved.</div><div>For personal use only. Any commercial reuse of NEJM Group content requires <a href="mailto:permissions@nejm.org">permission</a>.</div></section><section class="core-history"><h4>History</h4><div><b class="core-label">Published online</b>: August 18, 2021</div><div><b class="core-label">Published in issue</b>: August 19, 2021</div></section><section data-location="recirc_topics_article" class="core-classifications"><h4>Topics</h4><div class="keywords"><ol><li><a href="/browse/topic/clinical-medicine-general" alt="View article keyword Clinical Medicine General" data-interactiontype="article_recirculation_click">Clinical Medicine General</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/neurology-neurosurgery-general" alt="View article keyword Neurology/Neurosurgery General" data-interactiontype="article_recirculation_click">Neurology/Neurosurgery General</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li></ol></div></section></section><section id="tab-contributors" aria-labelledby="tab-contributors-label" role="tabpanel" tabindex="-1"><h3>Authors</h3><section class="core-authors"><h4>Authors</h4><div role="paragraph"><span property="author" typeof="Person"><span property="givenName">Jessica</span> <span property="familyName">Ailani</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Richard B.</span> <span property="familyName">Lipton</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Peter J.</span> <span property="familyName">Goadsby</span>, <span property="honorificSuffix">M.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0003-3260-5904" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0003-3260-5904</a></span>, <span property="author" typeof="Person"><span property="givenName">Hua</span> <span property="familyName">Guo</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Rosa</span> <span property="familyName">Miceli</span>, <span property="honorificSuffix">B.S.N.</span></span>, <span property="author" typeof="Person"><span property="givenName">Lawrence</span> <span property="familyName">Severt</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Michelle</span> <span property="familyName">Finnegan</span>, <span property="honorificSuffix">M.P.H.</span></span>, and <span property="author" typeof="Person"><span property="givenName">Joel M.</span> <span property="familyName">Trugman</span>, <span property="honorificSuffix">M.D.</span></span>, for <span property="author" typeof="Person">the ADVANCE Study Group<sup><a href="#fn1" role="doc-noteref">*</a></sup></span></div></section><section class="core-affiliations"><h4>Affiliations</h4><div property="affiliation" typeof="Organization"><span property="name">From MedStar Georgetown University Hospital, Washington, DC (J.A.); Albert Einstein College of Medicine and Montefiore Headache Center, New York (R.B.L.); the National Institute for Health Research–Wellcome Trust King’s Clinical Research Facility, King’s College London, London (P.J.G.); the Department of Neurology, University of California, Los Angeles, Los Angeles (P.J.G.); and AbbVie, Madison, NJ (H.G., R.M., L.S., M.F., J.M.T.).</span></div></section><section class="core-authors-notes"><h4>Notes</h4><div role="doc-footnote">Address reprint requests to Dr. Ailani at MedStar Georgetown University Hospital, 3800 Reservoir Rd. NW, Washington, DC 20007, or at <a href="mailto:jessica.ailani@gunet.georgetown.edu">jessica.ailani@gunet.georgetown.edu</a>.</div><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="fn1" role="paragraph">The members of the ADVANCE Study Group are listed in the <a href="#ap2">Supplementary Appendix</a>, available at NEJM.org.</div></div></section></section></div><div id="core-collateral-metrics" role="tabpanel" data-core-tabs="core-collateral-metrics" tabindex="-1" aria-labelledby="pane-core-collateral-metrics"><header><h2 id="pane-core-collateral-metrics"><i class="icon-timeline" aria-hidden="true"></i>Metrics &amp; Citations</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-metrics-inner" role="tab" id="tab-metrics-inner-label" aria-selected="true" class="active" data-interactiontype="article_tab" data-tabname="metricsWindow">Metrics</button><button aria-controls="tab-citations" role="tab" id="tab-citations-label" tabindex="-1" aria-selected="false" data-interactiontype="article_tab" data-tabname="metricsWindow">Citations<span class="citations-count">207</span></button></div><section id="tab-metrics-inner" aria-labelledby="tab-metrics-inner-label" role="tabpanel" tabindex="0"><h3>Metrics</h3><section>









    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="95ea9f58-ec0e-4db2-b2ab-280fc876af53" data-location="article_metrics_article">
        



        
            <h4 class="">
                Altmetrics
            </h4>
        
        <div data-badge-details="right" data-badge-type="large-donut" data-doi="10.1056/NEJMoa2035908" data-hide-no-mentions="true" data-link-target="_blank" class="altmetric-embed" data-uuid="55d13b79-4033-040c-e9a1-3224936ba113"><div style="overflow:hidden;">
    <div class="altmetric-normal-legend">
        <a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=112001122" style="display:inline-block;">
                <img alt="Article has an altmetric score of 1221" src="https://badges.altmetric.com/?size=320&amp;score=1221&amp;types=mabrtwfd" width="180" height="180" style="border:0; margin:0; max-width: none;">
        </a>
        <p class="altmetric-see-more-details" style="padding-top: 10px; text-align: center;"><a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=112001122">See more details</a></p>
    </div>
    <div id="_altmetric_popover_el_55d13b79-4033-040c-e9a1-3224936ba113" class="altmetric-embed right" style="margin:0; padding:0; display:inline-block; float:left; position:relative;">
        <div class="altmetric_container">
            <div class="altmetric-embed altmetric-popover-inner right">
                <div style="padding:0; margin: 0;" class="altmetric-embed altmetric-popover-content">
                        <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #FF0000;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=112001122&amp;tab=news">
          Picked up by <b>152</b> news outlets
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #ffd140;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=112001122&amp;tab=blogs">
          Blogged by <b>5</b>
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #9f79f2;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=112001122&amp;tab=policy-documents">
          Referenced in <b>2</b> policy sources
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #74CFED;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=112001122&amp;tab=twitter">
          Posted by <b>74</b> X users
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #f27700;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=112001122&amp;tab=patents">
          Referenced in <b>9</b> patents
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #2445bd;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=112001122&amp;tab=facebook">
          On <b>5</b> Facebook pages
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #958899;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=112001122&amp;tab=wikipedia">
          Referenced in <b>1</b> Wikipedia pages
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #D5E8F0;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=112001122&amp;tab=reddit">
          Reddited by <b>1</b>
      </a>
    </div>

    <div class="altmetric-embed readers" style="margin-top: 10px;">
          <div class="altmetric-embed tip_mendeley" style="padding-left: 10px; line-height:18px; border-left: 16px solid #A60000;">
              <b>218</b> readers on Mendeley
          </div>
    </div>

                </div>
            </div>
        </div>
    </div>
</div></div>
<script async="" type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" nonce="9523aece44e40cec-GRU"></script>

        </div>
    

</section></section><section id="tab-citations" aria-labelledby="tab-citations-label" role="tabpanel" tabindex="-1"><h3>Citations</h3><section>



        
            <h4 class="">
                Export citation
            </h4>
        
        <div class="citation-download cd-sec">
<p class="citation-download_msg">Select the format you want to export the citation of this publication.</p>
<form action="/action/downloadCitation" name="frmCitmgr" method="post" target="_self" class="citation-download_form"><input type="hidden" name="doi" value="10.1056/NEJMoa2035908"> <input type="hidden" name="downloadFileName" value="csp_385_"> <input type="hidden" name="include" value="abs">
<div class="dropdown dropdown-selectable dropdown-selectable--form-control"><input type="hidden" name="format" value=""> <label class="form-label">Format*</label> <button id="slct_format" type="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="btn dropdown-toggle d-flex align-items-center justify-content-between">Please Select </button>
<div aria-labelledby="slct_format" role="listbox" class="dropdown-menu"><a href="#" data-value="ris" class="dropdown-item">RIS (ProCite, Reference Manager)</a><a href="#" data-value="endnote" class="dropdown-item">EndNote</a><a href="#" data-value="bibtex" class="dropdown-item">BibTex</a><a href="#" data-value="medlars" class="dropdown-item">Medlars</a><a href="#" data-value="refworks" class="dropdown-item">RefWorks</a></div>
<div class="invalid-feedback">Please select an item in the list</div>
</div>
<div class="citation-download_checkbox"><label class="checkbox--primary"><input type="checkbox" name="direct" value="true"><span class="checkbox--primary-icons"><span class="checkbox--primary-unchecked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxUnchecked"></use></svg></span></span><span class="checkbox--primary-checked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxChecked"></use></svg></span></span></span><span class="checkbox--primary-label"><span class="checkbox--primary-label-text">Direct Import</span></span></label></div>
<div class="citation-download_btn"><button type="submit" name="submit" value="Download" class="ng-btn_default ng-btn_iconLeft" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#citations"></use></svg></span><span class="ng-btn_text">Export citation</span></button></div>
</form></div>
</section><section>









    
    
        <div data-widget-def="UX3CitedByWidget" data-widget-id="efb4df9a-8e1a-47f9-bfb7-271959277a9f" data-location="citedby_article">
        



        
            <h4 class="">
                Cited by
            </h4>
        
        <section id="cited-by" class="cited-by"><div class="cited-by__wrapper"><div id="cited-by__content" class="cited-by__content"><ol data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2021.385.issue-8%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2035908%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" data-lazyload="false" data-total="207" class="cited-by__list list-unstyled"><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Alex Jaimes, </li><li class="list-inline-item cited-by__entry__author">Jaime Rodríguez-Vico, </li><li class="list-inline-item cited-by__entry__author">Olga Pajares, </li><li class="list-inline-item cited-by__entry__author">Ignacio Eguilior Caffarena, </li><li class="list-inline-item cited-by__entry__author">Anna Lena Nystrom Hernández, </li><li class="list-inline-item cited-by__entry__author">Andrea Gómez, </li><li class="list-inline-item cited-by__entry__author">Jesús Porta-Etessam, </li></ul><span class="cited-by__entry__title">Retrospective cohort study of anti-CGRP monoclonal antibody unresponsive migraine individuals treated with atogepant: The RESCUE study, </span><span class="cited-by__entry__series-title">Cephalalgia, </span><span class="cited-by__entry__volume"><strong>45</strong>, </span><span class="cited-by__entry__issue">6, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1177/03331024251346925" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1177/03331024251346925</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1177/03331024251346925" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Prakit Anukoolwittaya, </li><li class="list-inline-item cited-by__entry__author">Wanakorn Rattanawong, </li><li class="list-inline-item cited-by__entry__author">Kiratikorn Vongvaivanich, </li><li class="list-inline-item cited-by__entry__author">Thanakit Pongpitakmetha, </li><li class="list-inline-item cited-by__entry__author">Sekh Thanprasertsuk, </li><li class="list-inline-item cited-by__entry__author">Thaninjitra Poonpedpun, </li><li class="list-inline-item cited-by__entry__author">Pannathat Soontrapa, </li><li class="list-inline-item cited-by__entry__author">Kanokrat Suwanlaong, </li><li class="list-inline-item cited-by__entry__author">Kannikar Kongbunkiat, </li><li class="list-inline-item cited-by__entry__author">Surasak Komonchan, </li><li class="list-inline-item cited-by__entry__author">Petcharat Dusitanond, </li><li class="list-inline-item cited-by__entry__author">Chutithep Teekaput, </li><li class="list-inline-item cited-by__entry__author">Nopdanai Sirimaharaj, </li><li class="list-inline-item cited-by__entry__author">Nadolporn Yuvasilp, </li><li class="list-inline-item cited-by__entry__author">Surat Tanprawate, </li></ul><span class="cited-by__entry__title">Expert consensus on gepants for acute and preventive treatment of migraine in Thailand, </span><span class="cited-by__entry__series-title">The Journal of Headache and Pain, </span><span class="cited-by__entry__volume"><strong>26</strong>, </span><span class="cited-by__entry__issue">1, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1186/s10194-025-02074-4" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1186/s10194-025-02074-4</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1186/s10194-025-02074-4" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Savvas-Ilias Christofilos, </li><li class="list-inline-item cited-by__entry__author">Theodoros Mavridis, </li><li class="list-inline-item cited-by__entry__author">Viktor Gkotzamanis, </li><li class="list-inline-item cited-by__entry__author">Sofia Vasilopoulou, </li><li class="list-inline-item cited-by__entry__author">Christina I. Deligianni, </li><li class="list-inline-item cited-by__entry__author">Mitsikostas Dimos-Dimitrios, </li></ul><span class="cited-by__entry__title">Repurposed versus disease-specific medicinals for the prophylaxis of migraine: an updated systematic review, </span><span class="cited-by__entry__series-title">Pain Management, </span><span class="cited-by__entry__page-range">(1-15), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1080/17581869.2025.2509474" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1080/17581869.2025.2509474</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1080/17581869.2025.2509474" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Hongki Jeon, </li><li class="list-inline-item cited-by__entry__author">Jin-Man Cho, </li></ul><span class="cited-by__entry__title">Variant angina associated with a CGRP receptor antagonist: a case report, </span><span class="cited-by__entry__series-title">BMC Neurology, </span><span class="cited-by__entry__volume"><strong>25</strong>, </span><span class="cited-by__entry__issue">1, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1186/s12883-025-04260-y" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1186/s12883-025-04260-y</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1186/s12883-025-04260-y" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Piero Barbanti, </li><li class="list-inline-item cited-by__entry__author">Gabriella Egeo, </li><li class="list-inline-item cited-by__entry__author">Francesca Pistoia, </li><li class="list-inline-item cited-by__entry__author">Cinzia Aurilia, </li><li class="list-inline-item cited-by__entry__author">Paola Scatena, </li><li class="list-inline-item cited-by__entry__author">Steno Rinalduzzi, </li><li class="list-inline-item cited-by__entry__author">Silvia Strumia, </li><li class="list-inline-item cited-by__entry__author">Antonio Salerno, </li><li class="list-inline-item cited-by__entry__author">Fabio Frediani, </li><li class="list-inline-item cited-by__entry__author">Andrea Galli, </li><li class="list-inline-item cited-by__entry__author">Massimo Autunno, </li><li class="list-inline-item cited-by__entry__author">Laura Di Clemente, </li><li class="list-inline-item cited-by__entry__author">Maurizio Zucco, </li><li class="list-inline-item cited-by__entry__author">Maria Albanese, </li><li class="list-inline-item cited-by__entry__author">Francesco Bono, </li><li class="list-inline-item cited-by__entry__author">Pietrantonio Bruno, </li><li class="list-inline-item cited-by__entry__author">Laura Borrello, </li><li class="list-inline-item cited-by__entry__author">Stefano Messina, </li><li class="list-inline-item cited-by__entry__author">Alberto Doretti, </li><li class="list-inline-item cited-by__entry__author">Angelo Ranieri, </li><li class="list-inline-item cited-by__entry__author">Cecilia Camarda, </li><li class="list-inline-item cited-by__entry__author">Rosario Vecchio, </li><li class="list-inline-item cited-by__entry__author">Valeria Drago, </li><li class="list-inline-item cited-by__entry__author">Giulia Fiorentini, </li><li class="list-inline-item cited-by__entry__author">Carlo Tomino, </li><li class="list-inline-item cited-by__entry__author">Stefano Bonassi, </li><li class="list-inline-item cited-by__entry__author">Paola Torelli, </li><li class="list-inline-item cited-by__entry__author">Alice Mannocci, </li><li class="list-inline-item cited-by__entry__author">Marco Aguggia, </li><li class="list-inline-item cited-by__entry__author">Gennaro Alfieri, </li><li class="list-inline-item cited-by__entry__author">Diletta Alivernini, </li><li class="list-inline-item cited-by__entry__author">Raffaella Ardau, </li><li class="list-inline-item cited-by__entry__author">Maria Letizia Bartolozzi, </li><li class="list-inline-item cited-by__entry__author">Maria Carmela Bloise, </li><li class="list-inline-item cited-by__entry__author">Simone Braca, </li><li class="list-inline-item cited-by__entry__author">Antonio Bruno, </li><li class="list-inline-item cited-by__entry__author">Stefano Caproni, </li><li class="list-inline-item cited-by__entry__author">Ilaria Cetta, </li><li class="list-inline-item cited-by__entry__author">Alessandra Cherchi, </li><li class="list-inline-item cited-by__entry__author">Bruno Colombo, </li><li class="list-inline-item cited-by__entry__author">Eleonora Colombo, </li><li class="list-inline-item cited-by__entry__author">Alfonso Coppola, </li><li class="list-inline-item cited-by__entry__author">Domenico Cosenza, </li><li class="list-inline-item cited-by__entry__author">Francesca Cortese, </li><li class="list-inline-item cited-by__entry__author">Matteo De Bartolo, </li><li class="list-inline-item cited-by__entry__author">Roberto De Simone, </li><li class="list-inline-item cited-by__entry__author">Arianna Deidda, </li><li class="list-inline-item cited-by__entry__author">Alessandra Del Bene, </li><li class="list-inline-item cited-by__entry__author">Gianluca Demirtzidis, </li><li class="list-inline-item cited-by__entry__author">Alfonsina Di Summa, </li><li class="list-inline-item cited-by__entry__author">Valentina Favoni, </li><li class="list-inline-item cited-by__entry__author">Ludovica Ferraù, </li><li class="list-inline-item cited-by__entry__author">Isabella Ferdinanda Pestalozza, </li><li class="list-inline-item cited-by__entry__author">Cinzia Finocchi, </li><li class="list-inline-item cited-by__entry__author">Annalisa Gai, </li><li class="list-inline-item cited-by__entry__author">Rosario Grugno, </li><li class="list-inline-item cited-by__entry__author">Martina Guarinoni, </li><li class="list-inline-item cited-by__entry__author">Elisabetta Iannaccone, </li><li class="list-inline-item cited-by__entry__author">Giovanni Idone, </li><li class="list-inline-item cited-by__entry__author">Vincenzo Laterza, </li><li class="list-inline-item cited-by__entry__author">Riccardo Lo Presti, </li><li class="list-inline-item cited-by__entry__author">Luca Lombardi, </li><li class="list-inline-item cited-by__entry__author">Irene Madonia, </li><li class="list-inline-item cited-by__entry__author">Andrea Mancioli, </li><li class="list-inline-item cited-by__entry__author">Sara Matignaro, </li><li class="list-inline-item cited-by__entry__author">Silvia Nizzoli, </li><li class="list-inline-item cited-by__entry__author">Matteo Paolucci, </li><li class="list-inline-item cited-by__entry__author">Maristella Piccininni, </li><li class="list-inline-item cited-by__entry__author">Pietro Querzani, </li><li class="list-inline-item cited-by__entry__author">Simone Quintana, </li><li class="list-inline-item cited-by__entry__author">Micaela Robotti, </li><li class="list-inline-item cited-by__entry__author">Pamela Rosettani, </li><li class="list-inline-item cited-by__entry__author">Marco Russo, </li><li class="list-inline-item cited-by__entry__author">Sergio Salvemini, </li><li class="list-inline-item cited-by__entry__author">Giuliano Sette, </li><li class="list-inline-item cited-by__entry__author">Gabriele Sixt, </li><li class="list-inline-item cited-by__entry__author">Michela Sforza, </li><li class="list-inline-item cited-by__entry__author">Martina Sodano, </li><li class="list-inline-item cited-by__entry__author">Giorgio Spano, </li><li class="list-inline-item cited-by__entry__author">Maria Erminia Stochino, </li><li class="list-inline-item cited-by__entry__author">Denise Tedeschi, </li><li class="list-inline-item cited-by__entry__author">Rossana Terlizzi, </li><li class="list-inline-item cited-by__entry__author">Valentina Teresi, </li><li class="list-inline-item cited-by__entry__author">Daniela Ungaro, </li><li class="list-inline-item cited-by__entry__author">Fabio Valguarnera, </li><li class="list-inline-item cited-by__entry__author">Gianluca Vita, </li><li class="list-inline-item cited-by__entry__author">Laura Zanandrea, </li></ul><span class="cited-by__entry__title">GIANT: a prospective, multicenter, real-world study on the effectiveness, safety, and tolerability of atogepant in migraine patients with multiple therapeutic failures, </span><span class="cited-by__entry__series-title">The Journal of Headache and Pain, </span><span class="cited-by__entry__volume"><strong>26</strong>, </span><span class="cited-by__entry__issue">1, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1186/s10194-025-02068-2" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1186/s10194-025-02068-2</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1186/s10194-025-02068-2" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">David Moreno-Ajona, </li><li class="list-inline-item cited-by__entry__author">Helin Gosalia, </li><li class="list-inline-item cited-by__entry__author">Jan Hoffmann, </li><li class="list-inline-item cited-by__entry__author">Peter J. Goadsby, </li></ul><span class="cited-by__entry__title">Amylin and the amylin receptors in migraine: Is there another pathway to target?, </span><span class="cited-by__entry__series-title">Cephalalgia, </span><span class="cited-by__entry__volume"><strong>45</strong>, </span><span class="cited-by__entry__issue">5, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1177/03331024251340066" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1177/03331024251340066</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1177/03331024251340066" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Umer Najib, </li><li class="list-inline-item cited-by__entry__author">Eric M. Cheng, </li><li class="list-inline-item cited-by__entry__author">Rashmi B. Halker Singh, </li><li class="list-inline-item cited-by__entry__author">Neishay Ayub, </li><li class="list-inline-item cited-by__entry__author">Sarah E. Nelson, </li><li class="list-inline-item cited-by__entry__author">Patrick J. Bushard, </li><li class="list-inline-item cited-by__entry__author">Justin T. Jordan, </li><li class="list-inline-item cited-by__entry__author">Jason J. Sico, </li><li class="list-inline-item cited-by__entry__author">Madeline Turbes, </li><li class="list-inline-item cited-by__entry__author">Wayne E. Anderson, </li></ul><span class="cited-by__entry__title">AAN Position, </span><span class="cited-by__entry__series-title">Neurology, </span><span class="cited-by__entry__volume"><strong>104</strong>, </span><span class="cited-by__entry__issue">9, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1212/WNL.0000000000213544" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1212/WNL.0000000000213544</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1212/WNL.0000000000213544" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Nai Lee, </li><li class="list-inline-item cited-by__entry__author">Jihoon Ok, </li><li class="list-inline-item cited-by__entry__author">Yonghoon Kwon, </li><li class="list-inline-item cited-by__entry__author">Su-jin Rhee, </li><li class="list-inline-item cited-by__entry__author">Yun Kim, </li></ul><span class="cited-by__entry__title">Identifying signals of disproportionate reporting for calcitonin gene-related peptide inhibitors: real-world evidence from the FDA adverse event reporting system, </span><span class="cited-by__entry__series-title">Expert Opinion on Drug Safety, </span><span class="cited-by__entry__page-range">(1-10), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1080/14740338.2025.2497394" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1080/14740338.2025.2497394</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1080/14740338.2025.2497394" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Marcin Straburzyński, </li><li class="list-inline-item cited-by__entry__author">Daria Kopyt, </li><li class="list-inline-item cited-by__entry__author">Karol Marschollek, </li><li class="list-inline-item cited-by__entry__author">Bartłomiej Błaszczyk, </li><li class="list-inline-item cited-by__entry__author">Ewa Kuca-Warnawin, </li><li class="list-inline-item cited-by__entry__author">Weronika Kurowska, </li><li class="list-inline-item cited-by__entry__author">Błażej Misiak, </li><li class="list-inline-item cited-by__entry__author">Kuan-Po Peng, </li><li class="list-inline-item cited-by__entry__author">Marta Waliszewska-Prosół, </li><li class="list-inline-item cited-by__entry__author">Arne May, </li></ul><span class="cited-by__entry__title">Increased infection risk in patients on preventive CGRP-targeting therapies– a meta-analysis and clinical effect assessment, </span><span class="cited-by__entry__series-title">The Journal of Headache and Pain, </span><span class="cited-by__entry__volume"><strong>26</strong>, </span><span class="cited-by__entry__issue">1, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1186/s10194-025-02040-0" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1186/s10194-025-02040-0</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1186/s10194-025-02040-0" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Raffaele Ornello, </li><li class="list-inline-item cited-by__entry__author">Valeria Caponnetto, </li><li class="list-inline-item cited-by__entry__author">Fayyaz Ahmed, </li><li class="list-inline-item cited-by__entry__author">Haidar M. Al-Khazali, </li><li class="list-inline-item cited-by__entry__author">Anna Ambrosini, </li><li class="list-inline-item cited-by__entry__author">Sait Ashina, </li><li class="list-inline-item cited-by__entry__author">Carlo Baraldi, </li><li class="list-inline-item cited-by__entry__author">Alessia Bellotti, </li><li class="list-inline-item cited-by__entry__author">Filippo Brighina, </li><li class="list-inline-item cited-by__entry__author">Paolo Calabresi, </li><li class="list-inline-item cited-by__entry__author">Francesco Casillo, </li><li class="list-inline-item cited-by__entry__author">Sabina Cevoli, </li><li class="list-inline-item cited-by__entry__author">Shuli Cheng, </li><li class="list-inline-item cited-by__entry__author">Chia-Chun Chiang, </li><li class="list-inline-item cited-by__entry__author">Alberto Chiarugi, </li><li class="list-inline-item cited-by__entry__author">Rune Häckert Christensen, </li><li class="list-inline-item cited-by__entry__author">Min Kyung Chu, </li><li class="list-inline-item cited-by__entry__author">Gianluca Coppola, </li><li class="list-inline-item cited-by__entry__author">Ilenia Corbelli, </li><li class="list-inline-item cited-by__entry__author">Santiago Crema, </li><li class="list-inline-item cited-by__entry__author">Roberto De Icco, </li><li class="list-inline-item cited-by__entry__author">Marina de Tommaso, </li><li class="list-inline-item cited-by__entry__author">Cherubino Di Lorenzo, </li><li class="list-inline-item cited-by__entry__author">Vincenzo Di Stefano, </li><li class="list-inline-item cited-by__entry__author">Hans-Christoph Diener, </li><li class="list-inline-item cited-by__entry__author">Esme Ekizoğlu, </li><li class="list-inline-item cited-by__entry__author">Adriana Fallacara, </li><li class="list-inline-item cited-by__entry__author">Valentina Favoni, </li><li class="list-inline-item cited-by__entry__author">Kimberly N. Garces, </li><li class="list-inline-item cited-by__entry__author">Pierangelo Geppetti, </li><li class="list-inline-item cited-by__entry__author">Maria Teresa Goicochea, </li><li class="list-inline-item cited-by__entry__author">Antonio Granato, </li><li class="list-inline-item cited-by__entry__author">Franco Granella, </li><li class="list-inline-item cited-by__entry__author">Simona Guerzoni, </li><li class="list-inline-item cited-by__entry__author">Woo-Seok Ha, </li><li class="list-inline-item cited-by__entry__author">Amr Hassan, </li><li class="list-inline-item cited-by__entry__author">Koichi Hirata, </li><li class="list-inline-item cited-by__entry__author">Jan Hoffmann, </li><li class="list-inline-item cited-by__entry__author">Eva-Maria Hüssler, </li><li class="list-inline-item cited-by__entry__author">Mona Hussein, </li><li class="list-inline-item cited-by__entry__author">Luigi Francesco Iannone, </li><li class="list-inline-item cited-by__entry__author">Bronwyn Jenkins, </li><li class="list-inline-item cited-by__entry__author">Alejandro Labastida-Ramirez, </li><li class="list-inline-item cited-by__entry__author">Anna Laporta, </li><li class="list-inline-item cited-by__entry__author">Morris Levin, </li><li class="list-inline-item cited-by__entry__author">Antonino Lupica, </li><li class="list-inline-item cited-by__entry__author">Edoardo Mampreso, </li><li class="list-inline-item cited-by__entry__author">Daniele Martinelli, </li><li class="list-inline-item cited-by__entry__author">Teshamae S. Monteith, </li><li class="list-inline-item cited-by__entry__author">Ilaria Orologio, </li><li class="list-inline-item cited-by__entry__author">Aynur Özge, </li><li class="list-inline-item cited-by__entry__author">Li-Ling Hope Pan, </li><li class="list-inline-item cited-by__entry__author">Lavindren Luke Panneerchelvam, </li><li class="list-inline-item cited-by__entry__author">Mario F. P. Peres, </li><li class="list-inline-item cited-by__entry__author">Marcio Nattan Portes Souza, </li><li class="list-inline-item cited-by__entry__author">Patricia Pozo-Rosich, </li><li class="list-inline-item cited-by__entry__author">Maria Pia Prudenzano, </li><li class="list-inline-item cited-by__entry__author">Silvia Quattrocchi, </li><li class="list-inline-item cited-by__entry__author">Innocenzo Rainero, </li><li class="list-inline-item cited-by__entry__author">Volodymyr Romanenko, </li><li class="list-inline-item cited-by__entry__author">Marina Romozzi, </li><li class="list-inline-item cited-by__entry__author">Antonio Russo, </li><li class="list-inline-item cited-by__entry__author">Grazia Sances, </li><li class="list-inline-item cited-by__entry__author">Paola Sarchielli, </li><li class="list-inline-item cited-by__entry__author">Todd J. Schwedt, </li><li class="list-inline-item cited-by__entry__author">Marcello Silvestro, </li><li class="list-inline-item cited-by__entry__author">Diego Belandrino Swerts, </li><li class="list-inline-item cited-by__entry__author">Cristina Tassorelli, </li><li class="list-inline-item cited-by__entry__author">Alessandro Tessitore, </li><li class="list-inline-item cited-by__entry__author">Mansoureh Togha, </li><li class="list-inline-item cited-by__entry__author">Gloria Vaghi, </li><li class="list-inline-item cited-by__entry__author">Shuu-Jiun Wang, </li><li class="list-inline-item cited-by__entry__author">Messoud Ashina, </li><li class="list-inline-item cited-by__entry__author">Simona Sacco, </li></ul><span class="cited-by__entry__title">Evidence-based guidelines for the pharmacological treatment of migraine, </span><span class="cited-by__entry__series-title">Cephalalgia, </span><span class="cited-by__entry__volume"><strong>45</strong>, </span><span class="cited-by__entry__issue">4, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1177/03331024241305381" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1177/03331024241305381</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1177/03331024241305381" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry--see-more"><a href="javascript:void(0)" data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2021.385.issue-8%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2035908%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" class="cited-by__see-more">See more</a></li></ol></div><div class="cited-by__spinner justify-content-center align-items-center d-none"><div role="status" class="spinner-border text-gray"><span class="sr-only">Loading...</span></div></div></div></section>

        </div>
    

</section></section></div><div id="core-collateral-fulltext-options" role="tabpanel" data-core-tabs="core-collateral-fulltext-options" tabindex="-1" aria-labelledby="pane-core-collateral-fulltext-options"><header><h2 id="pane-core-collateral-fulltext-options"><i class="icon-eye" aria-hidden="true"></i>View Options</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div class="section--wrapper"><h3>View options</h3><section class="format--pdf"><h4> <abbr title="Portable Document Format">PDF</abbr></h4><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2035908" class="btn btn--pdf" aria-label="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2035908" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2035908.pdf"><i aria-hidden="true" class="icon-pdf"></i><span>View PDF</span></a></section></div><!-- Its needed to duplicate this for PB check Collateral.js as well--></div><div id="core-collateral-media" role="tabpanel" data-core-tabs="core-collateral-media" tabindex="-1" aria-labelledby="pane-core-collateral-media"><header><h2 id="pane-core-collateral-media"><i class="icon-photo" aria-hidden="true"></i>Media</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-figures" role="tab" id="tab-figures-label" aria-selected="true" class="active">Figures</button><button aria-controls="tab-other" role="tab" id="tab-other-label" tabindex="-1" aria-selected="false" class="inactive" aria-disabled="true">Other</button></div><section id="tab-figures" aria-labelledby="tab-figures-label" role="tabpanel" tabindex="0"><h3>Figures</h3><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#figures"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-f1"><figure class="graphic"><a class="open-in-viewer" href="#f1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2035908_f1.jpg"><img src="/cms/10.1056/NEJMoa2035908/asset/2bb4f5ab-4ae7-47e5-8e14-9177e4a46c61/assets/images/large/nejmoa2035908_f1.jpg" height="2647" width="2640" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Screening, Randomization, and Follow-up.</div><div class="notes"><div role="doc-footnote">Participants could have more than one reason for exclusion before randomization. The safety population included all randomly assigned participants who received at least one dose of atogepant or placebo. The modified intention-to-treat population included all randomly assigned participants who received at least one dose of atogepant or placebo, had a baseline period of electronic-diary data that could be evaluated, and had at least one postbaseline 4-week period of electronic-diary data during the double-blind treatment period that could be evaluated.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f1"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2035908_f1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-f2"><figure class="graphic"><a class="open-in-viewer" href="#f2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2035908_f2.jpg"><img src="/cms/10.1056/NEJMoa2035908/asset/ff30f63f-0710-4fc3-b304-6a06c0dcc963/assets/images/large/nejmoa2035908_f2.jpg" height="1312" width="2231" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Time Course of Efficacy (Modified Intention-to-Treat Population).</div><div class="notes"><div role="doc-footnote">Shown is the least-squares mean change from baseline in migraine days per month. 𝙸 bars indicate standard errors.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f2"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2035908_f2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></section><section id="tab-other" aria-labelledby="tab-other-label" role="tabpanel" tabindex="-1"><h3>Other</h3></section></div><div id="core-collateral-tables" role="tabpanel" data-core-tabs="core-collateral-tables" tabindex="-1" aria-labelledby="pane-core-collateral-tables"><header><h2 id="pane-core-collateral-tables"><i class="icon-tables" aria-hidden="true"></i>Tables</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><!-- There is no content. --><div class="section--wrapper"><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#tables"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-t1"><figure class="table"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2035908_t1.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2035908/asset/1a251a34-95ba-4831-b494-d41cf3175af1/assets/images/large/nejmoa2035908_t1.jpg" height="1654" width="1999" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders">Placebo<br>(N=222)</th><th class="txxx-borders">Atogepant, 10 mg<br>(N=221)</th><th class="txxx-borders">Atogepant, 30 mg<br>(N=228)</th><th class="txxx-borders">Atogepant, 60 mg<br>(N=231)</th><th class="txxr-borders">Total<br>(N=902)</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading">Age — yr</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Mean</td><td class="xxxx-borders">40.3±12.8</td><td class="xxxx-borders">41.4±12.0</td><td class="xxxx-borders">42.1±11.7</td><td class="xxxx-borders">42.5±12.4</td><td class="xxxr-borders">41.6±12.2</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Range</td><td class="xxxx-borders shading">18–69</td><td class="xxxx-borders shading">18–73</td><td class="xxxx-borders shading">19–70</td><td class="xxxx-borders shading">18–72</td><td class="xxxr-borders shading">18–73</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Sex — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Male</td><td class="xxxx-borders shading">24 (10.8)</td><td class="xxxx-borders shading">21 (9.5)</td><td class="xxxx-borders shading">24 (10.5)</td><td class="xxxx-borders shading">32 (13.9)</td><td class="xxxr-borders shading">101 (11.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Female</td><td class="xxxx-borders">198 (89.2)</td><td class="xxxx-borders">200 (90.5)</td><td class="xxxx-borders">204 (89.5)</td><td class="xxxx-borders">199 (86.1)</td><td class="xxxr-borders">801 (88.8)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Race or ethnic group — no. (%)<a href="#core-t1fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">White</td><td class="xxxx-borders">194 (87.4)</td><td class="xxxx-borders">181 (81.9)</td><td class="xxxx-borders">185 (81.1)</td><td class="xxxx-borders">192 (83.1)</td><td class="xxxr-borders">752 (83.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Black</td><td class="xxxx-borders shading">24 (10.8)</td><td class="xxxx-borders shading">34 (15.4)</td><td class="xxxx-borders shading">38 (16.7)</td><td class="xxxx-borders shading">28 (12.1)</td><td class="xxxr-borders shading">124 (13.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Asian</td><td class="xxxx-borders">2 (0.9)</td><td class="xxxx-borders">2 (0.9)</td><td class="xxxx-borders">1 (0.4)</td><td class="xxxx-borders">7 (3.0)</td><td class="xxxr-borders">12 (1.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">American Indian or Alaska Native</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (0.5)</td><td class="xxxx-borders shading">1 (0.4)</td><td class="xxxx-borders shading">1 (0.4)</td><td class="xxxr-borders shading">3 (0.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Multiple<a href="#core-t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">2 (0.9)</td><td class="xxxx-borders">3 (1.4)</td><td class="xxxx-borders">3 (1.3)</td><td class="xxxx-borders">2 (0.9)</td><td class="xxxr-borders">10 (1.1)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Body-mass index</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Mean</td><td class="xxxx-borders">30.8±8.7</td><td class="xxxx-borders">30.3±7.6</td><td class="xxxx-borders">31.1±7.6</td><td class="xxxx-borders">29.9±7.3</td><td class="xxxr-borders">30.6±7.8</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Range</td><td class="xxxx-borders shading">16.9–82.0</td><td class="xxxx-borders shading">16.4–60.3</td><td class="xxxx-borders shading">17.1–66.2</td><td class="xxxx-borders shading">16.3–57.3</td><td class="xxxr-borders shading">16.3–82.0</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">No. of migraine days per month in past 3 mo</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Mean</td><td class="xxxx-borders shading">7.7±2.6</td><td class="xxxx-borders shading">7.2±2.5</td><td class="xxxx-borders shading">7.3±2.4</td><td class="xxxx-borders shading">7.3±2.4</td><td class="xxxr-borders shading">7.4±2.5</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Range</td><td class="xxxx-borders">4–14</td><td class="xxxx-borders">4–14</td><td class="xxxx-borders">4–14</td><td class="xxxx-borders">4–13</td><td class="xxxr-borders">4–14</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">No. of headache days per month in past 3 mo</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Mean</td><td class="xxxx-borders">9.5±2.8</td><td class="xxxx-borders">9.3±2.7</td><td class="xxxx-borders">9.2±2.7</td><td class="xxxx-borders">9.1±2.7</td><td class="xxxr-borders">9.3±2.7</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12 shading" data-xml-align="left">Range</td><td class="xbxx-borders shading">4–14</td><td class="xbxx-borders shading">4–14</td><td class="xbxx-borders shading">4–14</td><td class="xbxx-borders shading">4–14</td><td class="xbxr-borders shading">4–14</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t1fn1" role="paragraph" data-to-manipulate="true">Plus–minus values are means ±SD. The safety population included all randomly assigned participants who received at least one dose of atogepant or placebo. Percentages may not total 100 because of rounding.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t1fn2" role="paragraph" data-to-manipulate="true">Race and ethnic group were reported by the participants. One participant in the 60-mg atogepant group had missing data.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t1fn3" role="paragraph" data-to-manipulate="true">Shown are participants who reported multiple races or ethnic groups.</div></div></div></figcaption></a><figcaption><div class="caption">Demographic and Clinical Characteristics of the Participants at Baseline (Safety Population).<a href="#core-t1fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t1"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2035908_t1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t2"><figure class="table"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2035908_t2.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2035908/asset/2d32edcb-d879-4d83-a5de-3822603bcdfd/assets/images/large/nejmoa2035908_t2.jpg" height="3062" width="1999" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">End Point</th><th class="txxx-borders">Placebo<br>(N=214)</th><th class="txxx-borders">Atogepant, 10 mg<br>(N=214)</th><th class="txxx-borders">Atogepant, 30 mg <br>(N=223)</th><th class="txxr-borders">Atogepant, 60 mg<br>(N=222)</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Primary efficacy end point</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Migraine days per month</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Mean no. of days at baseline</td><td class="xxxx-borders shading">7.5±2.4</td><td class="xxxx-borders shading">7.5±2.5</td><td class="xxxx-borders shading">7.9±2.3</td><td class="xxxr-borders shading">7.8±2.3</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Change from baseline in mean no. of days across the 12-wk treatment period</td><td class="xxxx-borders">−2.5±0.2</td><td class="xxxx-borders">−3.7±0.2</td><td class="xxxx-borders">−3.9±0.2</td><td class="xxxr-borders">−4.2±0.2</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Difference vs. placebo (95% CI)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">−1.2 (−1.8 to −0.6)</td><td class="xxxx-borders shading">−1.4 (−1.9 to −0.8)</td><td class="xxxr-borders shading">−1.7 (−2.3 to −1.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Adjusted P value</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&lt;0.001</td><td class="xxxx-borders">&lt;0.001</td><td class="xxxr-borders">&lt;0.001</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Secondary efficacy end points</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Headache days per month</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Mean no. of days at baseline</td><td class="xxxx-borders shading">8.4±2.6</td><td class="xxxx-borders shading">8.4±2.8</td><td class="xxxx-borders shading">8.8±2.6</td><td class="xxxr-borders shading">9.0±2.6</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Change from baseline in mean no. of days across the 12-wk treatment period</td><td class="xxxx-borders">−2.5±0.2</td><td class="xxxx-borders">−3.9±0.2</td><td class="xxxx-borders">−4.0±0.2</td><td class="xxxr-borders">−4.2±0.2</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Difference vs. placebo (95% CI)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">−1.4 (−2.0 to −0.8)</td><td class="xxxx-borders shading">−1.5 (−2.1 to −0.9)</td><td class="xxxr-borders shading">−1.7 (−2.3 to −1.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Adjusted P value</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&lt;0.001</td><td class="xxxx-borders">&lt;0.001</td><td class="xxxr-borders">&lt;0.001</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Days of use of medication for the treatment of migraine attacks per month</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Mean no. of days at baseline</td><td class="xxxx-borders">6.5±3.1</td><td class="xxxx-borders">6.6±3.0</td><td class="xxxx-borders">6.7±3.0</td><td class="xxxr-borders">6.9±3.2</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Change from baseline in mean no. of days across the 12-wk treatment period</td><td class="xxxx-borders shading">−2.4±0.2</td><td class="xxxx-borders shading">−3.7±0.2</td><td class="xxxx-borders shading">−3.7±0.2</td><td class="xxxr-borders shading">−3.9±0.2</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Difference vs. placebo (95% CI)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">−1.3 (−1.8 to −0.8)</td><td class="xxxx-borders">−1.3 (−1.8 to −0.8)</td><td class="xxxr-borders">−1.5 (−2.0 to −1.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Adjusted P value</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&lt;0.001</td><td class="xxxx-borders shading">&lt;0.001</td><td class="xxxr-borders shading">&lt;0.001</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">≥50% Reduction in 3-mo average of mean no. of migraine days per month — no. (%)</td><td class="xxxx-borders">62 (29.0)</td><td class="xxxx-borders">119 (55.6)</td><td class="xxxx-borders">131 (58.7)</td><td class="xxxr-borders">135 (60.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Odds ratio vs. placebo (95% CI)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">3.1 (2.0 to 4.6)</td><td class="xxxx-borders shading">3.5 (2.4 to 5.3)</td><td class="xxxr-borders shading">3.8 (2.6 to 5.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Adjusted P value</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&lt;0.001</td><td class="xxxx-borders">&lt;0.001</td><td class="xxxr-borders">&lt;0.001</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Score on Role Function–Restrictive domain of MSQ<a href="#core-t2fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Mean monthly score at baseline</td><td class="xxxx-borders">46.8±19.7</td><td class="xxxx-borders">44.9±21.4</td><td class="xxxx-borders">44.0±19.6</td><td class="xxxr-borders">46.8±20.4</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Change from baseline in score at wk 12</td><td class="xxxx-borders shading">20.4±1.6</td><td class="xxxx-borders shading">30.3±1.6</td><td class="xxxx-borders shading">30.5±1.6</td><td class="xxxr-borders shading">31.2±1.6</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Difference vs. placebo (95% CI)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">9.9 (5.4 to 14.4)</td><td class="xxxx-borders">10.1 (5.7 to 14.5)</td><td class="xxxr-borders">10.8 (6.4 to 15.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Adjusted P value</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&lt;0.001</td><td class="xxxx-borders shading">&lt;0.001</td><td class="xxxr-borders shading">&lt;0.001</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Score on Performance of Daily Activities domain of AIM-D<a href="#core-t2fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Mean monthly score at baseline</td><td class="xxxx-borders shading">15.2±8.3</td><td class="xxxx-borders shading">15.5±8.9</td><td class="xxxx-borders shading">16.9±8.0</td><td class="xxxr-borders shading">15.9±8.3</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Change from baseline in mean monthly score across the 12-wk treatment period</td><td class="xxxx-borders">−6.1±0.5</td><td class="xxxx-borders">−7.3±0.5</td><td class="xxxx-borders">−8.6±0.5</td><td class="xxxr-borders">−9.4±0.5</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Difference vs. placebo (95% CI)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">−1.2 (−2.6 to 0.2)</td><td class="xxxx-borders shading">−2.5 (−3.9 to −1.2)</td><td class="xxxr-borders shading">−3.3 (−4.7 to −2.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Adjusted P value</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">0.09</td><td class="xxxx-borders">&lt;0.001</td><td class="xxxr-borders">&lt;0.001</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Score on Physical Impairment domain of AIM-D<a href="#core-t2fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Mean monthly score at baseline</td><td class="xxxx-borders">11.2±8.1</td><td class="xxxx-borders">11.7±8.5</td><td class="xxxx-borders">13.0±8.0</td><td class="xxxr-borders">11.6±7.9</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Change from baseline in mean monthly score across the 12-wk treatment period</td><td class="xxxx-borders shading">−4.0±0.4</td><td class="xxxx-borders shading">−5.1±0.4</td><td class="xxxx-borders shading">−6.0±0.4</td><td class="xxxr-borders shading">−6.5±0.4</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Difference vs. placebo (95% CI)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">−1.1 (−2.3 to 0.1)</td><td class="xxxx-borders">−2.0 (−3.2 to −0.8)</td><td class="xxxr-borders">−2.5 (−3.7 to −1.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12 shading" data-xml-align="left">Adjusted P value</td><td class="xbxx-borders shading">&nbsp;</td><td class="xbxx-borders shading">0.09</td><td class="xbxx-borders shading">0.002</td><td class="xbxr-borders shading">&lt;0.001</td></tr></tbody></table></div></a><figcaption><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2035908_t2.jpg"></a><div class="notes"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2035908_t2.jpg"></a><div role="doc-footnote" data-has="label"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2035908_t2.jpg"><div class="label">*</div></a><div id="core-t2fn1" role="paragraph" data-to-manipulate="true"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2035908_t2.jpg">Plus–minus values are means ±SD for baseline values and least-squares means ±SE for changes from baseline. Differences from placebo are least-squares mean differences. The confidence intervals (CIs) were not adjusted for multiple comparisons. P values were adjusted for multiple comparisons and are from the test between the atogepant dose group and placebo as described in Figure 1 in the </a><a href="#ap2">Supplementary Appendix</a> and in the statistical analysis plan. The analyses were performed with the use of observed cases only, without imputation of missing values. The modified intention-to-treat population included all randomly assigned participants who received at least one dose of atogepant or placebo, had a baseline period of electronic-diary data that could be evaluated, and had at least one postbaseline 4-week period of electronic-diary data during the double-blind treatment period that could be evaluated.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t2fn2" role="paragraph" data-to-manipulate="true">The Migraine-Specific Quality of Life Questionnaire (MSQ), version 2.1, is a 14-item questionnaire that measures health-related quality-of-life impairments attributed to migraine in the past 4 weeks, divided into three domains. Scores on the Role Function–Restrictive domain range from 0 to 100, with higher scores indicating a lesser effect of migraine on daily activities; the minimally important difference is 3.2 points.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t2fn3" role="paragraph" data-to-manipulate="true">The Activity Impairment in Migraine–Diary (AIM-D) is an 11-item daily diary measure that assesses the effect of migraine on two domains: Performance of Daily Activities (7 items) and Physical Impairment (4 items). The AIM-D domain scores range from 0 to 100, with higher scores indicating greater effect of migraine.</div></div></div></figcaption><figcaption><div class="caption">Primary and Secondary Efficacy End Points, According to Trial Group (Modified Intention-to-Treat Population).<a href="#core-t2fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t2"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2035908_t2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t3"><figure class="table"><a class="open-in-viewer" href="#t3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2035908_t3.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2035908/asset/ec286228-5c77-457e-8691-aa225ccf8f09/assets/images/large/nejmoa2035908_t3.jpg" height="1864" width="1711" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Adverse Event</th><th class="txxx-borders">Placebo<br>(N=222)</th><th class="txxx-borders">Atogepant, 10 mg<br>(N=221)</th><th class="txxx-borders">Atogepant, 30 mg<br>(N=228)</th><th class="txxr-borders">Atogepant, 60 mg<br>(N=231)</th></tr><tr class="head3" data-type="row head3"><td class="xxlx-borders">&nbsp;</td><th class="xxxr-borders" colspan="4"><span>number of participants (percent)</span></th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Any adverse event</td><td class="xxxx-borders shading">126 (56.8)</td><td class="xxxx-borders shading">117 (52.9)</td><td class="xxxx-borders shading">119 (52.2)</td><td class="xxxr-borders shading">124 (53.7)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Adverse events reported in ≥2% of participants in any trial group<a href="#core-t3fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Constipation</td><td class="xxxx-borders shading">1 (0.5)</td><td class="xxxx-borders shading">17 (7.7)</td><td class="xxxx-borders shading">16 (7.0)</td><td class="xxxr-borders shading">16 (6.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Upper respiratory tract infection</td><td class="xxxx-borders">10 (4.5)</td><td class="xxxx-borders">9 (4.1)</td><td class="xxxx-borders">13 (5.7)</td><td class="xxxr-borders">9 (3.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Nausea</td><td class="xxxx-borders shading">4 (1.8)</td><td class="xxxx-borders shading">11 (5.0)</td><td class="xxxx-borders shading">10 (4.4)</td><td class="xxxr-borders shading">14 (6.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Urinary tract infection</td><td class="xxxx-borders">8 (3.6)</td><td class="xxxx-borders">3 (1.4)</td><td class="xxxx-borders">9 (3.9)</td><td class="xxxr-borders">9 (3.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Nasopharyngitis</td><td class="xxxx-borders shading">8 (3.6)</td><td class="xxxx-borders shading">4 (1.8)</td><td class="xxxx-borders shading">8 (3.5)</td><td class="xxxr-borders shading">8 (3.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Fatigue</td><td class="xxxx-borders">4 (1.8)</td><td class="xxxx-borders">3 (1.4)</td><td class="xxxx-borders">7 (3.1)</td><td class="xxxr-borders">9 (3.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Somnolence</td><td class="xxxx-borders shading">2 (0.9)</td><td class="xxxx-borders shading">7 (3.2)</td><td class="xxxx-borders shading">4 (1.8)</td><td class="xxxr-borders shading">4 (1.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Increased blood creatine kinase level</td><td class="xxxx-borders">2 (0.9)</td><td class="xxxx-borders">5 (2.3)</td><td class="xxxx-borders">2 (0.9)</td><td class="xxxr-borders">7 (3.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Sinusitis</td><td class="xxxx-borders shading">3 (1.4)</td><td class="xxxx-borders shading">4 (1.8)</td><td class="xxxx-borders shading">3 (1.3)</td><td class="xxxr-borders shading">5 (2.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Gastroenteritis</td><td class="xxxx-borders">4 (1.8)</td><td class="xxxx-borders">2 (0.9)</td><td class="xxxx-borders">5 (2.2)</td><td class="xxxr-borders">3 (1.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Increased alanine aminotransferase level</td><td class="xxxx-borders shading">6 (2.7)</td><td class="xxxx-borders shading">3 (1.4)</td><td class="xxxx-borders shading">2 (0.9)</td><td class="xxxr-borders shading">2 (0.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Influenza</td><td class="xxxx-borders">2 (0.9)</td><td class="xxxx-borders">3 (1.4)</td><td class="xxxx-borders">2 (0.9)</td><td class="xxxr-borders">5 (2.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Sinus congestion</td><td class="xxxx-borders shading">5 (2.3)</td><td class="xxxx-borders shading">1 (0.5)</td><td class="xxxx-borders shading">2 (0.9)</td><td class="xxxr-borders shading">4 (1.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Increased aspartate aminotransferase level</td><td class="xxxx-borders">6 (2.7)</td><td class="xxxx-borders">2 (0.9)</td><td class="xxxx-borders">2 (0.9)</td><td class="xxxr-borders">1 (0.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Anxiety</td><td class="xxxx-borders shading">2 (0.9)</td><td class="xxxx-borders shading">2 (0.9)</td><td class="xxxx-borders shading">1 (0.4)</td><td class="xxxr-borders shading">5 (2.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Adverse event related to atogepant or placebo<a href="#core-t3fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">20 (9.0)</td><td class="xxxx-borders">51 (23.1)</td><td class="xxxx-borders">34 (14.9)</td><td class="xxxr-borders">45 (19.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Serious adverse event</td><td class="xxxx-borders shading">2 (0.9)</td><td class="xxxx-borders shading">2 (0.9)</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Serious adverse event related to atogepant or placebo<a href="#core-t3fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">0</td><td class="xxxx-borders">1 (0.5)</td><td class="xxxx-borders">0</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Death</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging02" data-xml-align="left">Adverse event leading to discontinuation of atogepant or placebo</td><td class="xbxx-borders">6 (2.7)</td><td class="xbxx-borders">9 (4.1)</td><td class="xbxx-borders">4 (1.8)</td><td class="xbxr-borders">6 (2.6)</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t3fn1" role="paragraph" data-to-manipulate="true">Participants were counted only once within each category.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t3fn2" role="paragraph" data-to-manipulate="true">Adverse events are listed in decreasing order of the frequency reported in the overall population.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t3fn3" role="paragraph" data-to-manipulate="true">The relatedness of adverse events to atogepant or placebo was determined by the investigator.</div></div></div></figcaption></a><figcaption><div class="caption">Adverse Events, According to Trial Group (Safety Population).<a href="#core-t3fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t3"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2035908_t3.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></div></div><div id="core-collateral-share" role="tabpanel" data-core-tabs="core-collateral-share" tabindex="-1" aria-labelledby="pane-core-collateral-share"><header><h2 id="pane-core-collateral-share"><i class="icon-share" aria-hidden="true"></i>Share</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>Share</h3><div class="section--wrapper"><section><h4>CONTENT LINK</h4><div id="share-self"><p data-id="article-share-self-link" class="share-self__source">https://www.nejm.org/doi/full/10.1056/NEJMoa2035908</p><button data-id="article-share-access" aria-label="CONTENT LINK" class="share-self__action btn btn--inverse"><i aria-hidden="true" class="icon-copy-o"></i><span>Copy Link</span></button><div aria-live="polite" class="share-self__status"><p class="share-self__success"><i aria-hidden="true" class="icon-check_circle"></i><span>Copied!</span></p><p class="share-self__failed"><i aria-hidden="true" class="icon-x_btnclose"></i><span>Copying failed.</span></p></div></div></section><section data-location="share_tools_article"><h4>Share</h4><div class="share-buttons a2a a2a_kit" style="line-height: 16px;"><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i><span>Facebook</span></a><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i><span>X (formerly Twitter)</span></a><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i><span>LinkedIn</span></a><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i><span>email</span></a><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i><span>Bluesky</span></a></div></section></div></div><div data-location="references_article" id="core-collateral-references" role="tabpanel" aria-labelledby="pane-core-collateral-references" data-core-tabs="core-collateral-references" tabindex="-1"><header><h2 id="pane-core-collateral-references"><i aria-hidden="true" class="icon-references"></i>References</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>References</h3><div role="list" class="section--wrapper"><div role="listitem" data-has="label"><div class="label">1.</div><div id="core-r1" class="citations"><div class="citation"><div class="citation-content">American Headache Society. The American Headache Society position statement on integrating new migraine treatments into clinical practice. <em>Headache</em> 2019;59:1-18.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r1-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/head.13456" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30536394/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000454118200001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+American+Headache+Society+position+statement+on+integrating+new+migraine+treatments+into+clinical+practice.&amp;publication_year=2019&amp;journal=Headache&amp;pages=1-18&amp;doi=10.1111%2Fhead.13456&amp;pmid=30536394" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r1-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r3-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] and onabotulinumtoxinA, are also used. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r1-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] and elsewhere without regulatory approval. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="core-r2" class="citations"><div class="citation"><div class="citation-content">Loder E, Burch R, Rizzoli P. The 2012 AHS/AAN guidelines for prevention of episodic migraine: a summary and comparison with other recent clinical practice guidelines. <em>Headache</em> 2012;52:930-945.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r3-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/j.1526-4610.2012.02185.x" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22671714/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000304800600002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+2012+AHS%2FAAN+guidelines+for+prevention+of+episodic+migraine%3A+a+summary+and+comparison+with+other+recent+clinical+practice+guidelines.&amp;publication_year=2012&amp;journal=Headache&amp;pages=930-945&amp;doi=10.1111%2Fj.1526-4610.2012.02185.x&amp;pmid=22671714" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="core-r3" class="citations"><div class="citation"><div class="citation-content">Evers S, Afra J, Frese A, et al. EFNS guideline on the drug treatment of migraine — revised report of an EFNS task force. <em>Eur J Neurol</em> 2009;16:968-981.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r3-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/j.1468-1331.2009.02748.x" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19708964/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000268791500005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=EFNS+guideline+on+the+drug+treatment+of+migraine+%E2%80%94+revised+report+of+an+EFNS+task+force.&amp;publication_year=2009&amp;journal=Eur+J+Neurol&amp;pages=968-981&amp;doi=10.1111%2Fj.1468-1331.2009.02748.x&amp;pmid=19708964" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r3-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r3-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] and onabotulinumtoxinA, are also used. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r15" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] reuptake inhibitors. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="core-r4" class="citations"><div class="citation"><div class="citation-content">Croop R, Lipton RB, Kudrow D, et al. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. <em>Lancet</em> 2021;397:51-60.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(20)32544-7" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33338437/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000607268300026" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Oral+rimegepant+for+preventive+treatment+of+migraine%3A+a+phase+2%2F3%2C+randomised%2C+double-blind%2C+placebo-controlled+trial.&amp;publication_year=2021&amp;journal=Lancet&amp;pages=51-60&amp;doi=10.1016%2FS0140-6736%2820%2932544-7&amp;pmid=33338437" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="core-r5" class="citations"><div class="citation"><div class="citation-content">Dodick DW, Lipton RB, Ailani J, et al. Ubrogepant for the treatment of migraine. <em>N Engl J Med</em> 2019;381:2230-2241.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_6_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2035908&amp;key=10.1056%2FNEJMoa1813049&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31800988/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000505219800008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Ubrogepant+for+the+treatment+of+migraine.&amp;publication_year=2019&amp;journal=N+Engl+J+Med&amp;pages=2230-2241&amp;doi=10.1056%2FNEJMoa1813049&amp;pmid=31800988" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="core-r6" class="citations"><div class="citation"><div class="citation-content">Goadsby PJ, Reuter U, Hallström Y, et al. A controlled trial of erenumab for episodic migraine. <em>N Engl J Med</em> 2017;377:2123-2132.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_7_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2035908&amp;key=10.1056%2FNEJMoa1705848&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29171821/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000416555000006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+controlled+trial+of+erenumab+for+episodic+migraine.&amp;publication_year=2017&amp;journal=N+Engl+J+Med&amp;pages=2123-2132&amp;doi=10.1056%2FNEJMoa1705848&amp;pmid=29171821" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="core-r7" class="citations"><div class="citation"><div class="citation-content">Hansen JM, Hauge AW, Olesen J, Ashina M. Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura. <em>Cephalalgia</em> 2010;30:1179-1186.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1177/0333102410368444" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20855363/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000285052900005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Calcitonin+gene-related+peptide+triggers+migraine-like+attacks+in+patients+with+migraine+with+aura.&amp;publication_year=2010&amp;journal=Cephalalgia&amp;pages=1179-1186&amp;doi=10.1177%2F0333102410368444&amp;pmid=20855363" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="core-r8" class="citations"><div class="citation"><div class="citation-content">Ho TW, Edvinsson L, Goadsby PJ. CGRP and its receptors provide new insights into migraine pathophysiology. <em>Nat Rev Neurol</em> 2010;6:573-582.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nrneurol.2010.127" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20820195/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000282643100009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=CGRP+and+its+receptors+provide+new+insights+into+migraine+pathophysiology.&amp;publication_year=2010&amp;journal=Nat+Rev+Neurol&amp;pages=573-582&amp;doi=10.1038%2Fnrneurol.2010.127&amp;pmid=20820195" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="core-r9" class="citations"><div class="citation"><div class="citation-content">Lipton RB, Croop R, Stock EG, et al. Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine. <em>N Engl J Med</em> 2019;381:142-149.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_10_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2035908&amp;key=10.1056%2FNEJMoa1811090&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31291516/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000475668100009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Rimegepant%2C+an+oral+calcitonin+gene-related+peptide+receptor+antagonist%2C+for+migraine.&amp;publication_year=2019&amp;journal=N+Engl+J+Med&amp;pages=142-149&amp;doi=10.1056%2FNEJMoa1811090&amp;pmid=31291516" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="core-r10" class="citations"><div class="citation"><div class="citation-content">Silberstein SD, Dodick DW, Bigal ME, et al. Fremanezumab for the preventive treatment of chronic migraine. <em>N Engl J Med</em> 2017;377:2113-2122.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_11_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2035908&amp;key=10.1056%2FNEJMoa1709038&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29171818/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000416555000005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Fremanezumab+for+the+preventive+treatment+of+chronic+migraine.&amp;publication_year=2017&amp;journal=N+Engl+J+Med&amp;pages=2113-2122&amp;doi=10.1056%2FNEJMoa1709038&amp;pmid=29171818" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="core-r11" class="citations"><div class="citation"><div class="citation-content">Min KC, Kraft WK, Bondiskey P, et al. Atogepant is not associated with clinically meaningful alanine aminotransferase elevations in healthy adults. <em>Clin Transl Sci</em> 2021;14:599-605.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r11-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/cts.12917" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33142014/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000591846800001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Atogepant+is+not+associated+with+clinically+meaningful+alanine+aminotransferase+elevations+in+healthy+adults.&amp;publication_year=2021&amp;journal=Clin+Transl+Sci&amp;pages=599-605&amp;doi=10.1111%2Fcts.12917&amp;pmid=33142014" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r11-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r11-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] concentrations are reached by 1 to 2 hours. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r11-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] with a half-life of approximately 11 hours. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="core-r12" class="citations"><div class="citation"><div class="citation-content">Goadsby PJ, Dodick DW, Ailani J, et al. Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial. <em>Lancet Neurol</em> 2020;19:727-737.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r12-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1474-4422(20)30234-9" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32822633/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000562556500015" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Safety%2C+tolerability%2C+and+efficacy+of+orally+administered+atogepant+for+the+prevention+of+episodic+migraine+in+adults%3A+a+double-blind%2C+randomised+phase+2b%2F3+trial.&amp;publication_year=2020&amp;journal=Lancet+Neurol&amp;pages=727-737&amp;doi=10.1016%2FS1474-4422%2820%2930234-9&amp;pmid=32822633" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r12-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r12-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] trial involving 834 participants. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r24" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] participants with episodic migraine. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r12-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] extend those of a previous phase 2–3 trial. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="core-r13" class="citations"><div class="citation"><div class="citation-content">Hoffmann J, Akerman S, Goadsby PJ. Efficacy and mechanism of anticonvulsant drugs in migraine. <em>Expert Rev Clin Pharmacol</em> 2014;7:191-201.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r15"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1586/17512433.2014.885835" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24494792/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000349989200011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Efficacy+and+mechanism+of+anticonvulsant+drugs+in+migraine.&amp;publication_year=2014&amp;journal=Expert+Rev+Clin+Pharmacol&amp;pages=191-201&amp;doi=10.1586%2F17512433.2014.885835&amp;pmid=24494792" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="core-r14" class="citations"><div class="citation"><div class="citation-content">Schürks M, Diener HC, Goadsby P. Update on the prophylaxis of migraine. <em>Curr Treat Options Neurol</em> 2008;10:20-29.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r15"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s11940-008-0003-3" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/18325296/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000258902900003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Update+on+the+prophylaxis+of+migraine.&amp;publication_year=2008&amp;journal=Curr+Treat+Options+Neurol&amp;pages=20-29&amp;doi=10.1007%2Fs11940-008-0003-3&amp;pmid=18325296" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="core-r15" class="citations"><div class="citation"><div class="citation-content">Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. <em>Neurology</em> 2012;78:1337-1345.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r15"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1212/WNL.0b013e3182535d20" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22529202/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000303324100017" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Evidence-based+guideline+update%3A+pharmacologic+treatment+for+episodic+migraine+prevention+in+adults%3A+report+of+the+Quality+Standards+Subcommittee+of+the+American+Academy+of+Neurology+and+the+American+Headache+Society.&amp;publication_year=2012&amp;journal=Neurology&amp;pages=1337-1345&amp;doi=10.1212%2FWNL.0b013e3182535d20&amp;pmid=22529202" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="core-r16" class="citations"><div class="citation"><div class="citation-content">Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. <em>Cephalalgia</em> 2018;38:1-211.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r16-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1177/0333102417738202" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29368949/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000425149500001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+International+Classification+of+Headache+Disorders%2C+3rd+edition.&amp;publication_year=2018&amp;journal=Cephalalgia&amp;pages=1-211&amp;doi=10.1177%2F0333102417738202&amp;pmid=29368949" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r16-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r16-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] with migraine onset before 50 years of age. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r16-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] 1 or during the 28-day baseline period. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="core-r17" class="citations"><div class="citation"><div class="citation-content">Cala ML, Graham CA, Lipton RB, et al. The activity impairment in migraine–diary (AIM-D): a novel migraine-specific patient-reported outcome measure to assess functioning based on activity impairment in episodic and chronic migraine patients. <em>Cephalalgia</em> 2018;38:Suppl:4-5. abstract.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r17"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000443829800006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+activity+impairment+in+migraine%E2%80%93diary+%28AIM-D%29%3A+a+novel+migraine-specific+patient-reported+outcome+measure+to+assess+functioning+based+on+activity+impairment+in+episodic+and+chronic+migraine+patients.&amp;publication_year=2018&amp;journal=Cephalalgia&amp;pages=4-5" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="core-r18" class="citations"><div class="citation"><div class="citation-content">Cole JC, Lin P, Rupnow MFT. Minimal important differences in the Migraine-Specific Quality of Life Questionnaire (MSQ) version. <em>Cephalalgia</em> 2009;29:1180-1187.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r18"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/j.1468-2982.2009.01852.x" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19830883/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000270587600006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Minimal+important+differences+in+the+Migraine-Specific+Quality+of+Life+Questionnaire+%28MSQ%29+version.&amp;publication_year=2009&amp;journal=Cephalalgia&amp;pages=1180-1187&amp;doi=10.1111%2Fj.1468-2982.2009.01852.x&amp;pmid=19830883" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="core-r19" class="citations"><div class="citation"><div class="citation-content">Negro A, Lionetto L, Simmaco M, Martelletti P. CGRP receptor antagonists: an expanding drug class for acute migraine? <em>Expert Opin Investig Drugs</em> 2012;21:807-818.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r20"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1517/13543784.2012.681044" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22512641/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000304063400006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=CGRP+receptor+antagonists%3A+an+expanding+drug+class+for+acute+migraine%3F&amp;publication_year=2012&amp;journal=Expert+Opin+Investig+Drugs&amp;pages=807-818&amp;doi=10.1517%2F13543784.2012.681044&amp;pmid=22512641" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="core-r20" class="citations"><div class="citation"><div class="citation-content">Messina R, Goadsby PJ. CGRP — a target for acute therapy in migraine: clinical data. <em>Cephalalgia</em> 2019;39:420-427.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r20"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1177/0333102418768095" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29616830/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000460298300009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=CGRP+%E2%80%94+a+target+for+acute+therapy+in+migraine%3A+clinical+data.&amp;publication_year=2019&amp;journal=Cephalalgia&amp;pages=420-427&amp;doi=10.1177%2F0333102418768095&amp;pmid=29616830" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="core-r21" class="citations"><div class="citation"><div class="citation-content">Bigal ME, Dodick DW, Rapoport AM, et al. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. <em>Lancet Neurol</em> 2015;14:1081-1090.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1474-4422(15)00249-5" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26432182/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000362975200012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Safety%2C+tolerability%2C+and+efficacy+of+TEV-48125+for+preventive+treatment+of+high-frequency+episodic+migraine%3A+a+multicentre%2C+randomised%2C+double-blind%2C+placebo-controlled%2C+phase+2b+study.&amp;publication_year=2015&amp;journal=Lancet+Neurol&amp;pages=1081-1090&amp;doi=10.1016%2FS1474-4422%2815%2900249-5&amp;pmid=26432182" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="core-r22" class="citations"><div class="citation"><div class="citation-content">Dodick DW, Goadsby PJ, Silberstein SD, et al. Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. <em>Lancet Neurol</em> 2014;13:1100-1107.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1474-4422(14)70209-1" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25297013/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000343783900017" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Safety+and+efficacy+of+ALD403%2C+an+antibody+to+calcitonin+gene-related+peptide%2C+for+the+prevention+of+frequent+episodic+migraine%3A+a+randomised%2C+double-blind%2C+placebo-controlled%2C+exploratory+phase+2+trial.&amp;publication_year=2014&amp;journal=Lancet+Neurol&amp;pages=1100-1107&amp;doi=10.1016%2FS1474-4422%2814%2970209-1&amp;pmid=25297013" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="core-r23" class="citations"><div class="citation"><div class="citation-content">Dodick DW, Goadsby PJ, Spierings ELH, Scherer JC, Sweeney SP, Grayzel DS. Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study. <em>Lancet Neurol</em> 2014;13:885-892.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1474-4422(14)70128-0" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25127173/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000341405400013" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Safety+and+efficacy+of+LY2951742%2C+a+monoclonal+antibody+to+calcitonin+gene-related+peptide%2C+for+the+prevention+of+migraine%3A+a+phase+2%2C+randomised%2C+double-blind%2C+placebo-controlled+study.&amp;publication_year=2014&amp;journal=Lancet+Neurol&amp;pages=885-892&amp;doi=10.1016%2FS1474-4422%2814%2970128-0&amp;pmid=25127173" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="core-r24" class="citations"><div class="citation"><div class="citation-content">Ho TW, Connor KM, Zhang Y, et al. Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention. <em>Neurology</em> 2014;83:958-966.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1212/WNL.0000000000000771" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25107879/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000341883600005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Randomized+controlled+trial+of+the+CGRP+receptor+antagonist+telcagepant+for+migraine+prevention.&amp;publication_year=2014&amp;journal=Neurology&amp;pages=958-966&amp;doi=10.1212%2FWNL.0000000000000771&amp;pmid=25107879" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">25.</div><div id="core-r25" class="citations"><div class="citation"><div class="citation-content">Mallinckrodt CH, Lane PW, Schnell D, Peng Y, Mancuso JP. Recommendations for the primary analysis of continuous endpoints in longitudinal clinical trials. <em>Drug Inf J</em> 2008;42:303-319.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r25"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1177/009286150804200402" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000257155100002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Recommendations+for+the+primary+analysis+of+continuous+endpoints+in+longitudinal+clinical+trials.&amp;publication_year=2008&amp;journal=Drug+Inf+J&amp;pages=303-319&amp;doi=10.1177%2F009286150804200402" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">26.</div><div id="core-r26" class="citations"><div class="citation"><div class="citation-content">Bretz F, Maurer W, Brannath W, Posch M. A graphical approach to sequentially rejective multiple test procedures. <em>Stat Med</em> 2009;28:586-604.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r26"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/sim.3495" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19051220/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000263005700004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+graphical+approach+to+sequentially+rejective+multiple+test+procedures.&amp;publication_year=2009&amp;journal=Stat+Med&amp;pages=586-604&amp;doi=10.1002%2Fsim.3495&amp;pmid=19051220" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">27.</div><div id="core-r27" class="citations"><div class="citation"><div class="citation-content">Temple R. Hy’s law: predicting serious hepatotoxicity. <em>Pharmacoepidemiol Drug Saf</em> 2006;15:241-243.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r27"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/pds.1211" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/16552790/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000236995000005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Hy%E2%80%99s+law%3A+predicting+serious+hepatotoxicity.&amp;publication_year=2006&amp;journal=Pharmacoepidemiol+Drug+Saf&amp;pages=241-243&amp;doi=10.1002%2Fpds.1211&amp;pmid=16552790" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">28.</div><div id="core-r28" class="citations"><div class="citation"><div class="citation-content">Diener HC, Tassorelli C, Dodick DW, et al. Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine attacks in episodic migraine in adults. <em>Cephalalgia</em> 2020;40:1026-1044.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r28"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1177/0333102420941839" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32722936/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000555082600001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Guidelines+of+the+International+Headache+Society+for+controlled+trials+of+preventive+treatment+of+migraine+attacks+in+episodic+migraine+in+adults.&amp;publication_year=2020&amp;journal=Cephalalgia&amp;pages=1026-1044&amp;doi=10.1177%2F0333102420941839&amp;pmid=32722936" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">29.</div><div id="core-r29" class="citations"><div class="citation"><div class="citation-content">Falkenberg K, Bjerg HR, Olesen J. Two-hour CGRP infusion causes gastrointestinal hyperactivity: possible relevance for CGRP antibody treatment. <em>Headache</em> 2020;60:929-937.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r30"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/head.13795" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32227602/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000522313600001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Two-hour+CGRP+infusion+causes+gastrointestinal+hyperactivity%3A+possible+relevance+for+CGRP+antibody+treatment.&amp;publication_year=2020&amp;journal=Headache&amp;pages=929-937&amp;doi=10.1111%2Fhead.13795&amp;pmid=32227602" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">30.</div><div id="core-r30" class="citations"><div class="citation"><div class="citation-content">L’Heureux MC, St-Pierre S, Trudel L, Plourde V, Lepage R, Poitras P. Digestive motor effects and vascular actions of CGRP in dog are expressed by different receptor subtypes. <em>Peptides</em> 2000;21:425-430.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r30"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0196-9781(00)00160-1" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/10793227/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000086995900016" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Digestive+motor+effects+and+vascular+actions+of+CGRP+in+dog+are+expressed+by+different+receptor+subtypes.&amp;publication_year=2000&amp;journal=Peptides&amp;pages=425-430&amp;doi=10.1016%2FS0196-9781%2800%2900160-1&amp;pmid=10793227" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">31.</div><div id="core-r31" class="citations"><div class="citation"><div class="citation-content">Ashina M. Migraine. <em>N Engl J Med</em> 2020;383:1866-1876.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r32"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_32_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2035908&amp;key=10.1056%2FNEJMra1915327&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33211930/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000604334000015" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Migraine.&amp;publication_year=2020&amp;journal=N+Engl+J+Med&amp;pages=1866-1876&amp;doi=10.1056%2FNEJMra1915327&amp;pmid=33211930" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">32.</div><div id="core-r32" class="citations"><div class="citation"><div class="citation-content">Kielbasa W, Helton DL. A new era for migraine: pharmacokinetic and pharmacodynamic insights into monoclonal antibodies with a focus on galcanezumab, an anti-CGRP antibody. <em>Cephalalgia</em> 2019;39:1284-1297.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r32"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1177/0333102419840780" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30917684/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000482243200010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+new+era+for+migraine%3A+pharmacokinetic+and+pharmacodynamic+insights+into+monoclonal+antibodies+with+a+focus+on+galcanezumab%2C+an+anti-CGRP+antibody.&amp;publication_year=2019&amp;journal=Cephalalgia&amp;pages=1284-1297&amp;doi=10.1177%2F0333102419840780&amp;pmid=30917684" target="_blank">Google Scholar</a></div></div></div></div></div></div></div></div><aside data-core-aside="right-rail">



        
        <div id="DTM_Position_MedRectangle" class="ad">
 <!--emptycomment-->
</div>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="relatedArticlesWidget" data-widget-id="8206d5cd-cb8c-4ff9-8c46-3d22e0dee215" data-location="recirc_curatedRelated_article">
        



        
        <div class="ng-related-articles"><h3 class="ng-subsection-title"><span class="ng-subsection-title_text">Related articles</span></h3><ul class="ng-related-articles_list"><li class="ng-related-articles_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/perspective" class="issue-item_type">Perspective</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Oct 26, 2022</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMp2213217" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Migraine — Patient Perspectives</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">C.E. Armand and Others</span></div></div></div></div></div></li></ul></div>

        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <div id="nejm_jobs" class="nejm_jobs"> <!-- top red rectangle --><div id="nejm-widget" class="nejm-widget" style="display: block;"><div class="nejm-widget_logo">	<a target="nejm-win" href="https://www.nejmcareercenter.org/?query=fjw">		<img alt="CareerCenter" src="https://apps1.nejmcareercenter.org/images/nejmCCID-JobsWidget.gif" width="140" height="36">	</a></div><div class="nejm-widget_cont"> <!-- content --><div class="nejm-widget_title">PHYSICIAN JOBS</div><div class="nejm-widget_date">June 19, 2025</div><div class="nejm-widget_item"><div><span> Texas</span></div><div><span>Urology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/883539/urologist-texas-urology-specialists-austin/?query=fjwp&amp;rid=5696">Urologist - Texas Urology Specialists Austin</a></div></div><div class="nejm-widget_item"><div><span> Loma Linda, California</span></div><div><span>Surgery, Neurological</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/894001/academic-neurosurgeon-spine-opportunity-in-southern-california/?query=fjwp&amp;rid=69418">Academic Neurosurgeon - Spine Opportunity in Southern California</a></div></div><div class="nejm-widget_item"><div><span> Newport News, Virginia</span></div><div><span>Neonatal / Perinatal Medicine</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/895373/neonatologist/?query=fjwf&amp;rid=49812">Neonatologist</a></div></div><div class="nejm-widget_item"><div><span> Manchester, New Hampshire</span></div><div><span>Otolaryngology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/895443/general-otolaryngologist/?query=fjwf&amp;rid=217510">General Otolaryngologist</a></div></div><div class="nejm-widget_item"><div><span> San Francisco, California</span></div><div><span>Surgery, Transplant</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/880194/swbmg-hepatology-transplant-/?query=fjwf&amp;rid=845672">SWBMG - Hepatology (Transplant)</a></div></div><div class="nejm-widget_item"><div><span> Woburn, Massachusetts</span></div><div><span>Psychiatry</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/890411/outpatient-psychiatrist-child-or-adult-/?query=fjwf&amp;rid=377088">Outpatient Psychiatrist (Child or Adult)</a></div></div></div> <!-- content --> <!-- footer --></div> <!-- nejm-widget --></div><script src="https://apps1.nejmcareercenter.org/?width=300&amp;sp=all"></script>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="literatumAd" data-widget-id="001e4aa7-b6fe-4b21-9d5b-5bde81227c67" id="ad-article-right-rail-300x250-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <a href="/action/clickThrough?id=128129&amp;url=https%3A%2F%2Fstore.nejm.org%2Fsignup%2Fnejm%2Fregister%2Falerts%3Fpromo%3DONFQSR51%26query%3Dcm_rr%26utm_source%3Dnejm%26utm_medium%3Dcm%26utm_campaign%3Dalerts23&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2035908&amp;pubId=41395316&amp;placeholderId=101337&amp;productId=1035"><img src="/sda/128129/rightRail--SpecialtyUpdates23-001.jpg" width="300" height="250"></a>
            
        </div>
    

    

    



        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <script src="https://widgets.nejm.org/onepub-widgets/loader/webcomponents-loader.js" async="" nonce="9523aece44e40cec-GRU">
<script src="https://widgets.nejm.org/onepub-widgets/loader/polyfill-support.js"  nonce="9523aece44e40cec-GRU"></script>
<script src="https://widgets.nejm.org/onepub-widgets/more-like-this.js" type="module" nonce="9523aece44e40cec-GRU"></script>

<more-like-this class="onepub-widget" dataid="onepub-more-like-this" collections="catalyst-article, clinician-article, evidence-article, nejm-ai-article, nejm-article" headertitle="More Like This" maxitems="5"><!----><div class="more-like-this onepub-more-like-this_"><!--?lit$901502469$--><onepub-fonts><wc-fetch></wc-fetch><!--?lit$901502469$--><div class="mlt-wrapper"><div class="mlt-header-container"><div class="mlt-header-content-left"><div class="mlt-header-title-container"><span class="mlt-header-title">More Like This</span></div><!--?lit$901502469$--></div></div><div class="mlt-body"><!--?lit$901502469$--><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$901502469$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$901502469$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$901502469$-->Sep 05, 2024</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2314577?query=recirc_Semantic" target="_self">A Monoclonal Antibody to PACAP for Migraine Prevention</a></div><div class="mlt-article-authors"><!--?lit$901502469$-->M. Ashina and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/clinical-practice" target="_self"><!--?lit$901502469$-->Clinical Practice</a> <span class="mlt-article-site-label"><!--?lit$901502469$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$901502469$-->Jan 30, 2025</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMcp2400691?query=recirc_Semantic" target="_self">Sport-Related Concussion</a></div><div class="mlt-article-authors"><!--?lit$901502469$-->J.J. Leddy</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/case-records-of-the-massachusetts-general-hospital" target="_self"><!--?lit$901502469$-->Case Records of the Massachusetts General Hospital</a> <span class="mlt-article-site-label"><!--?lit$901502469$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$901502469$-->Dec 19, 2024</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMcpc2402504?query=recirc_Semantic" target="_self">Case 40-2024: A 56-Year-Old Woman with End-Stage Liver Disease and Headache</a></div><div class="mlt-article-authors"><!--?lit$901502469$-->S.J. Herzig and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/images-in-clinical-medicine" target="_self"><!--?lit$901502469$-->Images in Clinical Medicine</a> <span class="mlt-article-site-label"><!--?lit$901502469$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$901502469$-->Apr 17, 2025</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMicm2415568?query=recirc_Semantic" target="_self">Hemiplegic Migraine</a></div><div class="mlt-article-authors"><!--?lit$901502469$-->J.C. Feemster and K.E. Green</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/perspective" target="_self"><!--?lit$901502469$-->Perspective</a> <span class="mlt-article-site-label"><!--?lit$901502469$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$901502469$-->Mar 27, 2025</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMp2500379?query=recirc_Semantic" target="_self">Partnerships between Pharmaceutical and Telehealth Companies — Increasing Access or Driving Inappropriate Prescribing?</a></div><div class="mlt-article-authors"><!--?lit$901502469$-->E.C. Fuse Brown, O.J. Wouters, and A. Mehrotra</div></div><!----></div><div class="mlt-footer"></div></div></onepub-fonts><style>:host{display:block}@keyframes fadeIn{0%{opacity:0}100%{opacity:1}}.more-like-this{max-width:25rem}.more-like-this *{font-variant-numeric:lining-nums}.mlt-wrapper{animation:fadeIn 1s}.mlt-header-container{border-bottom:#4d4d4d solid .0625rem;border-top:#4d4d4d solid .125rem}.mlt-header-title{color:#1a1a1a;display:block;font-family:var(--sans-serif);font-size:1rem;font-weight:700;letter-spacing:.02rem;line-height:1.5rem;padding-bottom:.94rem;padding-top:.94rem;text-transform:uppercase}.mlt-header-description{color:#333;display:block;font-family:ff-scala-sans-pro;font-size:.75rem;letter-spacing:.05rem;margin-top:-.5rem;padding-bottom:1rem;text-transform:uppercase}.mlt-article-container{border-bottom:#e5e5e5 solid .0625rem;margin-top:1.38rem}.mlt-article-container-header{font-family:var(--sans-serif);font-size:.6875rem;letter-spacing:.04em;line-height:1.125rem;margin:0 0 1rem;text-transform:uppercase}.mlt-article-type{font-weight:700;line-height:1.25rem;letter-spacing:.04rem;text-decoration:none}.mlt-article-type:hover{text-decoration:underline}.nejm{color:#f30}.nejm-ai{color:#006197}.nejm-catalyst{color:#5708a6}.nejm-evidence{color:#69a323}.mlt-article-site-label::after,.mlt-article-type::after{border-right:1px solid #e5e5e5;content:'';display:inline;padding:.1875rem .375rem .125rem 0;margin:0 .375rem 0 0}.mlt-article-pubdate{color:#666;font-style:normal;font-weight:700;line-height:1.25rem;letter-spacing:.04em}.mlt-article-authors{color:#666;font-family:var(--sans-serif);font-size:1rem;font-style:normal;font-weight:400;letter-spacing:normal;line-height:1.5rem;margin-bottom:1.38rem}.mlt-article-site-label{color:#666;font-style:normal;font-weight:700;letter-spacing:.04em}.mlt-article-title{margin-bottom:.5rem}.mlt-article-title>a{background-image:linear-gradient(#f30,#f30);background-position:0 90%;background-repeat:no-repeat;background-size:0 0;color:#1a1a1a;font-family:var(--quadraat-web);font-size:1.25rem;font-style:normal;font-weight:700;letter-spacing:normal;line-height:1.8rem;margin:1.5rem 0 .35rem 0;text-decoration:none;transition:background .25s ease-in-out}.mlt-article-title>a:hover{background-position:0 98%;background-size:100% .125rem;text-decoration:none}.skeleton-card{box-shadow:0 0 4px 1px rgba(0,0,0,.1);margin:1rem 0;padding:1rem}</style></div></more-like-this>




        
        <div><div class="pb-dropzone" data-pb-dropzone="col-0" title="col-0"></div></div>










    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="ad06db99-f228-4c92-9ad7-c4ae0fdbdbf1" id="bc-web-rec">
        



        
        <!-- BlueConic TEST empty HTML widget with DIV wrapper with id=bc-web-rec -->

        </div>
    

</aside></article><div data-extent="article-wrapper"><div class="core-container"></div><div class="after-credits"><div class="core-container"><a href="/doi/pdf/10.1056/NEJMoa2035908?download=true" id="downloadPdfUrl" data-doi="10.1056/NEJMoa2035908" data-behavior="trackDownloadEvent" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2035908.pdf"><span>Download PDF</span></a></div></div></div><script id="axel-publication-metadata" type="application/json">{"doi":"10.1056/NEJMoa2035908"}
</script><script type="text/javascript" data-ot-ignore="data-ot-ignore" defer="defer" src="https://static.addtoany.com/menu/page.js" class="optanon-category-C0004 ot-vscat-C0004"></script><div class="articles-nav"></div><template id="figure_nav_template"><nav><a href="#" title="Open in viewer" class="open-in-viewer"><i aria-hidden="true" class="icon-expand"></i></a></nav></template><template id="fv_panel_template" data-sharesocial="Share"><div class="fv__panel js--hidden"><div class="fv__panel__text"><div class="fv__panel__contentTitle"></div><div class="fv__panel__contentText"></div></div></div></template>
<template id="fv_directory_template" data-overlay="View figure"><div class="fv__directory"><div class="fv__header"><nav class="tab__nav"></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"></div></div></template><template id="fv_directory_tabItem_template" data-figures="Figures" data-others="Others" data-tables="Tables"><button role="tab" data-toggle="tab" class="tab__nav__item"></button></template>
<template id="fv_lightbox_template" data-sr-back="Go to figure location within the article" data-sr-closealt="Close" data-sr-download="Toggle download panel" data-sr-download-pptx="Download PPT" data-sr-info="Toggle information panel" data-sr-panel="Close panel" data-sr-share="Toggle share panel" data-sr-zoom="Zoom" data-text-close="Back to article" data-text-nav-figures="All figures" data-text-nav-others="All others" data-text-nav-tables="All tables" data-text-viewall="View all material" data-title-back="Back to article" data-title-closealt="Close" data-title-download="Download" data-title-download-pptx="Download PPT" data-title-info="Info" data-title-share="Share" data-title-zoom="Zoom"></template>
<template id="fv_toolbar_template"><div class="fv__toolbar__info"><strong class="fv__toolbar__contentTitle uppercase"></strong><p class="fv__toolbar__contentText"></p></div></template><template id="toCitationLink" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></a></div></template><template id="toCitationButton" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><button class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></button></div></template><template id="toCitationAccordion" data-collapse-citation="Hide Citations" data-expand-citation="Show Citations" data-collapse-footnote="Hide Footnotes" data-expand-footnote="Show Footnotes"><div class="to-citation__wrapper"><button aria-controls="aria-controls" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="data-expand-title" data-collapsed-title="data-collapsed-title" class="accordion__toggle__title"></span></button><div role="menu" aria-label="links" class="to-citation__accordion no-separator"><ul></ul></div></div></template><template id="toCitationAccordionItem"><li><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span></span></a></li></template><template id="citations_truncate_template"><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary"><span>Show all references</span></button></div></template><template id="collateral_texts_template" data-references="References" data-figure="Go to Figure" data-media="Go to Media" data-more="More" data-original="Go to original" data-table="Go to Table" data-inviewer="Open in Viewer" data-allinviewer="Open all in viewer"><svg data-tags="copyright" viewBox="0 0 24 24"><path d="M12 20.016q3.281 0 5.648-2.368T20.016 12t-2.368-5.648T12 3.984 6.352 6.352 3.984 12t2.368 5.648T12 20.016zm0-18q4.125 0 7.055 2.93T21.985 12t-2.93 7.055T12 21.985t-7.055-2.93T2.015 12t2.93-7.055T12 2.015zm-.14 7.125q-1.876 0-1.876 2.718v.282q0 2.718 1.875 2.718.704 0 1.172-.398t.469-1.008h1.781q0 1.172-1.031 2.063-.984.843-2.39.843-1.876 0-2.86-1.125t-.984-3.093v-.282q0-1.921.937-3 1.125-1.265 2.906-1.265 1.547 0 2.438.89.984.985.984 2.297H13.5q0-.328-.14-.61-.235-.468-.329-.562-.469-.468-1.172-.468z"></path></svg><span>Request permissions</span><i aria-hidden="true" class="icon-open_in_new"></i></template><template id="collapsible_authors_template"><button aria-expanded="false" data-expandable="all" data-label-expand="Expand All" data-label-collapse="Collapse All" class="collateral-contributors-control"><span>Expand All</span></button></template>
<template id="collapsible_tables_collapse_template"><div class="collapsible-figure-btn__wrapper expanded"><button aria-expanded="true" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-up"></i><span class="text-uppercase">Collapse</span></button></div></template>
<template id="collapsible_tables_expand_template"><div class="collapsible-figure-btn__wrapper collapsed"><button aria-expanded="false" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-down"></i><span class="text-uppercase">Expand Table</span></button></div></template><template id="authorsAffiliationsLink"><a href="#tab-contributors" class="to-authors-affiliations">Authors Info &amp; Affiliations</a></template>

        <div role="navigation" aria-label="Sticky Navigation" class="st-header"><div class="st-header__content"><div class="st-header__item st-header__menu"></div><div class="st-header__current st-header__item"><div class="st-header__label">Now Reading:</div><div class="st-header__title">Atogepant for the Preventive Treatment of Migraine</div></div><div class="st-header__share st-header__item"><div class="share-dropblock dropdown"><a id="sticky-header-dropBlock" href="#" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="dropdown-toggle"><span title="" data-toggle="tooltip" data-trigger="hover" data-original-title="Share options"><span class="sr-only">Share</span><i aria-hidden="true" class="icon-share"></i></span></a><div aria-labelledby="sticky-header-dropBlock" data-location="share_tools_article" class="dropdown-menu"><ul class="rlist--inline a2a a2a_kit" style="line-height: 16px;"><li><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i></a></li><li><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i></a></li><li><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i></a></li><li><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i></a></li><li><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i></a></li></ul></div></div></div><div class="st-header__nav st-header__item"><div class="content-navigation"><a href="/doi/full/10.1056/NEJMoa2106391" aria-label="Previous article" aria-disabled="false" class="content-navigation__prev"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>PREVIOUS ARTICLE</h6><div>Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma</div></div></div><i aria-hidden="true" class="icon-arrow-left"></i><span>Previous</span></a><a href="/doi/full/10.1056/NEJMoa2028973" aria-label="Next article" aria-disabled="false" class="content-navigation__next"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>NEXT ARTICLE</h6><div>Variant PNLDC1, Defective piRNA Processing, and Azoospermia</div></div></div><span>Next</span><i aria-hidden="true" class="icon-arrow-right"></i></a></div></div></div><div class="st-header__track"><div id="progress-tracker" class="st-header__tracker" style="width: 0px;"></div></div></div><div class="fv figureViewer js--has-focus-mode"><div class="fv__directory" data-core-tabs="default" style="display: flex;"><div class="fv__header"><nav class="tab__nav" role="tablist"><button role="tab" data-toggle="tab" class="tab__nav__item active" aria-controls="#tab-pane-figures" aria-selected="true">Figures</button><button role="tab" data-toggle="tab" class="tab__nav__item" aria-controls="#tab-pane-tables" tabindex="-1" aria-selected="false">Tables</button></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"><div class="tab__pane fv__list fv__list--figures" id="tab-pane-figures" aria-label="All figures" tabindex="0" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f1" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2035908_f1.jpg"><img src="/cms/10.1056/NEJMoa2035908/asset/2bb4f5ab-4ae7-47e5-8e14-9177e4a46c61/assets/images/large/nejmoa2035908_f1.jpg" height="2647" width="2640" aria-labelledby="f1" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 1</div><div class="fv__item__description"><figcaption><div class="caption">Screening, Randomization, and Follow-up.</div><div class="notes"><div role="doc-footnote">Participants could have more than one reason for exclusion before randomization. The safety population included all randomly assigned participants who received at least one dose of atogepant or placebo. The modified intention-to-treat population included all randomly assigned participants who received at least one dose of atogepant or placebo, had a baseline period of electronic-diary data that could be evaluated, and had at least one postbaseline 4-week period of electronic-diary data during the double-blind treatment period that could be evaluated.</div></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f2" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2035908_f2.jpg"><img src="/cms/10.1056/NEJMoa2035908/asset/ff30f63f-0710-4fc3-b304-6a06c0dcc963/assets/images/large/nejmoa2035908_f2.jpg" height="1312" width="2231" aria-labelledby="f2" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 2</div><div class="fv__item__description"><figcaption><div class="caption">Time Course of Efficacy (Modified Intention-to-Treat Population).</div><div class="notes"><div role="doc-footnote">Shown is the least-squares mean change from baseline in migraine days per month. 𝙸 bars indicate standard errors.</div></div></figcaption></div></div></div><div class="tab__pane fv__list fv__list--tables" id="tab-pane-tables" aria-label="All tables" tabindex="-1" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t1" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 1</div><div class="fv__item__description"><figcaption><div class="caption">Demographic and Clinical Characteristics of the Participants at Baseline (Safety Population).<a href="#fv-t1fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t2" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 2</div><div class="fv__item__description"><figcaption><div class="caption">Primary and Secondary Efficacy End Points, According to Trial Group (Modified Intention-to-Treat Population).<a href="#fv-t2fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t3" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 3</div><div class="fv__item__description"><figcaption><div class="caption">Adverse Events, According to Trial Group (Safety Population).<a href="#fv-t3fn1" role="doc-noteref">*</a></div></figcaption></div></div></div></div></div></div><div class="references-pop-up fade" aria-hidden="true"><div class="references-pop-up__heading text-dark d-flex align-items-center"><div class="references-pop-up__title flex-grow-1">Reference <span class="references-pop-up__heading-number">1</span></div><a class="references-pop-up__close text-dark" href="#" title="close pop-up" tabindex="-1" aria-hidden="true"><i class="icon-close" aria-hidden="true"></i></a></div><div class="references-pop-up__items citations to-citation__accordion external-links"></div></div></main>
    

</div>

                    
                        



        
        <div class="ng-page_layout ng-page_layout-fullWidth"><div class="container-fluid"><div class="row"><div class="col-12">



        
        




        
        <div class="ng-page_layout-contentSpacing"></div>










    
    
        <div data-widget-def="oneSearchMultiSearch" data-widget-id="778b3ad8-1a8d-43d8-8196-63b03df4a138" data-location="recirc_inIssue_bottom_article">
        



        
        <div class="os-ms os-ms-more-from-issue"><h3 class="ng-subsection-title"><a href="/toc/nejm/385/8" class="ng-subsection-title_link animation-icon-shift"><span class="ng-subsection-title_text">More from Vol. 385 No. 8</span><span class="ng-subsection-title_icon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-longArrowRight"></use></svg></span></span></a></h3><ul class="os-ms-more-from-issue_list"><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Aug 19, 2021</span></li><li data-toggle="tooltip" data-original-title="Video" class="issue-item_meta-item"><span role="img" aria-label="Video" tabindex="0" class="issue-item_video"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-video"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2106391" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">T.K. Choueiri and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Aug 19, 2021</span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2107051" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Brief Report: Adjunct Immune Globulin for Vaccine-Induced Immune Thrombotic Thrombocytopenia</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">A. Bourguignon and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Aug 19, 2021</span></li><li data-toggle="tooltip" data-original-title="Video" class="issue-item_meta-item"><span role="img" aria-label="Video" tabindex="0" class="issue-item_video"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-video"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2028973" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Variant <em>PNLDC1</em>, Defective piRNA Processing, and Azoospermia</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">L. Nagirnaja and Others</span></div></div></div></div></div></li></ul></div>

        </div>
    

</div></div></div></div>

                    
                        



        
        <div class="ng-page_layout-bottomAd"><div class="container-fluid"><div class="row"><div class="col-12">









    
    
        <div data-widget-def="literatumAd" data-widget-id="7e022d0d-4a48-44a7-af66-033cf5c13eb8" id="ad-article-bottom-FULLx320-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <!-- START: Circulation Footer 3 -->
<aside class="g-cta-subscribe">
	<style>
.bads_footer-banner24-ONJQNRF1{background:url(/pb-assets/contextual_messaging/footer-yel-background-2x-1513629627453.jpg) center center no-repeat;padding:20px;display:block;margin:0;min-height:inherit;background-size:cover;text-decoration:none!important;color:#1a1a1a;text-align:left}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:42px;line-height:44px;letter-spacing:.2px;margin:0 0 20px;font-family:ff-quadraat-web-pro,sans-serif;font-weight:600}.bads_footer-banner24-ONJQNRF1-inner{max-width:1300px;margin:0 auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions .a-btn{width:130px;padding-left:12px}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{position:static;color:#000;font-size:18px;line-height:27px;border:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:20px 0 20px 0;list-style-type:none;padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login a{color:#0a68ad}.bads_clearfix:after{visibility:hidden;display:block;font-size:0;content:" ";clear:both;height:0}.bads_clearfix{display:block}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{float:left;width:50%;padding:30px 0}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{float:left;padding-left:30px;width:50%}.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{display:block;max-width:100%;height:auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:18px;text-transform:uppercase;line-height:24px;font-weight:600;margin:-15px 0 0;letter-spacing:.2px}@media only screen and (max-width:480px){.bads_footer-banner24-ONJQNRF1-inner .bads_device-img,.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{width:100%;float:none}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{padding-left:0}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:27px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding-top:0;padding-bottom:0}.bads_footer-banner24-ONJQNRF1{height:auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:0 0 12px;list-style-type:none}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{line-height:25px;font-size:15px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1 .bads_device-img{width:280px!important;margin:0 auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 3px;font-size:14px}}@media only screen and (min-width:480px) and (max-width:1024px){.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:30px;margin-bottom:15px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{font-size:14px}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:13px;margin-top:0}}@media only screen and (min-width:1025px) and (max-width:1200px){.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:10px 0}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 5px}}@media only screen and (min-width:1401px){.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{float:right}}
	</style>
	<div class="bads_footer-banner24-ONJQNRF1">
	  <div class="bads_footer-banner24-ONJQNRF1-inner bads_clearfix">
		 <div class="bads_subs-btn">
			<p class="g-cta-subscribe__title">Tap into groundbreaking research and clinically relevant insights</p>
			<ul class="g-cta-subscribe__actions">
				<li class="g-cta-subscribe__actions-primary">
				  <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dsubscribe%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2035908%26promo%3DONFQNRF1&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2035908&amp;pubId=41395316&amp;placeholderId=101336&amp;productId=1035" class="ng-btn_primary ng-btn_iconRight"><span class="ng-btn_text">Subscribe </span><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#arrows-longArrowRight"></use></svg></span></a>
				</li>
			</ul>
			<p class="g-cta-subscribe__login">Already a subscriber? <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dactivate%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2035908%26promo%3DONFQANR4&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2035908&amp;pubId=41395316&amp;placeholderId=101336&amp;productId=1035">Activate</a> your online access.</p>
		 </div>

		<div class="bads_device-img">
		   <img src="/sda/127716/footer-devices-2x.png" alt="Devices">
		</div>
	   </div>
	</div>
</aside>
<!--/END: Circulation Footer 3 -->
            
        </div>
    

    

    



        </div>
    

</div></div></div></div>

                    
                        



        
        <footer class="ng-footer footer__top" style="position: relative;"><div data-location="footer" class="ng-footer_columns"><div class="container-fluid"><div class="row"><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">ARTICLE CATEGORIES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item">
        <a href="/browse/nejm-article-category/research" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Research</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/review" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reviews</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/clinical-cases" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Clinical Cases</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/perspective" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Perspective</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/commentary" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Commentary</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/other" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Other</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/medical-article-index" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Browse all Articles</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/toc/nejm/current" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Current Issue</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/loi/nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Issue Index</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">RESOURCES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Authors &amp; Reviewers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Submit a Manuscript</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Subscribers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://tools.ovid.com/ovidtools/nejm.html" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Administrators</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/media" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Media</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/how-to-advertise" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertisers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/information-for-subscription-agents" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Agents</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/permissions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Permissions &amp; Licensing</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/reprints" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reprints</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a>
    </li>
</ul>
</div></div></div><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="About us">ABOUT US</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/about-nejm/about-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">About NEJM</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmgroup.org/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM Group</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Products &amp; Services</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/editors-and-publishers" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Editors &amp; Publishers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/advertising-policies" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertising Policies</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/contact-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text" aria-label="Contact us">Contact Us</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions?#Accessibility" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Accessibility</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">FAQs</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/help" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Help</span></a></li>
    <li class="ng-footer_column-list-item"><a href="mailto:sitefeedback@nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Site Feedback</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">SUBSCRIPTIONS</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Subscribe</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=renew&amp;product=nejm&amp;promo=ONFLNRR3&amp;prc=ONFARN52" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Renew</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=activate&amp;promo=ONFLNAA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Activate Subscription</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC4" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Manage Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=paybill&amp;product=nejm&amp;promo=BNFLPBA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Pay Bill</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.wolterskluwer.com/en/solutions/ovid/nejm-complete-collection" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Sales</span></a></li>    
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/special-content" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Special Content</span></a></li>
</ul>
</div></div></div><div class="col-lg-4 col-md-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">STAY CONNECTED</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/emails?section=NEJM" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Email Alerts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Apps</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Podcasts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">RSS Feed</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/institutional-access" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Remote Access</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="Follow us">FOLLOW US</h4>
<ul class="ng-footer_column-list">
<li class="ng-footer_column-list-item"><a href="https://www.facebook.com/TheNewEnglandJournalofMedicine" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-facebook"></use></svg></span></span><span class="ng-footer_column-link-text">Facebook</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://twitter.com/nejm" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-twitter"></use></svg></span></span><span class="ng-footer_column-link-text">X (formerly Twitter)</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.instagram.com/nejm/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-instagram"></use></svg></span></span><span class="ng-footer_column-link-text">Instagram</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.youtube.com/user/NEJMvideo" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-youtube"></use></svg></span></span><span class="ng-footer_column-link-text">Youtube</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.linkedin.com/company/nejm-group" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-linkedin"></use></svg></span></span><span class="ng-footer_column-link-text">LinkedIn</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://bsky.app/profile/nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-bluesky"></use></svg></span></span><span class="ng-footer_column-link-text">Bluesky</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.tiktok.com/@nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-tiktok"></use></svg></span></span><span class="ng-footer_column-link-text">TikTok</span></a></li>
</ul>
</div></div></div></div></div></div><div data-location="footer" class="ng-footer_journals"><div class="container-fluid"><div class="row"><div class="col-12">



        
        <h4 class="ng-footer_journals-label">JOURNALS</h4>
<ul class="ng-footer_journals-list">
<li class="ng-footer_journals-item"><a href="https://www.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">The New England Journal of Medicine</a></li>
<li class="ng-footer_journals-item"><a href="https://catalyst.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Catalyst Innovations in Care Delivery</a></li>
<li class="ng-footer_journals-item"><a href="https://evidence.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Evidence</a></li>
<li class="ng-footer_journals-item"><a href="https://ai.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM AI</a></li>
</ul>
</div></div></div></div><div data-location="legal" class="ng-footer_bottom"><div class="container-fluid"><div class="row"><div class="col-lg-7 col-md-6 ng-footer_bottom-left">



        
        <p>Copyright © 2025 <a href="https://www.massmed.org/" target="_blank" rel="noopener" class="ng-footer_bottom-link"><b>Massachusetts Medical Society</b></a>. All rights reserved, including those for text and data mining, AI training, and similar technologies. Electronic ISSN 1533-4406. Print ISSN 0028-4793.The content of this site is intended for health care professionals.</p>
</div><div class="col-lg-5 col-md-6 ng-footer_bottom-right">



        
        <style>
  #teconsent a {
    color: #666;
    text-decoration: none;
  }
  #teconsent a:hover {
    color: #666;
    text-decoration: underline;
  }
</style>
<ul class="ng-footer_bottom-list">
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/copyright-information.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Copyright</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/terms-of-use.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Terms</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/privacy-policy.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Privacy Policy</a></li>
<li class="ng-footer_bottom-list-item"><span id="teconsent" consent="undefined" aria-label="Open Cookie Preferences Modal" role="complementary"><a role="link" id="icon-id03277191621108084" tabindex="0" lang="en" aria-haspopup="dialog" aria-label="Cookie Preferences, opens a dedicated popup modal window" class="truste_cursor_pointer">Cookie Preferences</a></span></li>
</ul>
<a href="https://www.nejmgroup.org/" title="NEJM Group" target="_blank" rel="noopener" class="ng-footer_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/logo_group.svg" alt="NEJM Group logo" class="ng-footer_logo" loading="lazy" width="103" height="40"></a>
</div></div></div></div><div data-show-after="400" class="back-to-top back-to-top--align-right  "><button data-snap="footer__top" class="back-to-top__action position-relative p-0 m-0 border-0 d-flex flex-column align-items-center justify-content-center"><svg viewBox="0 0 36 36" class="position-relative"><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" class="back-to-top__action__ring-bg"></path><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" stroke-dasharray="0, 100" class="back-to-top__action__ring"></path></svg><span class="back-to-top__action-icon position-absolute d-flex"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-up"></use></svg></span></span><span class="sr-only">Back to top</span></button></div></footer>

                    
                        



        
        <!-- TrustArc: Banner -->
<div id="consent_blackbar"><style>  #consent_blackbar{    position:relative;    width:100%;    z-index: 999999;  }    #trustarc-banner-overlay {  background-color: rgb(0, 0, 0);   opacity: 0.3;   position: fixed;   z-index: 1000000;   width: 100%;  height: 100%;   top: 0px;   left: 0px;   overflow: hidden;}.truste-title {  /*font-family: "Source Sans Pro", sans-serif;  font-size: 23px;  font-style: normal;  font-stretch: normal;*/  color: #222;  margin-bottom: 20px;  text-align: center;/*  font-weight:bold;*/}.truste-footer {  margin: 0 auto;      }.truste-left {  margin: 0px 0px 15px 15px;/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;    */}.truste-banner { margin: 0 auto; }.truste-messageColumn {/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;*/  color: #666666;  margin: 0px;}#truste-consent-button, #truste-consent-required {    background-color: #FF1E00;    color: #F2F1F1;    padding: 5px 10px;    border: 1px solid #FF1E00;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }      #truste-show-consent {    background-color: #FF1E00;    color: #F2F1F1;    border: 1px solid #FF1E00;    padding: 5px 10px;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }div.truste-consent-track-class {  position: fixed;  z-index:9999999;   background: #666;   border: 1px solid #333;    /*padding: 10px 60px;*/    bottom:0px;    right:0px;    left:0px;    margin: 10px;}.truste-left {  margin: 0;}div.text-content {  display: flex;  flex-direction: column;  align-self: baseline;}#truste-consent-text {    /*font-family: "Source Sans Pro", sans-serif;    font-size: 16px;*/    color: #fff;    margin: 15px 0px;}.truste-footer {  padding-top: 15px;}#truste-consent-content {  margin: 0 auto;    padding: 0 10px;    max-width: 1366px;}.truste-consent-footer {  display: none;}.flex-container {  display: block;  align-items: center;  justify-content: space-between;}#truste-consent-buttons {  float: right;  margin: 10px 5px 10px 0px;}#truste-show-consent { background: #F30 !important;}#truste-consent-button, #truste-consent-required { background: #F30 !important; } /* MEDIA QUERIES */  @media screen and (max-width: 500px) {  #truste-consent-track {    padding: 5px 20px;  }  }@media screen and (max-width: 375px) {  .truste-buttonsColumn {    float: none;    margin: 0;  }  #truste-consent-button, #truste-consent-required, #truste-show-consent {    width: 100%;    margin-bottom: 5px;  }          #truste-consent-buttons {  float: none;  margin: 10px 0px 10px 0px;	}}</style><div id="truste-consent-track" style="display: block; opacity: 1;">  <div id="trustarc-banner-overlay"></div>  <div class="truste-consent-track-class">    <div id="truste-consent-content" class="truste-banner">        <div class="flex-container">          <div class="text-content">            <div id="truste-consent-text" class="truste-messageColumn">This site uses cookies and related technologies, as described in our privacy policy, for purposes that may include site operation, analytics, enhanced user experience, or advertising. You may choose to consent to our use of these technologies, or manage your own preferences.                       </div>          </div>          <div id="truste-consent-buttons" class="truste-buttonsColumn">            <button id="truste-show-consent" aria-haspopup="dialog">Manage Settings</button>      <button id="truste-consent-button">Accept</button>      <!-- <button id="truste-consent-required">Decline All</button> -->          </div>        </div>                <div style="clear:both;"></div>    </div>  </div></div><!--emptycomment--></div>
<!-- /TrustArc: Banner -->

                    
                        



        
        <link rel="stylesheet" href="https://cssjs.nejm.org/mmsWidgets.css"><script nonce="9523aece44e40cec-GRU" type="text/javascript" src="https://cssjs.nejm.org/mmsWidgets.js"></script><script nonce="9523aece44e40cec-GRU" type="text/javascript">var litSSO = {
    "ucid": null,
    "accessToken": null,
    "authState": null
};

var loginUri = '/action/doSsoLogin';
var logoutUri = '/action/doLogout';

displayAuthenticatedMessage();

mmsWidgets.init({
    clientId: 'qsra7g4d6jwdsgn3zbe6udp6r6278mr9',
    origin: 'NEJM',
    xdReceiver: 'http://www.nejm.org/pb-assets/sso/xd.html',
    isFullPageSignIn: isSignInPage(),
    debug: true,

    onReady: function (e) {
        console.log('<<<<<<<<<< client: received onReady event.');
        $("A.litSsoLogin").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0) {
                mmsWidgets.signIn(e);
                return false;
            }
        });
        $("A.litSsoLogout").click(function (e) {
            mmsWidgets.signOut(e);
            return false;
        });
        $("A.litSsoCreate").click(function (e) {
            mmsWidgets.showRegModal(e);
            return false;
        });
        $("A.litSsoSubscribe").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0)
                location.assign(e.currentTarget.href);
            return false;
        });
        if (window.doSSOLogin) {
            window.setTimeout(function () {
                mmsWidgets.signIn();
            }, 500);
        }
        ;
    },
    onLoginSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLoginSuccess event.' + JSON.stringify(e));

        const redirectUrl = getRedirectUri(window.location.search, location.href.replace(window.location.origin, ""));
        document.cookie = "skipSso=; expires=; path=/";
        if (!litSSO.ucid || e.ucid != litSSO.ucid || !litSSO.accessToken || e.accessToken != litSSO.accessToken) {
            location.assign(loginUri + "?ucid=" + e.profile.ucid
                + "&accessToken=" + e.accessToken
                + "&authState=" + e.authState
                + "&email=" + encodeURIComponent(e.profile.email)
                + "&givenNames=" + e.profile.givenName
                + "&surname=" + e.profile.familyName
                + "&redirectUri=" + redirectUrl
                + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                + "&rememberMe=" + e.rememberMe);
        }
    },
    onAuthStateReady: function (e) {
        console.log('<<<<<<<<<< client: received onAuthStateReady event.' + JSON.stringify(e))

        var isMmsSsoAuthenticated = (e.authState && e.authState !== "anonymous" && e.authState !== "lead" && e.ucid && e.accessToken) ? true : false;
        var isLitSsoAuthenticated = (litSSO.ucid && litSSO.accessToken && litSSO.authState) ? true : false;
        console.log('           isMmsSsoAuthenticated=' + isMmsSsoAuthenticated + ', isLitSsoAuthenticated=' + isLitSsoAuthenticated);

        if (isMmsSsoAuthenticated) {
            if (!isLitSsoAuthenticated || litSSO.ucid != e.ucid) {
                if (window.skipSso)
                    document.cookie = "skipSso=" + encodeURIComponent(e.ucid) + "; expires=; path=/";

                if (!window.skipSso && document.cookie.indexOf("skipSso=" + encodeURIComponent(e.ucid)) == -1) {
                    location.assign(loginUri + "?ucid=" + e.profile.ucid
                        + "&accessToken=" + e.accessToken
                        + "&authState=" + e.authState
                        + "&email=" + encodeURIComponent(e.profile.email)
                        + "&givenNames=" + e.profile.givenName
                        + "&surname=" + e.profile.familyName
                        + "&redirectUri=" + location.href.replace(window.location.origin, "")
                        + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                        + "&rememberMe=" + e.rememberMe);
                } else
                    console.log('**** client: Skip SSO ****');
            } else if (e.accessToken !== litSSO.accessToken)
                updateLitSession(e.ucid, e.accessToken);
        } else if (isLitSsoAuthenticated)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));

        if (document.getElementById("ssoerr-ucid"))
            document.getElementById("ssoerr-ucid").innerHTML = e.ucid;

    },
    onRegistrationSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onRegistrationSuccess event.' + JSON.stringify(e))
        document.cookie = "skipSso=; expires=; path=/";
        var uccLastUpdatedDate = '1812-01-01 00:00:00.1 +0000';
        location.assign(loginUri + "?ucid=" + e.profile.ucid
            + "&accessToken=" + e.accessToken
            + "&authState=" + e.authState
            + "&email=" + encodeURIComponent(e.profile.email)
            + "&givenNames=" + e.profile.givenName
            + "&surname=" + e.profile.familyName
            + "&redirectUri=" + location.href.replace(window.location.origin, "")
            + "&uccLastUpdatedDate=" + encodeURIComponent(uccLastUpdatedDate)
            + "&rememberMe=" + e.rememberMe);
    },
    onLogoutSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLogoutSuccess event.' + JSON.stringify(e))

        document.cookie = "skipSso=; expires=; path=/";
        location.assign(logoutUri);
    },
});

function updateLitSession(ucid, accessToken) {
    $.ajax({
        method: "GET",
        url: "/action/doSsoSessionUpdate",
        data: {ucid: ucid, accessToken: accessToken},
        success: function (callData, textStatus) {
            console.log("Session accessToken updated")
            litSSO.accessToken = accessToken
        },
        error: function (jqXHR, textStatus, errorThrown) {
            alert("Your website session has expired and will now be reset.")
            console.log("Session update failed: " + jqXHR.responseText)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));
        }
    });
}

function getRedirectUri(location, fallback) {
    const urlParams = new URLSearchParams(location);
    const uriUrlParam = urlParams.get('uri');
    if (uriUrlParam)
        return encodeURIComponent(uriUrlParam);
    else
        return encodeURIComponent(fallback);
}

function isSignInPage() {
    return document.querySelector('meta[name="pbContext"]').content.indexOf("customPage:string:/sign-in") > -1;
}

function displayAuthenticatedMessage() {
    if (isSignInPage()) {
        var div = document.getElementById('authMsg');
        if ("" === "PersonUser") {
            div.innerHTML += "You are already signed in to " + window.location.origin.replace("https://", "").replace("www.", "") + ". If you would like to sign in with a different email address, please use the form below.";
        } else {
            div.innerHTML = '';
        }
    }
}</script>

                    
                
            </div>
        </div><iframe name="trustarc_notice" id="trustarcNoticeFrame" title="Trustarc Cross-Domain Consent Frame" src="https://consent.trustarc.com/get?name=crossdomain.html&amp;domain=nejm.com" style="display: none;"></iframe>
        


        
        

            <script src="/products/mms-nextgen/mms/releasedAssets/js/build.lazyload.bundle-c8c4e7d20884f81951fb.js" nonce="9523aece44e40cec-GRU"></script>

        <script src="/products/mms-nextgen/mms/releasedAssets/js/main.bundle-3819a02ec7bc2aca01ec.js" nonce="9523aece44e40cec-GRU"></script>
        


<div id="adModal" tabindex="-1" aria-labelledby="exampleModalCenterTitle" class="ng-modal modal" style="display: none;" aria-hidden="true">
    <div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered ad-promoLayer">
        <div class="ng-modal_content modal-content p-0">
            <div class="ng-modal_body modal-body m-0">
                <div class="ng-modal_header modal-header">
                    <button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#close"></use></svg></span></span>
                    </button>
                </div>

            </div>
        </div>
    </div>
</div>
<script type="text/javascript" src="/wro/1125813~product.js" nonce="9523aece44e40cec-GRU"></script>








<input id="showLayers" type="hidden" value="true">

    <!-- placeholder id=null, description=ad-layer-config -->
    <!-- placeholder id=null, description=ad-lauchLayer-1 -->
    <!-- placeholder id=null, description=ad-layer-promo-1 -->

    <input id="firstAd" type="hidden" value="">
    <input id="secondAd" type="hidden" value="">

    
    
    

    
    
    <input id="IsInstitution" type="hidden" value="false">
    <input id="IsSubscriber" type="hidden" value="true">
    <input id="CustomerId" type="hidden" value="">


<script type="text/javascript" nonce="9523aece44e40cec-GRU">
  jQuery.extend(jQuery.mmsLayers.config, {
    rules: [{
      "name": "Launch Layer Ad",
      "frequency": 30,
      "showOnPage": 5,
      "enabled": false,
      "cookieName": "MarketingLaunchLayer",
      "styleClass": "launchLayer"
    },
    {
      "name": "Promo Layer Ad",
      "frequency": 14,
      "enabled": true,
      "cookieName": "PromoLayer",
      "styleClass": "promoLayer"
    },
    {
      "name": "Interstitial Ad",
      "frequency": 7,
      "enabled": false,
      "cookieName": "InterstitialAd"
    },
    {
      "name": "Iperceptions - Ion Layer Ad",
      "showOnPage": 1,
      "enabled": false,
      "test": false,
      "cookieName":"Iperceptions"
    }]
 });
</script>

















    <script type="text/javascript" nonce="9523aece44e40cec-GRU">
        $(document).ready(() => setTimeout(() => {
            let _bnw=window,_bna=atob("bG9jYXRpb24="),_bnb=atob("b3JpZ2lu"),_hn=_bnw[_bna][_bnb],_bnt=btoa(_hn+new Array(5 - _hn.length % 4).join(" "));
            $.get("/resource/lodash?t="+_bnt);
        },4000));
    </script>












    

    
    

    
    
    
    
        
            
                <script type="text/javascript" src="/wro/1125813~article-metrics.js" nonce="9523aece44e40cec-GRU"></script>
            
            
            
        
    




<script type="text/javascript" src="/wro/1125813~full-text-analytics.js" nonce="9523aece44e40cec-GRU"></script>


    


            <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'9523aece2b590cec',t:'MTc1MDM0Mjk5MS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script><iframe height="1" width="1" style="position: absolute; top: 0px; left: 0px; border: none; visibility: hidden;"></iframe><script defer="" src="https://static.cloudflareinsights.com/beacon.min.js/vcd15cbe7772f49c399c6a5babf22c1241717689176015" integrity="sha512-ZpsOmlRQV6y907TI0dKBHq9Md29nnaEIPlkf84rnaERnq6zvWvPUqr2ft8M1aS28oN72PdrCzSjY4U6VaAw1EQ==" data-cf-beacon="{&quot;rayId&quot;:&quot;9523aece2b590cec&quot;,&quot;serverTiming&quot;:{&quot;name&quot;:{&quot;cfExtPri&quot;:true,&quot;cfEdge&quot;:true,&quot;cfOrigin&quot;:true,&quot;cfL4&quot;:true,&quot;cfSpeedBrain&quot;:true,&quot;cfCacheStatus&quot;:true}},&quot;version&quot;:&quot;2025.6.2&quot;,&quot;token&quot;:&quot;f55e150c7a5f4a4ab9ef82f4a1c9c43c&quot;}" crossorigin="anonymous"></script>

        
        
    

<div style="display:none;" id="signInEmbedded" class="ucc-fullpage-signin ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Sign In</h1>
  </div>    
  <div class="capture_signin">
    {* #signInForm *}
    <div class="ucc-form-inner-wrapper">
      {* signInEmailAddress *}
      {* currentPassword *}
      <div style="padding-top:10px;">
          <div class="capture_form_item capture_form_rememberme">
          <label class="ucc-form-checkbox">                
            <input checked="checked" id="ucc-remember-me-cb-embedded" name="ucc-remember-me-cb-embedded" type="checkbox" value="true">
            <span>Remember Me</span>
          </label>                           
          </div>
          <div class="capture_form_item capture_form_forgotpwd">
            <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
          </div>
      </div>
      <div class="capture_form_item">      
        <button id="ucc-sign-in-submit-embedded" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
      </div>
      <div class="capture_form_item capture_form_footer">
        <div class="ucc-no-acct-msg">Don't have an account?</div>
        <div class="ucc-no-acct-msg-2">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
          <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
        </div>
      </div>
      <div class="capture_form_item capture_form_submit">
        
      </div>      
    </div>
    {* /signInForm *}
  </div>
</div><div style="display:none;" id="forgotPassword" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Forgot Password</h1>
  </div>   
  <div class="ucc-form-inner-wrapper">
  <p style="color:black">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
  </div> 
  <div class="capture_forgotpassword">
    {* #forgotPasswordForm *}      
      <div class="ucc-form-inner-wrapper">
        {* forgotPasswordEmailAddress *}
        {* captcha *}
        <div class="capture_form_item" style="padding-top: 20px;">        
          <input id="ucc-widget-forgotpwd-submit" value="Continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
        </div>
      </div>
    {* /forgotPasswordForm *}
  </div>
  </div><div style="display:none;" id="forgotPasswordSuccess" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Create New Password</h1>
  </div>    
  <div class="capture_forgotpassword">
      <div class="ucc-form-inner-wrapper">
        <p style="padding-top: 30px; padding-bottom: 30px;">We've sent an email with instructions to create a new password. Your existing password has not been changed.</p>        
        <div class="capture_form_item">      
          <button class="capture_btn capture_primary capture-full-width-btn" onclick="janrain.capture.ui.modal.close()">CLOSE</button>
        </div>
      </div>
  </div>
  </div><div style="display:none;" id="resetPassword" class="ucc-widgets-nejm-next">
      <div class="row">      
        <div class="col-md-8 col-md-offset-2 reset-pwd-info"><p>To reset your password, enter a new password twice and click the 'Reset Password' button.</p></div>
      </div>
      <div class="col-md-4 col-md-offset-4">
        {* #changePasswordFormNoAuth *}
          {* newPassword *}
          {* newPasswordConfirm *}     
          <div class="capture_form_item">
            <input value="RESET PASSWORD" type="submit" class="capture_btn capture_primary capture-full-width-btn">
          </div>
          {* /changePasswordFormNoAuth *}
      </div>
    </div><div style="display:none;" id="resetPasswordSuccess">
        <div class="reset-pwd-info">
          <div class="reset-pwd-success-welcome"></div>
          <p class="reset-pwd-success-msg">Your password has been reset. You will need to <a href="/signin" onclick="mmsWidgets.signIn(event)">sign in</a> again using your new password to access site content and features.</p>
          <p class="reset-pwd-success-nav"></p>
        </div>      
    </div><div style="display:none;" id="resetPasswordRequestCode" class="ucc-widgets-nejm-next">
        {* #resetPasswordForm *}
        <div class="capture_form_error">The link that you followed to reset your password has expired.</div>
          <div class="col-md-8 col-md-offset-2">
            <p class="reset-pwd-info">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
          </div>
          <div class="col-md-4 col-md-offset-4">
            {* signInEmailAddress *}
            <div class="capture_form_item">
              <input value="continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
            </div>
          </div>
        {* /resetPasswordForm *}
    </div><div style="display:none;" id="resetPasswordRequestCodeSuccess">
      <div class="reset-pwd-info">
        <p>If the address matches an existing account, you will receive an email with instructions to reset your password.</p>
        <p class="reset-pwd-success-nav"></p>
      </div>
  </div><div id="addtoany" style="position: static;"><div class="a2a_overlay" id="a2a_overlay"></div><div id="a2a_modal" class="a2a_modal a2a_hide" role="dialog" tabindex="-1" aria-label=""><div class="a2a_modal_body a2a_menu a2a_hide" id="a2a_copy_link"><label for="a2a_copy_link_text" id="a2a_copy_link_icon" class="a2a_svg a2a_s_link a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><title>Copy link</title><path fill="#FFF" d="M7.591 21.177c0-.36.126-.665.377-.917l2.804-2.804a1.235 1.235 0 0 1 .913-.378c.377 0 .7.144.97.43-.026.028-.11.11-.255.25-.144.14-.24.236-.29.29a2.82 2.82 0 0 0-.2.256 1.056 1.056 0 0 0-.177.344 1.43 1.43 0 0 0-.046.37c0 .36.126.666.377.918a1.25 1.25 0 0 0 .918.377c.126.001.251-.015.373-.047.125-.037.242-.096.345-.175.09-.06.176-.127.256-.2.1-.094.196-.19.29-.29.14-.142.223-.23.25-.254.297.28.445.607.445.984 0 .36-.126.664-.377.916l-2.778 2.79a1.242 1.242 0 0 1-.917.364c-.36 0-.665-.118-.917-.35l-1.982-1.97a1.223 1.223 0 0 1-.378-.9l-.001-.004Zm9.477-9.504c0-.36.126-.665.377-.917l2.777-2.79a1.235 1.235 0 0 1 .913-.378c.35 0 .656.12.917.364l1.984 1.968c.254.252.38.553.38.903 0 .36-.126.665-.38.917l-2.802 2.804a1.238 1.238 0 0 1-.916.364c-.377 0-.7-.14-.97-.418.026-.027.11-.11.255-.25a7.5 7.5 0 0 0 .29-.29c.072-.08.139-.166.2-.255.08-.103.14-.22.176-.344.032-.12.048-.245.047-.37 0-.36-.126-.662-.377-.914a1.247 1.247 0 0 0-.917-.377c-.136 0-.26.015-.37.046-.114.03-.23.09-.346.175a3.868 3.868 0 0 0-.256.2c-.054.05-.15.148-.29.29-.14.146-.222.23-.25.258-.294-.278-.442-.606-.442-.983v-.003ZM5.003 21.177c0 1.078.382 1.99 1.146 2.736l1.982 1.968c.745.75 1.658 1.12 2.736 1.12 1.087 0 2.004-.38 2.75-1.143l2.777-2.79c.75-.747 1.12-1.66 1.12-2.737 0-1.106-.392-2.046-1.183-2.818l1.186-1.185c.774.79 1.708 1.186 2.805 1.186 1.078 0 1.995-.376 2.75-1.13l2.803-2.81c.751-.754 1.128-1.671 1.128-2.748 0-1.08-.382-1.993-1.146-2.738L23.875 6.12C23.13 5.372 22.218 5 21.139 5c-1.087 0-2.004.382-2.75 1.146l-2.777 2.79c-.75.747-1.12 1.66-1.12 2.737 0 1.105.392 2.045 1.183 2.817l-1.186 1.186c-.774-.79-1.708-1.186-2.805-1.186-1.078 0-1.995.377-2.75 1.132L6.13 18.426c-.754.755-1.13 1.672-1.13 2.75l.003.001Z"></path></svg></label><input id="a2a_copy_link_text" type="text" title="Copy link" readonly=""><div id="a2a_copy_link_copied">✓</div></div><div class="a2a_modal_body a2a_menu a2a_thanks a2a_hide" id="a2a_thanks"><div class="a2a_localize" data-a2a-localize="inner,ThanksForSharing">Thanks for sharing!</div></div></div><div class="a2a_menu a2a_full a2a_localize" id="a2apage_full" role="dialog" tabindex="-1" aria-label="Share" data-a2a-localize="title,Share"><div class="a2a_full_header"><div id="a2apage_find_container" class="a2a_menu_find_container"><label for="a2apage_find" id="a2apage_find_icon" class="a2a_svg a2a_s_find"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" aria-hidden="true"><title>Find any service</title><path fill="#CCC" d="M19.7 18.2l-4.5-4.5c.7-1.1 1.2-2.3 1.2-3.6 0-3.5-2.8-6.3-6.3-6.3s-6.3 2.8-6.3 6.3 2.8 6.3 6.3 6.3c1.4 0 2.6-.4 3.6-1.2l4.5 4.5c.6.6 1.3.7 1.7.2.5-.4.4-1.1-.2-1.7zm-9.6-3.6c-2.5 0-4.5-2.1-4.5-4.5 0-2.5 2.1-4.5 4.5-4.5 2.5 0 4.5 2.1 4.5 4.5s-2 4.5-4.5 4.5z"></path></svg></label><input id="a2apage_find" class="a2a_menu_find a2a_localize" type="text" autocomplete="off" title="Find any service" data-a2a-localize="title,FindAnyServiceToAddTo"></div></div><div class="a2a_full_services" id="a2apage_full_services" role="presentation"></div><div class="a2a_full_footer"><a href="https://www.addtoany.com" title="Share Buttons" rel="noopener" target="_blank"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span>AddToAny</a></div></div><div id="a2apage_dropdown" class="a2a_menu a2a_mini a2a_localize a2a_hide" tabindex="-1" aria-label="Share" data-a2a-localize="label,Share"><div class="a2a_mini_services" id="a2apage_mini_services"></div><div id="a2apage_cols_container" class="a2a_cols_container"><div class="a2a_col1" id="a2apage_col1"></div><div id="a2apage_2_col1" class="a2a_hide"></div><div class="a2a_clear"></div></div><div class="a2apage_wide a2a_wide"><a href="#addtoany" id="a2apage_show_more_less" class="a2a_more a2a_localize" title="Show all" data-a2a-localize="title,ShowAll"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span><span class="a2a_localize" data-a2a-localize="inner,More">More…</span></a></div></div><div style="height: 1px; width: 1px; position: absolute; z-index: 100000; top: 0px; visibility: hidden;"><iframe id="a2a_sm_ifr" title="AddToAny Utility Frame" aria-hidden="true" src="https://static.addtoany.com/menu/sm.25.html#type=core&amp;event=load" style="height: 1px; width: 1px; border: 0px; left: 0px; top: 0px; position: absolute; z-index: 100000; display: none;"></iframe></div></div><script type="text/javascript" src="https://api.altmetric.com/v1/internal-556fdf0f/doi/10.1056/nejmoa2035908?callback=_altmetric.embed_callback&amp;domain=www.nejm.org&amp;cache_until=11-19"></script><div role="status" aria-live="assertive" aria-relevant="additions" class="ui-helper-hidden-accessible"></div><div id="janrainEngageEmbed" style="display: none;"><div class="janrainContent" style="width: 380px !important; height: 156px !important; padding-left: 5px !important; padding-right: 5px !important; box-sizing: content-box !important; background-color: rgb(255, 255, 255) !important; border: 1px solid rgb(192, 192, 192) !important; border-radius: 10px !important; overflow: hidden !important; position: relative !important;"><div id="janrainView"><div class="janrainHeader" style="background-color: rgb(255, 255, 255) !important; font-size: 14px !important; color: rgb(102, 102, 102) !important; position: relative !important; height: 20px !important; left: -5px !important; padding: 5px 5px 0px !important; white-space: nowrap !important; width: 380px !important; z-index: 100 !important; border-radius: 10px 10px 0px 0px !important; text-align: left !important;"><div style="padding-left: 1px !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important;">Sign in using your account with</div></div><div id="janrainProviderPages" style="padding-top: 5px; left: 5px; position: absolute;"><div class="janrainPage" pageindex="0"><ul class="providers" id="janrainProviders_0" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-aol" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="1" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-aol" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-aol" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">AOL</span></a></li><li id="janrain-openid" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="3" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-openid" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-openid" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">OpenID</span></a></li></ul><ul class="providers" id="janrainProviders_1" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-yahoo" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="2" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-yahoo" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-yahoo" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">Yahoo!</span></a></li></ul></div></div><div style="background-color: rgb(255, 255, 255) !important; width: 380px !important; height: 10px !important; position: absolute !important; left: 0px !important; padding-left: 5px !important; padding-right: 5px !important; padding-bottom: 5px !important; bottom: 0px !important; font-size: 10px !important; text-align: left !important; color: rgb(102, 102, 102) !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; border-radius: 0px 0px 10px 10px !important;"><div style="padding-left: 1px !important;"><a href="http://janrain.com/products/engage/social-login?utm_source=mms.rpxnow.com&amp;utm_medium=Partner&amp;utm_campaign=attribution" target="_blank">Social Login by Janrain</a></div></div></div></div></div><iframe name="captureIFrame_z4n062gljrfzd11xv9y29k9k6yd3yel5hqesyvbl" data-transactionid="z4n062gljrfzd11xv9y29k9k6yd3yel5hqesyvbl" id="captureIFrame_z4n062gljrfzd11xv9y29k9k6yd3yel5hqesyvbl" src="about:blank" class="" data-captureiframeloadeventbound="yes" style="display: none;"></iframe><div id="janrainModalOverlay" style="inset: 0px; position: fixed; background-color: rgb(0, 0, 0); opacity: 0.4; display: none; z-index: 1000;"></div><div id="janrainModal" style="width: 380px; height: 131px; position: absolute; z-index: 1000; display: none;"><a href="#" class="janrain_modal_closebutton" style="position: absolute; cursor: pointer; z-index: 1000;">X</a><div style="display: block;" id="signIn" class="ucc-widgets-nejm-next janrain-capture-ui capture-ui-content capture_screen_container" data-capturescreenname="signIn" data-captureventadded="true">
    <div class="capture_header">
      <h1>Sign In</h1>
    </div>    
    <div class="capture_signin">
      <form id="capture_signIn_signInForm" name="signInForm" data-capturefield="signInForm" action="https://mms.us.janraincapture.com/widget/traditional_signin.jsonp" class="capture_form capture_signInForm" method="POST" novalidate="novalidate" data-transactionid="z4n062gljrfzd11xv9y29k9k6yd3yel5hqesyvbl" target="captureIFrame_z4n062gljrfzd11xv9y29k9k6yd3yel5hqesyvbl" accept-charset="UTF-8" next="{&quot;noop&quot;:&quot;&quot;}"><div id="capture_signIn_signInForm_defaultSavedProfileMessage"></div><div id="capture_signIn_signInForm_errorMessages"></div><input id="capture_signIn_utf8" data-capturefield="undefined" value="✓" type="hidden" class="capture_utf8" name="utf8"><input id="capture_signIn_screen_z4n062gljrfzd11xv9y29k9k6yd3yel5hqesyvbl" data-capturefield="undefined" value="signIn" type="hidden" class="capture_screen_z4n062gljrfzd11xv9y29k9k6yd3yel5hqesyvbl" name="capture_screen"><input id="capture_signIn_js_version_z4n062gljrfzd11xv9y29k9k6yd3yel5hqesyvbl" data-capturefield="undefined" value="d445bf4" type="hidden" class="capture_js_version_z4n062gljrfzd11xv9y29k9k6yd3yel5hqesyvbl" name="js_version"><input id="capture_signIn_transactionId_z4n062gljrfzd11xv9y29k9k6yd3yel5hqesyvbl" data-capturefield="undefined" value="z4n062gljrfzd11xv9y29k9k6yd3yel5hqesyvbl" type="hidden" class="capture_transactionId_z4n062gljrfzd11xv9y29k9k6yd3yel5hqesyvbl" name="capture_transactionId"><input id="capture_signIn_form_z4n062gljrfzd11xv9y29k9k6yd3yel5hqesyvbl" data-capturefield="undefined" value="signInForm" type="hidden" class="capture_form_z4n062gljrfzd11xv9y29k9k6yd3yel5hqesyvbl" name="form"><input id="capture_signIn_flow_z4n062gljrfzd11xv9y29k9k6yd3yel5hqesyvbl" data-capturefield="undefined" value="standard" type="hidden" class="capture_flow_z4n062gljrfzd11xv9y29k9k6yd3yel5hqesyvbl" name="flow"><input id="capture_signIn_client_id_z4n062gljrfzd11xv9y29k9k6yd3yel5hqesyvbl" data-capturefield="undefined" value="qsra7g4d6jwdsgn3zbe6udp6r6278mr9" type="hidden" class="capture_client_id_z4n062gljrfzd11xv9y29k9k6yd3yel5hqesyvbl" name="client_id"><input id="capture_signIn_redirect_uri_z4n062gljrfzd11xv9y29k9k6yd3yel5hqesyvbl" data-capturefield="undefined" value="https://www.nejm.org" type="hidden" class="capture_redirect_uri_z4n062gljrfzd11xv9y29k9k6yd3yel5hqesyvbl" name="redirect_uri"><input id="capture_signIn_response_type_z4n062gljrfzd11xv9y29k9k6yd3yel5hqesyvbl" data-capturefield="undefined" value="code" type="hidden" class="capture_response_type_z4n062gljrfzd11xv9y29k9k6yd3yel5hqesyvbl" name="response_type"><input id="capture_signIn_flow_version_z4n062gljrfzd11xv9y29k9k6yd3yel5hqesyvbl" data-capturefield="undefined" value="20240514181256512029" type="hidden" class="capture_flow_version_z4n062gljrfzd11xv9y29k9k6yd3yel5hqesyvbl" name="flow_version"><input id="capture_signIn_settings_version_z4n062gljrfzd11xv9y29k9k6yd3yel5hqesyvbl" data-capturefield="undefined" value="" type="hidden" class="capture_settings_version_z4n062gljrfzd11xv9y29k9k6yd3yel5hqesyvbl" name="settings_version"><input id="capture_signIn_locale_z4n062gljrfzd11xv9y29k9k6yd3yel5hqesyvbl" data-capturefield="undefined" value="en-US" type="hidden" class="capture_locale_z4n062gljrfzd11xv9y29k9k6yd3yel5hqesyvbl" name="locale"><input id="capture_signIn_recaptcha_version_z4n062gljrfzd11xv9y29k9k6yd3yel5hqesyvbl" data-capturefield="undefined" value="2" type="hidden" class="capture_recaptcha_version_z4n062gljrfzd11xv9y29k9k6yd3yel5hqesyvbl" name="recaptchaVersion">
      <div class="ucc-form-inner-wrapper">
        <div id="capture_signIn_form_item_signInEmailAddress" class="capture_form_item capture_email capture_form_item_signInEmailAddress" data-capturefield="undefined"><label for="capture_signIn_signInEmailAddress">Email Address</label><input id="capture_signIn_signInEmailAddress" data-capturefield="signInEmailAddress" value="" type="email" class="capture_signInEmailAddress capture_required capture_text_input" placeholder="Email Address" name="signInEmailAddress"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="signInEmailAddress">Validating</div><div class="capture_tip_error" data-elementname="signInEmailAddress"></div></div>
        <div id="capture_signIn_form_item_currentPassword" class="capture_form_item capture_password capture_form_item_currentPassword" data-capturefield="undefined"><label for="capture_signIn_currentPassword">Password</label><input id="capture_signIn_currentPassword" data-capturefield="currentPassword" value="" type="password" class="capture_currentPassword capture_required capture_text_input" placeholder="Password" name="currentPassword"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="currentPassword">Validating</div><div class="capture_tip_error" data-elementname="currentPassword"></div></div>
        <div style="padding-top:10px;">
            <div class="capture_form_item capture_form_rememberme">
                <label class="ucc-form-checkbox">                
                    <input checked="checked" id="ucc-remember-me-cb" name="ucc-remember-me-cb" type="checkbox" value="true">
                    <span>Remember Me</span>
                </label>          
            </div>
            <div class="capture_form_item capture_form_forgotpwd">
              <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
            </div>
        </div>
        <div class="capture_form_item">
          <button id="ucc-sign-in-submit" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
        </div>
       
        <div class="capture_form_item">
          <div class="ucc-no-acct-msg">Don't have an account?</div>
          <div class="ucc-no-acct-msg-2" id="signInModalCreateAccountLink">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

          <div class="ucc-no-acct-msg-2" id="signInModalCloseLink" style="display:none">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

        </div>
     
        <div class="capture_form_item capture_form_submit">
          
        </div>      
      </div>
      </form>
    </div>
  </div></div></body></html>